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 1 
Introduction 
 
Nothing should be done  
if the consequences might not be serious.  
George Bernard Shaw 
 
Since the rediscovery of Gregor Mendel‟s findings in the early twentieth century we have 
known that the observable traits of an organism are largely controlled by inherited functional 
units. In the years that have followed, much effort and progress have been made in genetics 
and functional genomics to understand the molecular basis of inheritance and how it translates 
into a particular phenotype. However, the simple hope that genomes can be viewed as 
blueprints from which phenotypes can be inferred has not been fulfilled. The term phenotype 
is generally used to describe the observable traits of an organism (for example, morphology, 
size, physiology and behaviour), that emerge from its genotype and the specific 
environmental conditions. As the sensitivity of biological and biochemical methods has 
increased, the term has been extended to various aspects of cellular and molecular 
organization. Taking into account the complexity of cellular systems, techniques have been 
developed over the years that allow the comprehensive analysis of molecular components.  
Unfortunately, the global analysis of proteins was exceedingly difficult in the past. The 
classical biochemical analysis of proteins has been a daunting and time-consuming task in the 
past, and has yielded incomplete data sets that provided little quantitative information. In 
addition, changes in protein abundance cannot be simply inferred from DNA microarray data 
as mRNA abundance poorly correlates with protein abundance. Recently, and partly as a 
consequence of the advances in genome sequencing, enormous progress has been achieved in 
mass spectrometry based proteomics. 
In the past decade mass spectrometry (MS) has experienced consistent instrumental 
improvements that enable biological research applications unheard of before. Due to such 
important developments and their associated creative applications the current role and 
potential of MS is enormous for proteomics based investigations. In fact, MS is today not just 
an established tool for structural proteomics research, it is more than ever at the forefront of 
functional proteomics. So far, however, most of the efforts devoted to proteomics have 
focused on developing methods that enable efficient identification (and where possible 
structural characterization) of large numbers of proteins in the samples, while protein 
quantification studies carried out so far are comparatively scarce. This situation is mainly 
derived from the great difficulties in obtaining the accurate and reliable determination of the 
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amount of a protein “buried” in a complex real protein mixture. Main challenges to be tackled 
when accurate protein quantitative analysis is pursued are i) the system to be analysed may be 
very small (e.g. a single cell, with 0.5 pL volume and ca. 50 pg total protein content); ii) the 
possible proteins expression dynamic range is very large (e.g. from 1 to 106 copies/cell) with 
proteins to be determined “buried” in a complex matrix; iii) the number of possible different 
proteins, e.g. in human samples, is huge (i.e. possibly 10–20 times the number of genes which 
codify the proteins) and iv) proteins show very large variations in their physicochemical 
properties. 
     In the following Ph.D. work, the line of research dealing with the developed of multiplex 
analytical methods for proteomic analysis is presented. The use of the term “targeted 
proteomic” refers to investigation in complex mixtures of specific proteins or peptides which 
are representatives for the definition of a particular state of the system analyze. Different 
applications were investigated, ranging from analysis of foods to human fluids or tissue 
samples.  
The manuscript is divided into four chapters which define in principle the theme enclosed, 
which is further explained in detail with proper introduction, experimental section, results and 
discussion and conclusions by the collection of different subchapters.  
     In Chapter 1, the application of a classic shotgun proteomic approach for the determination 
of hidden peanut allergenic proteins in food samples at the trace levels is developed. As 
general observation, working with molecular mass spectrometry on this subject highlighted 
one of the most common limitation relates to this technique: the MS signal intensity coming 
from such “soft” ionization source is strongly affected by the species considered like protein, 
peptide, sample matrix and also solvents. Therefore, the aim to develope methods for 
multiplex quantification inserts an additional level of difficult since the targeted analytes 
might be of very different physical-chemical properties. During this former part of the work, 
in order to obtain a more sensitive method a step of selective enrichment of the sample was 
applied with the introduction of analytes (proteins) purification with magnetic beads 
opportunely functionalized with monoclonal antibodies raised against the target proteins. Use 
of antibodies as specific “hunters” of targeted proteins in complex samples, suggested the 
possibility to develope a special immunoassay which can be coupled with a final detection of 
analytes by ICP-MS.  
Then, in Chapter 2 the first application for analysis in food samples by an immunoassay in 
ELISA format based on the use of a commercially available antibody labelled with lanthanide 
(Europium) ion is presented. The promising results obtained, pushed towards a direct 
comparison with the method prior developed in LC-ESI-MS for the same analytes. The best 
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sensitivity, precision and particularly the indipendence of ionization process from the sample 
analyzed by ICP-MS analysis, underline its role as technique of choice for quantification 
purpose. Furthermore, one of the principal feature of ICP-MS is its ability to perform multi-
element detection in quasi-simultaneous way, fitting for purpose of multiplexed targeted 
proteomic. However, since ICP-MS detector information is elemental, only useful 
heteroatoms are measured (i.e. metals and non-metals) and it should be note that all structural 
molecular information are lost as consequence of atomization process in ICP source. A wide 
part of proteome does not contain useful elements for a direct ICP-MS detection and therefore 
it still invisible to the analysis. To overcome this problem recently two different strategies 
were recently introduced in literature: i) the direct labeling of protein to be determined and ii) 
labelling of an antibody followed by a specific antibody-antigen (antibody-protein) reaction. 
The direct labelling of a metal or elemental tag to the target protein can be performed in two 
different ways, as well: either the metal, mostly lanthanides, is introduced in the form of a  
coordination complex, e.g. with DOTA, or the heteroelement is  bound directly to a specific 
amino acid via a covalent bond. For  the introduction of a lanthanide into a protein, its 
complexing reagents based on DOTA (1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-
tetraacetic acid) or DTPA (diethylentriamine-N, N,N',N'',N''-pentaacetic acid) are developed 
to target specific amino acid functions via thiol- or amine-reactive groups. Once covalently 
bound to the protein, the macrocycle ligand can be loaded by lanthanide ions with the result of 
thermodynamically highly stable complexes. These complexes, attached to desired proteins, 
are shown to be stable during a typical proteomic workflow, therefore the corresponding 
peptides could be characterised by MALDI- and ESI-MS and furthermore quantified by ICP-
MS. The second strategy follows the principle of immunoassays and makes use of the same 
labelling reactions described in the above paragraph. Here, antibodies are labelled with 
complexes of different lanthanides, which serve as sensitive elemental tags in ICP-MS 
detection. Based on the pioneering work of Zhang et al. several concepts and applications 
have been developed for the multiplexing protein determinations. Different antibodies were 
labelled with different lanthanides, and thus, different proteins could be detected by ICP-MS 
simultaneously. In order to increase the detection sensitivity for these elemental-tagged 
immunoassays, gold nanoparticles were attached to antibodies as well. However, the 
possibility of a multiplexed detection solely based on Au nanoparticle labelling is limited. 
Thus, a new concept was recently presented, in which different lanthanides were incorporated 
into antibodies in the form of multiple metal-chelating ligand. This approach combines 
accordingly the multiplexing (simultaneous multi-element detection) and highly sensitive 
(low detection limits) capabilities of ICP-MS for its emerging use in protein analysis. For our 
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purpose, the second strategy involving the immunoassay was chosen, because the former 
approach posses a weak point in the needs of an additional post-labelling passage of 
characterization of the proteins prior to ICP-MS quantification.  
     Chapter 3 represents the core of this thesis, and it is dedicated to the development of 
labelling procedure for monoclonal antibodies with lanthanides complexation based on 
DOTA conjugation to biomolecule. For the first time, elemental labelled monoclonal 
antibodies were used in a liquid phase immunoassay with a virtual absence of sample 
manipulation, and the coupling of size exclusion chromatography to separate bound/unbound 
forms of antibodies was found successful. In order to provide additional information 
regarding the control of labelling procedure, the stoichiometry metal/antibody was determined 
by a new method which exploite the High Resolution-ICP-MS capability to perform measure 
of sulphur content into antibody at low levels. Then, knowing the sulphur content into protein 
backbone prior of lanyhanides loading, the stoichiometry of labelling can be asses by the ratio 
tag/sulphur, where this element is a direct measure of antibody concentration. In addition, an 
approach aiming to the increase in sensitivity by the introduction of a high number of tags 
into antibody is presented with the use of dendrimers as useful carriers of multiple copies of 
DOTA ligands.   
     Finally, Chapter 4 is an external subject of research respect to former three chapters. The 
idea of this study rely in a previous research regarding the study of interaction between 
metallodrugs with model proteins, at that time performed by UV-VIS spectroscopy and NMR 
techniques. The acquisition of competences and knowledge in proteomic techniques, 
especially with ICP-MS, suggested the idea of study the non-covalent interactions between 
proteins (albumin and transferrin) and metallodrugs by more sensitive and accurate methods. 
Also if ICP-MS was already used for these purpose, the separation techniques employed 
normally involves the coupling of capillary zone electrophoresys or ion exchange 
chromatography. Nevertheless, the robustness of these methods is still scarce and the harsh 
conditions necessar for separation of bound/unbound metal species does not reflect a natural 
environment in  which interaction (i.e. human serum) take place. Then a new set up for this 
kind of studies involving size exclusion chromatography and ICP-MS is presented and results 
are further investigate by ESI-MS both on the whole tranferrin and on a model peptide 
mimicking the iron site.     
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E 'l duca lui: "Caron, non ti crucciare: 
vuolsi così colà dove si puote 
ciò che si vuole, e più non dimandare".     
Dante Aligieri, 
 Inferno, Canto III     
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1.1. Use of Specific Peptide Biomarkers for  
Quantitative Confirmation of Hidden  
Allergenic Peanut Proteins Ara h 2 and Ara h 3/4 for 
Food Control by Liquid Chromatography–Tandem 
Mass Spectrometry. 
 
Abstract. A liquid chromatography–electrospray-tandem mass spectrometry (LC–ESI-MS–
MS) method based on the detection of biomarker peptides from allergenic proteins was 
devised for confirming and quantifying peanut allergens in foods. Peptides obtained from 
tryptic digestion of Ara h 2 and Ara h 3/4 proteins were identified and characterized by LC–
MS and LC–MS–MS with a quadrupole-time of flight mass analyzer. Four peptides were 
chosen and investigated as biomarkers taking into account their selectivity, the absence of 
missed cleavages, the uniform distribution in the Ara h 2 and Ara h 3/4 protein isoforms 
together with their spectral features under ESIMS–MS conditions, and good repeatability of 
LC retention time. Because of the different expression levels, the selection of two different 
allergenic proteins was proved to be useful in the identification and univocal confirmation of 
the presence of peanuts in foodstuffs. Using rice crispy 
and chocolate-based snacks as model food matrix, an LC–MS–MS method with triple 
quadrupole mass analyzer allowed good detection limits to be obtained for Ara h2 (5 μg 
protein g
-1
 matrix) and Ara h3/4 (1 μg protein g-1matrix). Linearity of the method was 
established in the 10–200 μg g-1 range of peanut proteins in the food matrix investigated. 
Method selectivity was demonstrated by analyzing tree nuts (almonds, pecan nuts, hazelnuts, 
walnuts) and food ingredients such as milk, soy beans, chocolate, cornflakes, and rice crispy. 
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INTRODUCTION 
 
     In recent years peanut allergy seems to be on the rise in western countries, with a 
prevalence of 1% to 1.5% [1]. Together with tree nuts, peanuts account for the majority of 
food allergic reactions with fatal outcome both in children and in adults [2]. Since 
spontaneous resolution of peanut allergy is rare [3] and curative treatment is not yet available 
[4], strict elimination of peanuts is the rule, because traces of peanut can cause a severe 
allergic reaction in sensitive subjects [5, 6]. However, strict elimination is difficult, especially 
because food labeling practice can be still inadequate [7, 8] and contamination of 
nonallergenic foodstuffs with allergenic ingredients can easily occur during processing and 
transport. Recent developments intending to improve regulatory aspects of food labeling have 
led to increased advisory labeling [9–11].  
     Up to now several methods have been developed for the determination of peanut allergens 
in foods; these are mainly based on immunoassay (sandwich and competitive enzyme linked 
immunosorbent assay (ELISA) [12, 13], polymerase chain reaction (PCR), and real-time-PCR 
[14]. These approaches represent valid screening tools allowing simple analysis of a high 
number of samples. However, in such methods problems related to DNA–protein expression 
level, cross-reactivity, accuracy, and selectivity are still present. In a research program dealing 
with the development of new analytical strategies for the determination of hidden allergens in 
foods, very recently [15] we proposed a non-competitive sandwich immunoassay with 
inductively coupled plasma-mass spectrometric (ICP–MS) detection for the analysis of peanut 
proteins in different food matrices by using metal-tag antibodies. The method was 
demonstrated to be suitable for the detection of peanut allergens down to 1.5 mg peanuts kg
-1
 
matrix with good precision. The ICP–MS system presents several advantages, including high 
sensitivity and the capability of performing multi-tag detection. However, this technique does 
not overcome the limitations of immunoassay methods in terms of accuracy and selectivity. In 
such a context, the high selectivity of mass spectrometry in protein analysis can overcome 
some of the difficulties associated with the correct identification of peanut proteins in 
complex food matrices. In this work we propose a proteomic-based approach for quantitative 
confirmation of peanut allergens in foods. In particular, we devised a liquid chromatography–
electrospray-tandem mass spectrometry (LC–ESI-MS–MS) method with triple quadrupole 
(QqQ) analyzer for identification and determination of two major peanut allergens, i.e. Ara h 
2 and Ara h 3-4[17], by using characteristic peptide biomarkers. Recently, LC–ESI-MS–MS 
methods for the detection of Ara h 1 in ice-cream and dark chocolate have been published [18, 
19]. In those papers, the approach proposed was based on the detection of biomarker peptides 
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of one protein. i.e. Ara h 1, to directly identify peanut allergens at low parts per million level 
in food matrices. When complex matrices are analyzed, the selection of adequate peptide 
markers derived from different proteins for detection of hidden allergens is of great 
importance. In this context, very recently a characterization of potential peptide biomarkers of 
Ara h 1, A h 2, and Ara 3/4 using capillary LC-nanoESI-quadrupole-time-of-flight (QTOF)-
MS–MS has been proposed [20]. In that work, attention was paid to the establishment of a list 
of peptides that remain stable after peanut processing.  
     The key feature of the research study proposed here is the development of a LC–ESI-QqQ-
MS–MS method for two different proteins of the same allergenic source with the goal of 
combining the selectivity of the approach based on the detection of peptide biomarkers for 
different allergens with the capability of the method of performing quantitative analysis. In 
addition, attention was paid to assessment of method performance for both qualitative and 
quantitative purposes. The choice of two targets can offer the advantages of increasing the 
selectivity of allergen identification and better assessment of electrospray sensitivity for 
different peptides and thus the detection limits of the method. 
 
EXPERIMENTAL SECTION 
 
     Chemicals. Ara h2 was purified from raw peanuts following a procedure reported in the 
literature [21], whereas Ara h3/4 purified from raw peanuts was kindly provided by Dr W. 
Becker from the Leibniz Center for Medicine and Biosciences at the Research Center Borstel 
(Borstel, Germany). Native protein solutions were prepared and diluted in deionized water (18 
MΩ cm resistivity) which was obtained from a Milli-Q Element water-purification system 
(Millipore, Bedford, MA, USA). Acetonitrile (HPLC purity), trifluoroacetic acid, and formic 
acid (analytical reagent grade) were purchased from Carlo Erba (Milan, Italy). Trypsin from 
bovine pancreas, iodoacetamide, and dithiothreitol were from Sigma–Aldrich (St Louis, 
Missouri, USA). 
     Liquid chromatography–quadrupole/time of flight-mass spectrometry. Characterization of 
Ara h 2 and Ara h 3/4 peptides was carried out using a microLC–ESI-Q-TOF Micro 
(Waters,Milford, MA, USA) mass spectrometer. LC elution was performed on a Symmetry 
C18 capillary column (0.32 mm×150 mm, 5 μm) (Waters) using a gradient solvent system 
[(A) 0.1% (v/v) formic acid in water; (B) 0.08% (v/v) formic acid in acetonitrile]. Gradient 
elution was as follows: solvent B was set at 5% for 6 min, then delivered by a linear gradient 
from 5% to 90% in 28 min. Solvent B was maintained at 90% for 2 min before column re-
equilibration (10 min). Flow-rate was 6 μL min-1. Mobile phase was delivered by a CapLC 
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pump (Waters) equipped with a 48-vial capacity sample-management system. Standard or 
sample solution (10 μL) was loaded on a Symmetry 300 C18 (Waters) precolumn (0.32 
mm×10 mm, 5 μm) and eluted with the mobile phase on to the chromatographic column for 
on-column analyte enrichment and to avoid column contamination. The nebulizing gas 
(nitrogen, 99.999% purity) and the desolvation gas (nitrogen, 99.998% purity) were delivered 
at flow-rates of 10 and 600 L h
-1
 respectively. Q-TOF external calibration was performed 
using a peptide mixture solution and a fifth-order nonlinear calibration curve was usually 
adopted. The interface parameters were: ESI voltage 3.0 kV, cone voltage 30 V, rf lens 0.5 V, 
source temperature 50 °C, desolvation temperature 100 °C. Identification with the Q-TOF 
instrument was performed using accurate MS and MS–MS measurements of the selected 
target peptides. Continuum mode TOF mass spectra were acquired over the m/z range 400–
2000 using an acquisition time of 1 s and an interscan delay of 0.1 s. When operating in 
production mode, collision energy and the m/z range were optimized as a function of peptide 
charge and mass. 
     Liquid chromatography–triple quadrupole mass spectrometry. LC elution was carried out 
on a Poroshell C18 300 Å (75 mm×2.1 mm, 5 μm particles) (Agilent Technologies, Santa 
Clara, CA, USA) using a gradient solvent system [(A) aqueous formic acid (0.1% v/v)/(B) 
0.08% (v/v) formic acid in acetonitrile]. Gradient elution was the same as reported above. The 
flow-rate was 200 μL min-1. The mobile phase was delivered by a Waters 2690 series 
Alliance quaternary pump equipped with a 120-vial capacity sample-management system. 
Injection volume was 30 μL. A Quattro LC triple-quadrupole instrument (Micromass, 
Manchester, UK) equipped with a pneumatically assisted ESI interface was used. The system 
was controlled by Masslynx software version 4.0 (Micromass). The nebulizing gas (nitrogen, 
99.999% purity) and the desolvation gas (nitrogen, 99.998% purity) were delivered at flow-
rates of 55 and 500 L h
-1
, respectively. Full-scan, selected ion monitoring (SIM), product-ion, 
and selected-reaction monitoring (SRM) experiments were performed operating the mass 
spectrometer in PI mode. Optimized conditions of the interface were as follows: ESI voltage 
3.5 kV, cone voltage 35 V, rf lens 0.3 V, source temperature 130 °C, desolvation temperature 
250 °C. Fullscan mass spectra were acquired over the scan range m/z 200-2000 using a step 
size of 0.1 Da. SIM experiments were carried out on the doubly charged ions of selected 
peptides. For MS–MS experiments collision-induced dissociation (CID) was performed with 
a collision gas pressure of 2.3×10
−3
 mbar in the collision cell. The collision energies (CE) 
were optimized for the mass and charge state of each peptide in order to obtain selective and 
intense fragmentation. The SRM transitions monitored were as follows: m/z 807/1050 CE 35 
eV (CCNELNEFENNQR, Ara h 2), m/z 950/1120 CE 35 eV (CMCEALQQIMENQSDR, 
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Ara h 2), m/z 649/1089 CE 30 eV (AHYQVVDSNGDR, Ara h 3/4), m/z 695/700 CE 35 eV 
(SPDIYNPQAGSLK, Ara h3/4). Leucine–enkephalin was used as internal standard (m/z 
557/397; CE 20 eV). A ±0.5 mass resolution was set in Q1 and Q3. 
     Samples. Raw peanut samples (Arachis hypogaea) of the variety red skin from five 
different producers were purchased in commercial stores. 
Sample treatment. 
     Method 1. Peanut extracts and peanut-containing food extracts were prepared by adding 10 
mL Tris HCl 0.2 mol L
-1
 (pH 8.2) to 1 g ground sample. Proteins were extracted by shaking 
for 2 h at 60 °C, then the extract was centrifuged (3000 g, 5 min) and filtered through a 0.2-
μm Nylon filter. Sample concentration was performed on a 5 kDa MW cut-off cellulose filter 
(Millipore Billerica, MA, USA) by adding 5 mL protein extract and reducing the volume to 
0.5 mL. The sample was then digested with trypsin (5 μL, 0.6 mmol L-1 in tris HCl, pH 8.2). 
Different digestion conditions in terms of time (12 and 24 h) and temperature (37 °C, 50 °C) 
were tested. The final digestion conditions were: 50 °C for 24 h and reaction blocking with 1 
μL trifluoroacetic acid. Milk, cacao powder, soy beans, tree nuts, rice crispy, cornflakes (all 
purchased from a major store chain) were extracted by applying the same procedure. Peptide 
extracts were stored at −20 °C until analysis. 
      Method 2. The same procedure as for method 1 except for a further liquid–liquid 
extraction step with hexane before sample concentration on the cut-off filter. 
     Method 3. Sample (1 g) was incubated overnight in 10 mL 0.2 mol L
-1
 Tris HCl (pH 8.2) 
and 100 μL trypsin 0.6 mmol L−1 at 50 °C with vigorous shaking. The resulting mixture was 
centrifuged at 14000 rpm for 5 min. The supernatant was filtered through a 0.45-μm 
centrifugal filter (Millipore). The extract was further purified using Strata-X polymeric 
multimode solid-phase cartridges (Phenomenex, Torrance, CA, USA). The cartridge was 
washed with 2 mL 95:5 (v/v) water–acetonitrile and peptides were eluted with 1 mL 
acetonitrile. The eluate was dried under a nitrogen stream and re-suspended in 200 μL 60:40 
(v/v) water–acetonitrile containing 0.1% formic acid. 
     LC–QqQ-MS–MS method performance. Method performance was assessed in terms of 
limit of detection (LOD), limit of quantitation (LOQ), linearity, accuracy, and selectivity. For 
this purpose a rice crispy/cacao-based snack was chosen as the matrix. LOD and LOQ values 
were calculated for standard solution and for matrix as amounts for which the signal-to-noise 
ratios were 3:1 and 10:1, respectively. Instrumental linearity was calculated by spiking 
aqueous solutions with different amounts (0.1–20% w/v) peanut extract. A matrix matched 
calibration curve was built-up by spiking matrix extract with different amounts of peanut 
extract (1–20% w/v). Method precision was assessed by performing two extractions of matrix 
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fortified at two peanut concentration levels (1.25 and 5% w/w peanuts/matrix) and performing 
five LC injection replicates for each extract. Method selectivity was evaluated by analyzing 
tryptic digests of tree nuts, soybeans, milk, cacao powder, and rice crispy samples. 
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RESULTS AND DISCUSSION 
 
     LC–ESI-QTOF MS and MS–MS identification of Ara h 2 and Ara h 3/4 peptide 
biomarkers.Ara h 2 and Ara h 3/4 whole proteins were initially characterized by ESI-QTOF 
MS analysis. No protein interferences were found in the mass spectra, suggesting an excellent 
degree of purification of both proteins. In particular, Ara h 2, which was purified from peanut 
seeds in our laboratory, exhibited the typical doublet in the 16–18 kDa range, as reported in 
the literature [21]. In a further step, the tryptic digests of purified Ara h 2 and Ara h 3/4 were 
individually analyzed in LC–QTOF-MS in order to identify putative peptide biomarkers. 
Proteins were digested both in the native and reduced/alkylated (using dithiothreitol and 
iodoacetamide) forms. The results did not show significant differences among the most 
abundant peptides observed for both proteins digested under the two different conditions. 
Since no analytical advantages were obtained by performing digestion of reduced/alkylated 
proteins, the work was performed on the native forms. Several doubly charged ions of the 
tryptic digest peptides were identified for both proteins allowing a good degree of sequence 
coverage to be obtained (74% for Ara h 2 and 60% for Ara h 3/4).  Peptides were selected on 
the basis of the following criteria: signal intensity, retention time repeatability, lack of missed 
cleavages, specificity, and presence in the different Ara h 2 and Ara h 3/4 isoforms. In the 
case of Ara h 2 the peptides at m/z 807.2451 (CCNELNEFENNQR; doubly charged ion) and 
m/z 949.8894 (CMCEALQQIMENQSDR); doubly charged ion of the cysteine oxidized form 
were selected. Accurate mass measurements and product-ion MS–MS experiments were 
carried out to identify the peptide sequences and data collected for Ara h 2 protein are 
presented in Figure 1.  
 
 
 
Ara h 2.0101   
Average Mass = 16637.2527,  Monoisotopic Mass = 16626.6829
N-Terminus = H,  C-Terminus = OH
1 Arg-Gln-Gln-Trp-Glu-Leu-Gln-Gly-Asp-Arg-Arg-Cys-Gln-Ser-Gln-Leu-Glu-Arg-Ala-Asn-Leu-Arg-Pro-Cys-Glu-Gln-His-Leu-Met-Gln-Lys-Ile-Gln-
34 Arg-Asp-Glu-Asp-Ser-Tyr-Glu-Arg-Asp-Pro-Tyr-Ser-Pro-Ser-Gln-Asp-Pro-Tyr-Ser-Pro-Ser-Pro-Tyr-Asp-Arg-Arg-Gly-Ala-Gly-Ser-Ser-Gln-His-
67 Gln-Glu-Arg-Cys-Cys-Asn-Glu-Leu-Asn-Glu-Phe-Glu-Asn-Asn-Gln-Arg-Cys-Met-Cys-Glu-Ala-Leu-Gln-Gln-Ile-Met-Glu-Asn-Gln-Ser-Asp-Arg-Leu-
100 Gln-Gly-Arg-Gln-Gln-Glu-Gln-Gln-Phe-Lys-Arg-Glu-Leu-Arg-Asn-Leu-Pro-Gln-Gln-Cys-Gly-Leu-Arg-Ala-Pro-Gln-Arg-Cys-Asp-Leu-Asp-Val-Glu-
133 Ser-Gly-Gly-Arg-Asp-Arg-Tyr
1 Arg-Gln-Gln-Trp-Glu-Leu-Gln-Gly-Asp-Arg-Arg-Cys-Gln-Ser-Gln-Leu-Glu-Arg-Ala-Asn-Leu-Arg-Pro-Cys-Glu-Gln-His-Leu-Met-Gln-Lys-Ile-Gln-
34 Arg-Asp-Glu-Asp-Ser-Tyr-Glu-Arg-Asp-Pro-Tyr-Ser-Pro-Ser-Gln-Asp-Pro-Tyr-Ser-Pro-Ser-Pro-Tyr-Asp-Arg-Arg-Gly-Ala-Gly-Ser-Ser-Gln-His-
67 Gln-Glu-Arg-Cys-Cys-Asn-Glu-Leu-Asn-Glu-Phe-Glu-Asn-Asn-Gln-Arg-Cys-Met-Cys-Glu-Ala-Leu-Gln-Gln-Ile-Met-Glu-Asn-Gln-Ser-Asp-Arg-Leu-
100 Gln-Gly-Arg-Gln-Gln-Glu-Gln-Gln-Phe-Lys-Arg-Glu-Leu-Arg-Asn-Leu-Pro-Gln-Gln-Cys-Gly-Leu-Arg-Ala-Pro-Gln-Arg-Cys-Asp-Leu-Glu-Val-Glu-
133 Ser-Gly-Gly-Arg-Asp-Arg-Tyr
1 Arg-Gln-Gln-Trp-Glu-Leu-Gln-Gly-Asp-Arg-Arg-Cys-Gln-Ser-Gln-Leu-Glu-Arg-Ala-Asn-Leu-Arg-Pro-Cys-Glu-Gln-His-Leu-Met-Gln-Lys-Ile-Gln-
34 Arg-Asp-Glu-Asp-Ser-Tyr-Gly-Arg-Asp-Pro-Tyr-Ser-Pro-Ser-Gln-Asp-Pro-Tyr-Ser-Pro-Ser-Gln-Asp-Pro-Asp-Arg-Arg-Asp-Pro-Tyr-Ser-Pro-Ser-
67 Pro-Tyr-Asp-Arg-Arg-Gly-Ala-Gly-Ser-Ser-Gln-His-Gln-Glu-Arg-Cys-Cys-Asn-Glu-Leu-Asn-Glu-Phe-Glu-Asn-Asn-Gln-Arg-Cys-Met-Cys-Glu-Ala-
100 Leu-Gln-Gln-Ile-Met-Glu-Asn-Gln-Ser-Asp-Arg-Leu-Gln-Gly-Arg-Gln-Gln-Glu-Gln-Gln-Phe-Lys-Arg-Glu-Leu-Arg-Asn-Leu-Pro-Gln-Gln-Cys-Gly-
133 Leu-Arg-Ala-Pro-Gln-Arg-Cys-Asp-Leu-Glu-Val-Glu-Ser-Gly-Gly-Arg-Asp-Arg-Tyr
1 Arg-Gln-Gln-Trp-Glu-Leu-Gln-Gly-Asp-Arg-Arg-Cys-Gln-Ser-Gln-Leu-Glu-Arg-Ala-Asn-Leu-Arg-Pro-Cys-Glu-Gln-His-Leu-Met-Gln-Lys-Ile-Gln-
34 Arg-Asp-Glu-Asp-Ser-Tyr-Gly-Arg-Asp-Pro-Tyr-Ser-Pro-Ser-Gln-Asp-Pro-Tyr-Ser-Pro-Ser-Gln-Asp-Pro-Asp-Arg-Arg-Asp-Pro-Tyr-Ser-Pro-Ser-
67 Pro-Tyr-Asp-Arg-Arg-Gly-Ala-Gly-Ser-Ser-Gln-His-Gln-Glu-Arg-Cys-Cys-Asn-Glu-Leu-Asn-Glu-Phe-Glu-Asn-Asn-Gln-Arg-Cys-Met-Cys-Glu-Ala-
100 Leu-Gln-Gln-Ile-Met-Glu-Asn-Gln-Ser-Asp-Arg-Leu-Gln-Gly-Arg-Gln-Gln-Glu-Gln-Gln-Phe-Lys-Arg-Glu-Leu-Arg-Asn-Leu-Pro-Gln-Gln-Cys-Gly-
133 Leu-Arg-Ala-Pro-Gln-Arg-Cys-Asp-Leu-Asp-Val-Glu-Ser-Gly-Gly-Arg-Asp-Arg-Tyr
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Figure 1. Aminoacid s quence of Ara h2 protein a d the selected biomarker peptides T11 
(red line) and T12 (blue line). Below: ESI-QTof  mass spectra obtained by CID 
experiments for the accurate identification of the selected peptides T11 and T12. 
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No peptides covering the IgE-binding epitope giving the allergic reaction (two epitopes in the 
region aa57–74 contain the amino acid sequence DPYSP necessary for IgE binding, [22]) 
were found in the ESI mass spectrum of the tryptic digest of Ara h 2. Concerning Ara h 3/4, 
the peptides at m/z 648.8109 (AHYQVVDSNGDR, doubly charged ion), m/z 695.3468 
(SPDIYNPQAGSLK, doubly charged ion), and at m/z 732.8384 (AQSENYEYLAFK) were 
found to be the most abundant. However, considering the protein sequences reported in 
databases it was possible to observe that the sequence at m/z 732 is not present in all isoforms 
thus suggesting that this peptide can not be a useful biomarker.  
     To demonstrate this, peanut extracts from different providers were analyzed and the 
presence of the peptide at m/z 732 was observed only in two of the five samples analyzed. In 
addition, taking into account recovery of the extraction procedure and that the concentration 
of the protein extract is determined and made uniform before digestion, the peptide was 
detected with different abundances in the two varieties in which it was present. These findings 
suggest that the peptides useful as biomarkers must be present in all the different isoforms of 
the investigated proteins in order to detect them when different peanut cultivars are used in 
the food industry.  
     Further, the analysis of more than one allergenic protein for confirmation purposes allows 
reduction of the problem of a different level of expression of a protein in the vegetable 
system, which can significantly affect the detection limit of the peptides. In the case of Ara h 
2, the peptides at m/z 807 and 950 were found to be present with comparable signal intensity 
in all the varieties selected. In fact, the sequence coverage we obtained for Ara h 2 was 
predominantly on the conserved sequences and not on the sequences that differ in the various 
isoforms. On the basis of these results, the LC tandem mass spectrometry method using a 
triple-quadrupole was developed. 
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     LC–ESI-QqQ-MS–MS method. The chromatographic behavior of the four selected peptides 
(Fig. 2) exhibited excellent stability of the retention times (RSD<1.5%, n=10).  
In a preliminary step ESI ionization 
efficiency of the selected peptides was 
evaluated to study analytical sensitivity 
for quantitative purposes. In fact, since 
different ESI sensitivity is expected, it 
should be assessed to verify which 
peptides can be useful for obtaining the 
lowest detection limits. Calibration curves 
were calculated in SIM mode by 
performing several dilutions of the tryptic 
digests of Ara h 2 and Ara h 3/4 standard 
solutions. From the slope values obtained 
it was possible to observe comparable 
sensitivity for the peptides at m/z 807 [y = 
3593 ( 260)x] and m/z 950 (y = 2517 ( 320)x] (Ara h 2). Instead, in the case of the Ara h 3/4 
peptide m/z 695 [y = 22110 ( 1140)x], remarkably, the highest sensitivity was observed. The 
peptide at m/z 649 provided a sensitivity comparable to that observed or the Ara h 2 peptides 
[y = 3720 ( 167)x]. These findings suggest that the peptide at m/z 649 can be a good marker 
to improve method detectability.  
     Using a low-resolution mass analyzer it is necessary to perform SRM experiments to 
obtain good selectivity in peptide identification in a complex matrix. For this reason, the 
product-ion mass spectra of the target peptides were acquired by optimizing the collision 
energy in order to obtain selective fragment ions with high intensity. The MS–MS spectra of 
peptides at m/z 807 (Ara h2), 950 (Ara h2), 695 (Ara h3/4), and 649 (Ara h3/4) showed 
fragment ions distributed under and above each selected precursor ion mass yielding useful 
analytical data for the quantitative method.  
     
     Sample treatment procedure. In the development of a sensitive method for the detection of 
hidden allergens in food products, sample preparation should be optimized to obtain the best 
sensitivity improving peptide detection limits. For this purpose, three different extraction 
methods were applied to peanuts. By using the method involving extraction of whole proteins 
followed by enzymatic digestion (method 1), the signals of all selected peanut peptides were 
observed with excellent signal-to-noise ratio in the LC–MS–MS SRM chromatogram. 
 
Figure 2. LC–ESI-QqQ-MS–MS SRM 
chromatograms of a tryptic digest of Ara h2 and 
Ara h3/4 standard solutions (20 μg mL−1). 
Peaks: 1, m/z 649/1089 (Ara h3/4); 2, m/z 
695/700 (Ara h3/4); 3, m/z 807/1050 (Ara h2); 
4, m/z 950/1120 (Ara h2). 
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However, it was possible to observe an increase of column back-pressure and a signal 
intensity decrease as a consequence of ESI source dirt when a number of subsequent analyses 
were run (i.e. more than 20 injections). In order to reduce sample impurities, an additional 
extraction step with hexane was introduced to eliminate the lipid fraction of the sample 
(method 2). However, even though the problems related to unclean extracts were solved, a 
significant decrease (between 20 and 50%) in the peak area of the investigated peptides was 
observed with respect to method 1. To improve 
sample treatment the simultaneous extraction and 
digestion of peanut proteins was performed 
followed by an SPE clean-up step (method 3). 
This resulted in a decrease of peptide signal 
intensity (between 50 and 90%) with respect to 
method 1. This behavior could be the 
consequence of incomplete recovery of the 
peptides during digestion and purification or of a 
different matrix effect that can affect ESI 
ionization efficiency. On the basis of these 
findings, method 1 was chosen. Different digestion conditions were then assessed, as reported 
in the experimental section. The best result in 
terms of recovery of the peptides from peanut-
containing foods was observed when operating at 
50 °C for 24 h. In particular, these conditions led 
to an increase of the peak area of the four 
peptides monitored of between 20 and 120% 
compared with the other milder digestion 
conditions. 
 Assessment of LC–ESI-QqQ-MS–MS method 
performance with foods. To assess the 
applicability of the LC–ESI-MS–MS SRM 
method for detection of peanut allergens in food, 
rice crispy/cacao-based snacks were fortified 
with different amounts of raw peanuts. 
Instrumental linearity calculated by using 
aqueous solutions spiked with percentages from 
0.1 to 20% of a peanut peptide extract in general 
Figure 3. LC–ESI-QqQ-MS–MS SRM 
chromatograms of peptides (a) m/z 
695/700 [SPDIYNPQAGSLK, Ara h3/4] 
and (b) m/z 807/1050 
[CCNELNEFENNQR, Ara h2] in 
chocolate/rice crispy-based matrix 
fortified with Ara h2 and Ara h3/4 protein 
solutions at different concentrations. 
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demonstrated better sensitivity for the peptides selected for Ara h3/4 ( y = 10.48 ( 0.23)x and 
y = 3.78 (  0.12)x for the peptides at m/z 695 and m/z 649 respectively) with respect to those 
selected for Ara h2 (y = 4.23 ( 0.22)x and y = 2.68 ( 0.18)x for the peptides at m/z 807 and 
m/z 950 respectively). The peptide m/z 695 provided the lowest detection limit (1.5 μg mL-1) 
and quantitation limit (4.8 μg mL-1). The LOD and LOQ values for matrix were calculated for 
all the peptides investigated. The best result was obtained for the peptide at m/z 695 (Ara 
h3/4); the LOD and LOQ were 1 and 3.7 μg protein g-1 matrix, respectively (Fig. 3a). In the 
case of Ara h2, the peptide exhibiting the lowest LOD and LOQ values was that at m/z 807 
(LOD and LOQ values were 5 and 14 μg g-1, respectively; Fig. 3b). Method precision, 
expressed as RSD, was lower than 10% when calculated for 1.25 and 5% w/w peanuts/matrix 
concentration levels for all the peptides investigated. Trueness was evaluated as matrix effect 
and the results exhibited the presence of a significant suppression effect (from 30 to 50%) on 
the signals of the peptides of Ara h2, whereas in the case of Ara h3/4 peptides the suppression 
effect was lower than 10%. In general, the use of the internal standard selected did not 
completely overcome the matrix suppression effect but reduced it to within 5 and 30% for Ara 
h3/4 and Ara h2 peptides, respectively.       
     Further, specificity of the peptide biomarkers was assessed for the matrix. In fact, Ara h 2 
is a glycoprotein having sequence homologies with conglutin, the 2S albumin seed protein 
families, and the α-amylase from wheat. Ara h 3/4 is a protein belonging to the glycinin 
protein family and some of the IgE-binding epitopes (the C-terminal fragment appeared to 
bind more IgE) are conserved regions present in legumes (e.g. soy beans). Such IgE-binding 
sites provide a molecular explanation for the IgE cross-reactivity observed between soybean 
and peanut proteins [23]. For this purpose, research on protein databases was performed and 
the sequences of the selected peptides were found to be unique for peanuts. In fact, by 
analyzing peptide extracts from different food sources (tree nuts, soybeans, milk, cacao 
powder, rice crispy) no interfering signals were observed at the SRM transitions monitored 
for the peanut peptides. It should be noted that such selectivity was obtained by keeping a 
very narrow mass window (±0.5 Th) on the first quadrupole, thus reducing the number of ions 
transmitted to the collision cell in spite of method sensitivity. In fact, using a larger mass 
window (±1 Th), several signals were observed in the matrices tested. Such findings suggest 
that when a low-resolution mass analyzer is used, optimum selectivity can be obtained by 
selecting specific transitions and keeping a narrow m/z window on the first quadrupole for the 
MS–MS experiments. 
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CONCLUSIONS 
 
      The approach based on the simultaneous identification of biomarker peptides derived from 
two different proteins makes the proposed method highly selective towards peanut residues in 
foods. The capability of identification of both Ara h 2 and Ara h 3/4 at concentrations as low 
as 1 μg g−1 was demonstrated in a complex matrix such as rice crispy/chocolate-based 
snacks. Since the method combines highly selective identification with the capability of 
performing quantitative analysis at low concentration levels, it can be proposed as an effective 
quantitative confirmatory method for the detection and determination of hidden allergens in 
food. Further developments will concern the strategy of sample treatment with the aim of 
obtaining simultaneous extraction, purification, and enrichment of the investigated peanut 
proteins. The final goal is to reduce the time required for sample preparation and to make 
detection and quantification limits less prone to the effects of the complexity of the matrices. 
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1.2. Selective and Rapid 
Immunomagnetic Bead-Based Sample Treatment for 
Liquid Chromatography–Electrospray Ion-Trap 
Mass Spectrometry Detection of Ara h3/4 
Peanut Protein in Foods. 
 
 
Abstract. Complex matrices commonly affect the sensitivity and selectivity of liquid 
chromatography–mass spectrometry (LC–MS) analysis. Thus, selective sample enrichment 
strategies are useful particularly to analyze organic biomarkers present in low abundance in 
samples. A selective immunomagnetic extraction procedure to isolate trace peanut allergen 
protein Ara h3/4 from breakfast cereals combined with microwave-assisted tryptic digestion 
and liquid chromatography–electrospray ion-trap tandem mass spectrometry (LC–ESI-IT-
MS/MS) measurement was developed. Using protein A-coated magnetic bead (MB) support, 
anti-Ara h3/4 monoclonal antibodies (Abs) were used as selective capture molecules. The 
results obtained by LC–ESI-IT-MS/MS in terms of limit of detection (3mg peanuts/kg matrix) 
and a significantly reduced matrix effect demonstrated that the Ab-coated magnetic bead was 
very effective to selectively trap Ara h3/4 protein in breakfast cereals. The magnetic bead-
based sample treatment followed by LC–IT-MS/MS method here developed can be proposed 
as very rapid and powerful confirmatory analytical method to verify the reliability of enzyme-
linked immunosorbent assay (ELISA) screening methods, since the magnetic bead-LC–IT-
MS/MS method combines good sensitivity to the identification capabilities of mass 
spectrometry. 
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INTRODUCTION 
 
     Hidden allergens in foods represent a major health problem in the food safety issue, since 
they are recognized to induce a wide variety of hypersensitivity reactions [1]. A substance is a 
hidden allergen when it is unrecognized or not declared on the product label. This omission is 
not always intentional and there are many ways for allergens to be hidden in food, for 
example, through misleading labels, allergenic foods that can contaminate other safe foods, 
food that is listed by an uncommon term, and ingredient switching. The USA and EU 
legislations [2,3] on food labelling only refer to the allergenic foods added as known 
ingredients and do not prevent the unintentional presence of trace allergens.  
     The most sensitive method used to screen the presence of hidden allergens in food rely on 
enzyme-linked immunosorbent assay (ELISA) [4–6]. ELISA allows to obtain detection limits 
between 0.1 and 10 mg peanuts/kg matrix and is easy to use. However, the presence of false-
positive and false-negative results demands the availability of confirmatory methods. In 
addition, as well documented, the ELISA quantitative data are strongly dependent on the 
matrix tested leading to lack of accuracy, that still remains the main discussed analytical topic 
[7]. Liquid chromatography–tandem mass spectrometry (LC–MS/MS) has been proposed as 
confirmation technique to identify and also quantify proteins, but its major limitation still 
remains the low sensitivity achieved in complex matrices with respect to immunoassays [8–
11]. In a research program dealing with the development of new analytical strategies for the 
determination of hidden allergens in foods, we developed an ELISA-inductively coupled 
plasma mass spectrometry (ICP-MS) method [12] and a LC–electrospray (ESI) MS/MS 
method [8] for screening and confirmation purposes, respectively.  
     In particular,we demonstrated the potential of LC–ESI-MS/MS with triple quadrupole 
(QqQ) analyzer for the detection of peanut allergens (Ara h2 and Ara h3/4) in foods [8]. A 
proteomic bottom up-based approach based on the direct identification of Ara h2 and Ara 
h3/4, the biomarker peptides were used as a strategy to identify peanuts in complex food 
matrices. Selected reaction monitoring (SRM) analysis allowed to obtain very good selectivity 
in the biomarker peptide detection even with a low-resolution mass spectrometer by keeping a 
narrow mass window during precursor and product-ion transmission. This restriction allows 
to analyze complex digest extracts, even if it limits method sensitivity (0.5% (w/w) 
peanuts/matrix). In addition, besides ESI and LC column dirtying, a significant matrix effect 
reducing biomarker signal intensity was observed, affecting accuracy of the quantitative 
analysis.  
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     To achieve better sensitivity and accuracy of the LC–MS/MS method together with an 
improvement of column life-time, an efficient sample treatment step involving a purification 
and concentration of allergen proteins from complex matrices is needed. The procedures 
routinely used for the extraction of compounds from liquid or solid matrices (i.e. solid-phase 
extraction, solid–liquid extraction, etc.), despite their attractive features of simplicity and 
availability of supports, lack selectivity leading to a partial co-extraction of interfering 
substances. In addition, a multi-step treatment can lead to analyte loss. Recently, to enhance 
selectivity of the extraction procedure and improve accuracy of the LC–MS results, 
immunosorbent (IS) supports have been proposed for the different applications [13–16]. 
Based on the high affinity and selectivity of antigen–antibody (Ag–Ab) interactions, the IS 
materials allow a selective extraction of the target compounds from complex mixtures. A 
strategy based on immuno-recognition with materials combined with LC–ESI-MS/MS can 
therefore represent one of the most specific and sensitive analytical approaches to reach the 
analytical challenge of hidden allergen detection in foods.           
     Herein we propose an antibody magnetic bead (MB)-based method for the selective 
enrichment of Ara h3/4 protein in food extracts. Protein A-magnetic beads bound to 
monoclonal anti-Ara h3/4 antibodies were used as affinity probes to isolate the specific target 
protein. Further, we discuss a LC–ESI-MS/MS method with a linear ion-trap (IT) mass 
analyzer for the identification and determination of the Ara h3/4 peptide biomarkers in 
breakfast cereals. As a result, the combination of the use of magnetic affinity probes with LC–
ESI-IT-MS/MS analysis allows us to obtain an excellent sensitivity and selectivity for the 
identification and quantification of peanut as contaminant in this kind of food matrix. 
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EXPERIMENTAL SECTION 
 
     Chemicals. Anti-Ara h3/4 (Pn-b) monoclonal antibodies were obtained by using peanuts, 
which were roasted in shell to prevent molding and kindly provided by the Leibniz-Center for 
Medicine and Biosciences at the Research Center Borstel (Borstel, Germany). Antibody 
solutions were diluted with deionized water (Millipore, Bedford, MA, USA). Phosphate 
buffer (pH 8.0), acetonitrile (HPLC purity), and formic acid (analytical reagent grade) were 
purchased from Carlo Erba (Milan, Italy). Trypsin from bovine pancreas, leukine–enkefaline 
acetate hydrate, Trisma–HCl, Bradford reagent, bovine serum albumin (BSA), 
triethanolamine and DMP (dimethylprimelinidated·2HCl) were from Sigma–Aldrich (St. 
Louis, MO, USA). EDC {1-[3-(dimethylamino)propyl]-3-ethylcarbodiimide}was from Pierce 
(Bonn, Germany). A commercial ELISA kit (Veratox quantitative kit) specific for peanut 
allergens waspurchased from Neogen (Lansing, MI, USA) and used following the instructions 
given by the producers. 
     Samples. Roasted peanuts and different commercial breakfast cereals samples (cornflakes, 
breakfast cereals based on cereal flakes and dried fruit, cereal mix with fruit and chocolate, 
cereal mix with rice crispy and powder milk) were obtained at a local food store. The sample 
treatment and the LC–MS/MSmethods were developed and validated by using cornflakes free 
of peanuts. In all the other products used to test the method peanuts were not present as an 
ingredient and the labeling “may contain trace of nuts and soy”was reported. 
     Preparation of functional magnetic beads. Magnetizable polystyrene beads (diameter 
2.8±0.2 m, surface area 3–9 m2/109 beads) (Dynabeads, Invitrogen Dynal, Oslo, Norway) 
covalently coupled with recombinant protein A were used to capture anti-Ara h3/4 
monoclonal immunoglobulins G (IgG) for the small-scale purification of Ara h3/4 protein in 
food extracts. The antibody solution (100 L of a 1 mg/mL anti-Ara h3/4-IgG in sodium 
phosphate solution, 100 mM) was added to an Eppendorf containing 50 L of pre-washed 
protein A-magnetic beads. Incubation was performed at room temperature for 4 h to allow the 
binding of the Fc portion of the immunoglobulin to protein A. The protein A-anti-Ara h3/4 
IgG complex was isolated using the Dynal MPC (Invitrogen Dynal) magnet and washed twice 
with 500 L of 200 mM triethanolamine, pH 8.2. To ensure an efficient binding of the IgG to 
protein A, a crosslinking reaction was added to the procedure. Protein A-IgG complex was 
then incubated with 500 L of freshly made 20 mM DMP (dimethylprimelinidated·2HCl) in 
200 mM triethanolamine solution for 30min. Cross-linking reaction was quenched by 
isolating the magnetic beads and incubating with 500 L of 50 mM Tris–HCl pH 7.5 for 15 
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min. The beads were thus rinsed three times with 500 L of 100 mM phosphate buffer with 
0.02% Tween 20 before use. 
     Sample treatment. Peanut-containing food extractswere prepared by adding 10 mL of 100 
mM phosphate buffer to 1 g of ground sample. Proteins were extracted by shaking for 2 h at 
37°C, then the extract was centrifuged (3500×g, 5 min) and filtered on 0.2 m nylon filter 
before treatment with the magnetic beads. Sample extract (800 L) was incubated at different 
times (15min, 30 min, 1 h, 3 h and overnight) under slight agitation at room temperature with 
the protein A-IgG magnetic bead complex prepared as reported above. The beads were then 
washed three times with 500 L of 100 mM phosphate buffer, pH 8.0. After discharging the 
phosphate buffer, the beads-conjugated sample was then re-suspended in 60 L and digested 
with trypsin (5 L, 0.6 mM in 100 mM phosphate buffer) by using an accelerated microwave-
assisted digestion procedure (1 min, 700W) as reported in the literature [17]. The internal 
standard (5 L of 130 mM of leukine–enkefaline) was added to the solution just before LC 
analysis. 
     Liquid chromatography–ion-trap mass spectrometry. LC separation was carried out on a 
Poroshell C18 300 Å (75mm×2.1mm, 5 m particles) (Agilent Technologies, Santa Clara, CA, 
USA) using a gradient solvent elution system [(A) 0.1% (v/v) formic acid inwater/(B) 0.08% 
(v/v) formic acid in acetonitrile] as previously described [8]. The flow-rate was 200 L/min. 
The mobile phase was delivered by the Surveyor chromatographic system (ThermoElectron 
Corporation, San José, CA, USA) equipped with a 200-vial capacity sample tray. Injection 
volume was 50 L. A LTQ XL linear ion-trap instrument (ThermoElectron Corporation) 
equipped with a pneumatically assisted ESI interface was used. The system was controlled by 
the Xcalibur software. The sheath gas (nitrogen, 99.999% purity) and the auxiliary gas 
(nitrogen, 99.998% purity) were delivered at flow-rates of 45 and 5 arbitrary units, 
respectively. Optimized conditions of the interface were as follows: ESI voltage 3.5 kV, 
capillary voltage 20 V, capillary temperature 200°C. MS/MS experiments were performed 
under both product-ion and SRM conditions with a collision gas (He) pressure of 2.3×10
−3
 
mbar in the collision cell. In the product-ion scan mode the 200–1400 m/z range was 
monitored. The SRM transitions monitored were as follows: m/z 649/761 
(AHYQVVDSNGDR, Ara h3/4), m/z 695/977 (SPDIYNPQAGSLK, Ara h3/4) both operating 
with collision energy (CE) 35 eV. Leukine–enkefaline (m/z 557/397; CE 20 eV) was used as 
the internal standard. 
     Magnetic bead-LC–MS/MS method validation. Validation of the whole analytical 
procedure was performed on the fortified samples of breakfast cereals (mix of cereal flakes). 
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For this purpose, breakfast cereal samples were fortified with different peanut amounts and 
measurements were carried out by monitoring the most abundant MS/MS transition for each 
peptide as above reported. The detection limits (LODs) and the quantitation limits (LOQs) 
were calculated as the concentration of the two peptides corresponding to a signal-to-noise 
ratio (S/N) 3 and 10, respectively. Linearity was assessed in the 2.5–2500 mg peanuts/kg 
matrix range. Precision was evaluated by performing five independent extractions of 
cornflake samples fortified with 1 mg peanuts/kg matrix using the functionalized magnetic 
beads and by performing two LC–MS/MS injections for each extract. The matrix effect was 
assessed by comparing the slopes of an instrumental and a matrix-matched calibration curve 
applying a t-test. The matrix-matched calibration curve was obtained by analyzing the 
breakfast cereal sample extracts fortified with different peanut amounts and treated applying 
the whole analytical procedure. 
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RESULTS AND DISCUSSION 
 
     Liquid chromatography–ion-trap-tandem mass spectrometry method. This study started 
from the previously published results dealing with the ESI-MS behaviour of the biomarker 
peptides selected for Ara h2 and Ara h3/4 [8]. The biomarker peptides were previously chosen 
following different criteria (i.e. absence of missed cleavages, good ESI sensitivity, no post-
translational modification sites and detectability in both rawand roasted peanuts, sequence 
specificity) [8,11]. By analyzing a peanut protein aqueous solution, the LC–ITMS/MS profile 
of the peptides resulted to match that observed by LC–QqQ-MS/MS in terms of 
chromatographic behaviour and relative intensity. Also using the ESI-IT-MS instrument, the 
peptides chosen for Ara h3/4 exhibited a higher ionization efficiency with respect to those 
selected for Ara h2. On the basis of these 
results, in this work the immuno-strategy 
extraction method was developed targeting 
Ara h3/4 protein. The chromatographic 
profile of the two Ara h3/4 peptides showed 
both good peak shape and retention time 
stability [peptide of m/z 649 (tR 1.50±0.03 
min); peptide of m/z 695 (tR 8.76±0.17 
min)]. The identity of these two peptides 
was confirmed by both the doubly charge 
state detection, obtained by tuning the mass 
analyzer to higher resolution (UltraZoom 
scan) and by the ITMS/MS product-ion 
profiles. The MS/MS spectra exhibited 
several fragments of the y- and b-series to 
cover and confirm the peptide sequences 
(Fig. 1).  
By using the IT mass analyzer, product-ion and SRM acquisition modes were performed at 
the same time allowing simultaneously the unambiguous identification of the two peptides 
together with the quantitative analysis without loss of sensitivity. By contrast, when using the 
QqQ analyzer, as in the previous work, the production mode has lower sensitivity with respect 
to SRM acquisition mode due to the different duty cycles and did not allow to obtain 
qualitative information at low concentration levels [8]. These findings highlight the great 
appeal of the linear IT mass spectrometer for this application. 
 
 
Figure 1. LC–IT–MS/MS product-ion mass 
spectra of the doubly charged tryptic peptides of 
Ara h3/4: (A) m/z 649/761 
(AHYQVVDSNGDR) and (B) m/z 695/977 
(SPDIYNPQAGSLK). 
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     Development of the immunoaffinity-based Ara h3/4 extraction method. Isolation of target 
low-abundant proteins in foods containing a number of protein rich-ingredients (i.e. milk, soy, 
rice, eggs, etc.) represents a great analytical challenge. The use of cut-off filters or other 
traditional approaches (i.e. ultracentrifugation) does not allow to obtain target-enriched 
purified samples and in most cases loss of analytes can occur. The magnetic bead support 
functionalized with anti-Ara h3/4 monoclonal antibodies could represent an easy-to-use, fast 
and selective approach for extraction, purification and concentration of the target protein from 
complex mixtures.  
     In this work, different Ab-protein A-magnetic bead immobilization conditions were tested. 
Further, the optimization of the Ara h3/4 protein extraction from breakfast cereal samples free 
of peanuts fortified with different peanut amounts was performed. Selectivity of the 
monoclonal Abs used in this work has been previously tested in term of cross-reactivity with 
other food ingredients by ELISA-ICP-MS [12]. The results obtained evidenced an excellent 
Ag–Ab selectivity, thus proving the suitability of these monoclonal Abs for magnetic bead 
coating in this application.  
The efficiency of the protein A IgG binding 
reaction was initially tested by incubating the 
beads with the antibody solution (100 g Ab) 
at different times (1–5 h) with and without the 
cross-linking reaction. The antibody-coated 
beads thus obtained were incubated with a 
peanut protein aqueous solution (4 h) and the 
extract digested with trypsin by microwave-
assisted digestion (1 min, 700W). The LC–
MS/MS analysis of the peptides at m/z 649 and 
m/z 695 exhibited a significant increase 
(>40%) of their peak area in all the cases in 
which the IgG was covalently bound to the magnetic beads by the cross-linker. Further, the 
increase of the antibody incubation time from 1 to 4 h in the presence of the cross-linker 
allowed to obtain magnetic beads with the maximum extraction efficiency. No significant 
increases were observed from 4 to 5 h binding reaction (Fig. 2).  
In a further step of thework, the efficiency of the protein A-anti-Ara h3/4 IgG complex was 
studied by varying the amount of Abs (50, 70 and 100 g) while keeping the incubation time 
constant at 4 h. The best LC–MS/MS resultswere obtained using 100 g of antibody (data not 
shown). Confirmation of these findings was obtained by quantifying the antibody amount 
Figure 2. Plot of the Ara h3/4 LC–MS/MS 
peptide peak areas as a function of the antibody 
incubation time in the presence of the cross-
linker. 
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after the binding reaction with the beads using a Bradford assay with a standard IgG. In fact, 
we found the amount of anti-Ara h3/4 bound to be 15.1±0.7 g for 50 L bead solution. This 
result is in good agreement with the typical amount of antibody bound capacity of magnetic 
beads declared by the manufacturer (i.e. 50 L Dynabeads protein A are reported to isolate 
approximately 12–15 g antibodies).  
     In the past, the use of EDC reagent to activate terminal carboxyl groups was proposed to 
improve the antibody coating on protein A-magnetic beads [18]. On this basis, we tested the 
efficiency of EDC-activated magnetic beads following the procedure reported in the literature 
[16]. By analyzing a peanut protein aqueous solution (50 g peanuts/mL solution) no 
significant differences were observed between the magnetic beads prepared with and without 
EDC. These findings could be explained taking into account the results reported above about 
the typical amount of Ab bound to the beads that already reach an excellent value.  
By keeping the coating reaction time at 4 
h, the same amount of magnetic beads (50 
L of a 1.3 g/mL product density 
correspond to approximately 65 mg of 
beads) was used for the extraction of 
different volumes (200, 400, 600, 800, 
1200 and 1800 L) of peanut aqueous 
extract in order to evaluate both the 
trapping capacity of the functionalized 
support and the effect of different 
concentration factors. The sample was 
then incubated overnight. By keeping the 
sample concentration constant, itwas 
possible to observe a significant increase 
in the amount of trapped Ara h3/4 protein when sample volume increased from 200 to 800 
L, in particular for the peptide of m/z 695 (Fig. 3). Instead, by increasing the sample volume 
from 800 to 1800 L, no signal increase was observed. The peanut protein extract was 
quantified using a Bradford assay with BSA as the standard and the total protein 
concentration resulted to be around 7 mg/mL. This finding suggests that the magnetic beads 
prepared following a 4 h-Ab and cross-linker incubation protocol reach the saturation when 
800 L of a 7 mg/mL peanut protein extract are used as incubation sample.  
Figure 3. Plot of the Ara h3/4 LC–MS/MS peptide 
peak areas as a function of the sample volume 
(magnetic beads prepared by incubating the 
antibodies and the cross-linker for 4 h, sample 
incubation overnight, elution volume 70 L). Data 
corrected by the dilution factor. 
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     Further, different sample incubation times were investigated (15min, 30 min, 1 h and 3 h 
and overnight) using 800 L of aqueous peanut protein extract. The best results in terms of 
signal intensity and repeatability (RSD < 8%) were obtained by performing sample incubation 
for 3 h. No further signal increase was observed after the overnight incubation. As for 
selectivity, the overnight incubation of the magnetic beads without the Abs in a peanut 
aqueous extract resulted in a positive LC–MS/MS signal at the transitions monitored for the 
chosen peptides, suggesting the occurrence of non-specific binding. However, even if the 
results evidenced the capability of protein A to bind Ara h3/4, the MS signal was significantly 
lower (<10%) with respect to that obtained for the Ab-Ara h3/4 demonstrating that the Abs 
are required to reach an higher enrichment factor in the real samples. By keeping the sample 
incubation time at 3 h, a decrease of non specific interactions giving a signal comparable with 
that of the noise was observed. No decrease in capture efficiency was observed within 3 
weeks when the antibody-coated magnetic beads were kept at 4°C. The final scheme of the 
extraction procedure and sample analysis is reported in Fig. 4. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
       
     Method validation and application to the analysis of Ara h3/4 in breakfast cereal fortified 
with peanut. A good linearity with different sensitivity was established by using an aqueous 
peanut extract at different dilutions (percentages from 2.5 to 2500 g peanut/mL solution) for 
the two Ara h3/4 peptides (y = 29.2(±0.7)x, r
2
 0.988, n = 12 and y = 1.6(±0.2)x, r
2
 0.986, n = 
12 for the peptides at m/z 695 and m/z 649, respectively). The instrumental LOD and LOQ 
obtained for the peptide at m/z 695 exhibiting higher sensitivity resulted to be 0.8 and 2.5 g 
 
Figure 4. Scheme of the analytical protocol: Fe3O4-protein A-anti-Ara h3/4 IgG as affinity 
probes for selective enrichment and determination of Ara h3/4 protein from food sample 
using LC–ESI-MS/MS methods. 
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peanut aqueous extract/mL solution, respectively. Matrix-matched calibration curve 
calculated by using breakfast cereal fortified with different peanut amounts (percentages from 
0.001 to 0.25% w/w peanut/matrix corresponding to 10–2500 mg peanuts/kg matrix range) 
and treated with the magnetic beads exhibited an excellent linearity (y = 69.1(±0.9)x, r
2
 0.998, 
n = 12 and y = 3.4(±0.3)x, r
2
 0.997, n = 12 for the peptides at m/z 695 and m/z 649, 
respectively).  
     Trueness assessment allowed 
us to evidence a significant 
signal enhancement by 
comparing with a t-test the slope 
of the curve calculated 
analyzing the aqueous peanut 
extract and that of the matrix 
matched calibration curve 
(peptide at m/z 695 tcalculated = 
188, peptide at m/z 649 tcalculated 
=18, ttabulated,0.05,11 = 2.2). The 
slope of the matrix-matched 
calibration curve increased 
more than two times for both the peptides. This result 
can be explained on the basis of the effects of 
purification and enrichment of the samples when Ab-
coated beads are used. The LOD and LOQ obtained on 
matrix were 3 and 10 mg peanuts/kg matrix, 
respectively. The method precision expressed as RSD 
was lower than 8% when calculated at 10 and 100 mg 
peanuts/kg matrix concentration levels for all the 
peptides investigated. The method here developed was 
then applied for the detection of hidden peanut allergen 
Ara h3/4 in different commercially available breakfast 
cereal samples. In two out of seven samples (i.e. the 
cereal mix and the cereal mix with dried fruits, declared 
to “may contain traces of nuts”) the presence of Ara 
h3/4 was confirmed, and the other samples were found 
to be negative. The production mass spectra and the LC 
Figure 5. LC–MS/MS profile of a breakfast cereal (mix of 
cereal flakes) sample containing peanuts, treated with 
magnetic beads: Peaks: 1, peptide at m/z 649/761 and relative 
MS/MS product-ion mass spectrum (inset); 2, peptide at m/z 
695/977 and MS/MS product-ion mass spectrum (inset). 
SR
M
S
R
M
 
 
Fig. 6. LC–MS/MS profile of a 
breakfast cereal (mix of cereal 
flakes) sample containing peanuts 
without magnetic bead treatment. 
No signals corresponding to the 
two peptides investigated were 
detected. Chromatograms: 1, 
peptide at m/z 649/761; 2, peptide 
at m/z 695/977; 3, IS. 
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retention times were used to confirm the presence of peanut in samples (Fig. 5). In the 
positive samples, the peanut concentration was approximately 9.8±0.4 and 12.3±1.3mg/kg, 
respectively. The positive samples were analyzed by performing the same extraction 
procedure     without the use of magnetic beads. No signals corresponding to the two peptide 
investigated were observed at their corresponding retention times (Fig. 6). In a final step, the 
LC–MS/MS quantitative results were verified by testing the same samples with a 
commercially available ELISA kit to detect peanut hidden allergens. The ELISA datawere in 
agreement with those obtained by LC–MS/MS for positive and negative samples. In the case 
of the two positive samples, the ELISA screening data were 14.4±0.9 and 17±2mg/kg, 
respectively. Taking into account that the Veratox kit could over estimate samples [19], the 
ELISA data were consistent with those obtained by LC–MS/MS to indicate that 
thismethodwas successful in confirming the presence of hidden peanut allergens in breakfast 
cereals. 
 
CONCLUSIONS 
 
A strategy to coat protein A-magnetic beads with monoclonal anti-Ara h3/4 antibodies was 
devised. To our knowledge so far this is the first time that a selective antibody magnetic 
support is developed for enrichment of hidden peanut allergens. In conclusion, our 
methodology demonstrated numerous advantages. The application of immunomagnetic 
isolation of Ara h3/4 from complex matrices coupled with a microwave-assisted digestion 
resulted in the most fast and reliable method to purify, concentrate and digest sample extracts 
before LC–MS/MS analysis. The method works with a single monoclonal antibody with the 
linear ion-trap mass spectrometer as high selective detector. Taken together, the sensitivity 
and selectivity reached by the sample treatment method coupled with the LC–IT-MS/MS 
analysis developed (LOD 3mg peanuts/kg matrix) allow to propose a powerful method 
suitable to confirm the results of the ELISA screening procedures. 
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Chapter 2 
 
The ICP-MS Immunoassay Approach for Targeted 
Proteomic Analysis 
 38 
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2.1. ICP-MS as A Novel Detection System 
for Quantitative Element-Tagged Immunoassay 
of Hidden Peanut Allergens in Foods. 
 
 
Abstract. A novel ICP-MS-based ELISA immunoassay via element-tagged determination 
was devised for quantitative analysis of hidden allergens in food. The method was able to 
detect low amounts of peanuts (down to approximately 2 mg peanuts kg
−1
 cereal-based 
matrix) by using a europium-tagged antibody. Selectivity was proved by the lack of detectable 
cross-reaction with a number of protein-rich raw materials. 
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INTRODUCTION 
 
     Nowadays fluorescence-based enzyme-linked immunosorbent assay (ELISA) is the “gold 
standard” for general screening of food samples for allergen detection [1–3]. Recently, 
complementarydetection techniques have been developed for immunoassays [2]. Among 
these, inductively coupled plasma–mass spectrometry (ICP-MS) has been proposed for 
sensitive and quantitative element-tagged immunoassay for protein analysis in biological 
samples [4, 5]. Gold-cluster antibody and lanthanide (Eu, Tb, Dy,and Sm)-chelate antibody 
conjugates have been used to develop both direct competitive and non-competitive 
immunoassays, demonstrating that target human proteins can be detected at levels as low as 
0.1–0.5 ng/mL and that a linear response to protein concentration over 3 orders of magnitude 
can be obtained [4].  
     ICP-MS detection offers several advantages with respect to more conventional 
fluorescence such as lower matrix effects from other components of the biological sample, 
low detection limits, excellent linearity of the response, long-term sample storage, and 
capability of multiple analyte detection via different element tags. However, despite its 
potential up to now, metal-tagged ICP-MS immunoassay has not been applied for detecting 
and measuring food allergens and hidden allergens, i.e., those deriving from unintentional 
contamination during food manufacturing. In order to assist in the control of allergen levels in 
foods to acceptable levels, analysts require test methods designed to produce reliable 
analytical information using high-throughput instrumentation.  
     In this context the method developed in this work combines the advantages of the non-
competitive sandwich ELISA methods with the sensitivity and precision of ICPMS detection 
in quantitative protein analysis via elementtagged determination. The immediate result is an 
innovative and accurate method for the quantitative analysis of peanut proteins as hidden 
allergens in foods, having the ultimate goal of multiple allergen detection. Attention was 
focused on the determination of the Ara h1 and Ara h3/4 peanut proteins in cereal products. 
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EXPERIMENTAL SECTION 
 
     Reagents. Phosphate-buffered saline (PBS; 150 mM NaCl, 20 mM sodium phosphate, pH 
7.4), 0.01% Tween 20 in PBS, 7M nitric acid (Carlo Erba, Milan), Eu-labeled anti-mouse 
affinity purified rabbit polyclonal Abs (Delfia, Perkin Elmer Life Science, MA, USA) were 
used. The stoichiometry of the europium/antibody system was directly calculated in a range of 
Eu-labeled antibody concentrations (0.01–600 nM) by using an external calibration method 
with NIST-traceable europium standard solutions (High-Purity Standards, Charleston, SC, 
USA). The stoichiometry (10±2 Eu atoms) was found to be independent of the Ab 
concentration and in good agreement with that declared by the manufacturer (8 atoms of 
europium/antibody). Ara h1 and Ara h3/4 purified peanut proteins and anti-Ara h1 and anti-
Arah3/4 monoclonal antibodies were kindly provided by the Leibniz-Center for Medicine and 
Biosciences at the Research Center Borstel (Borstel,Germany). All antibody solutions were 
diluted with deionized water (Millipore, Bedford, MA, USA).  
      Instrumentation. Experimental measurements were performed on the ICPMS X SeriesII 
(Thermo Electron Corporation, Waltham, MA, USA) operating under Xt interface standard 
conditions. The instrument optimization was performed daily to assure a response of at least 
50,000 cps/ppb for indium and 80,000 cps/ppb for uranium in the high mass range. A GS50 
chromatographic pump (Dionex Corporation, Sunnyvale, CA, USA) was used to perform 
flow-injection analysis (FIA) with a 2% (m/v) nitric acid aqueous solution as a mobile phase 
delivered at a flow rate of 0.5 mL min
−1
. 
     Sample treatment. Peanut and peanut-containing food extracts were prepared by adding 25 
mL PBS to 1 g of ground sample. Proteins were extracted by shaking for 15 min at 60 °C, 
then centrifuged (14,000 rpm, 5 min) and filtered on 0.2-μm nylon filter. Milk, cacao powder, 
soy beans, tree nuts, rice crispies, cornflakes (all purchased in a big store), and cornflakes 
fortified with different amounts of peanuts were extracted by applying the same procedure. 
Using the BCA test the crude extracts were analyzed for protein content that was adjusted to 1 
mg mL
−1
 using PBS.Protein extracts were stored at 20 °C until analysis.  
     Immunoassay procedure. The assay format was based on an indirect ELISA using well-
plates coated with polyclonal antibodies targeting total soluble peanut proteins. Protein 
standard solutions and sample extracts diluted in PBS (100 μL) were incubated for 15 min at 
room temperature. After washing six times with 0.01% Tween 20 in PBS, two incubation 
steps were performed: the first with a mixture of the mouse anti-Ara h3/4 and anti-Ara h1 
antibodies and the second with the Eu-labeled anti-mouse antibodies. Each incubation step 
was carried out as for the sample. After digestion with 7M HNO3 (100 μL, 1 h, room 
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temperature), a 25-μL sample was injected into the FIA-ICP-MS system. To test cross-
reactivity, protein extracts of protein-rich raw materials (almonds, hazelnuts, walnuts, milk, 
soy beans) and other food products (cacao powder, cornflakes, rice crispies) commonly used 
in the food industry were analyzed. 
 
RESULTS AND DISCUSSION 
 
     The non-competitive sandwich ELISA ICP-MS assay is based on the determination of the 
element used to tag the antibody. The assay was constructed using polyclonal immunopurified 
antibodies as capture reagents and anti-Ara h1 
and anti-Ara h3/4 monoclonal antibodies (Ab I) 
for identification. Detection was performed with 
europium labeled rabbit anti-mouse polyclonal 
antibodies (Ab II). In the assay development, 
various parameters, such as Ab concentration, 
incubation time, and temperature, were shown to 
have a significant effect on method sensitivity.  
Ab I and Ab II concentrations were optimized as 
a function of the assay, since the results showed 
that the dynamic range of this method at low concentrations of antigen is limited by non-
specific binding. Results for the optimization of Ab I and Ab II concentration are reported in 
Table 1 and Figure 1.  
In fact, by increasing both reagent 
concentrations (Ab I from 20 to 200 μg 
mL
−1
; Ab II from 0.5 to 10 μg mL−1) 
and incubation times from 15 min up 
to 1 h, Eu signal increased 
significantly both when positive and 
negative controls were analyzed. 
Should be note that increase in signal 
for negative control at higher 
concentration of Ab II derives from the 
presence of the immobilized antibody onto ELISA plate. Infact Ab II reacts with all the 
mouse IgG, and antibody immobilized on the plate surface fall in this category. Then, when a 
lower antigen concentration is used or a negative control, the number of possible free site for  
Table 1: different concentration tested for 
optimization of Ab I and Ab II using a 25 
ng mL
-1
 of peanut proteins extract. 
Ab I  
( g mL
-1
) 
Ab II  
( g mL
-1
) 
 
153
Eu response(cps x 
s) 
200 10 326145(±85924) 
200 5 367631(±52313) 
100 5 363801(±27765) 
100 2 118065(±15729) 
100 1 76434(±7932) 
20 1 58062(±8982) 
20 0,5 36039(±11324) 
 
Figure 1: optimization of Ab II concentration with a 
fixed amount 100 g mL
-1
 of Ab I. Non-competitive 
ELISA was always performed with a 25 ng mL
-1
 of 
peanut proteins extract. 
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antibody-Ab II interaction is more favourite. 
So, a kinetic control must be applied to 
counter balance this undesiderate effect. 
Changes in the intensities of europium 
observed for the increase in the incubation 
times are shown in Fig.2. Incubation was 
carried out at room temperature and at 37 °C, 
but not significant differences were observed 
in terms of Eu signal intensity. These findings 
suggested that in order to detect very low 
amounts of antigen it is necessary to maintain 
a low background of Eu and a low amount of 
proteins that can form non-specific binding to 
the anti-Ara h1 and Ara h3/4 antibodies. 
Hence, optimal conditions were those 
obtained using the highest amount of 
antibodies tested and the lowest incubation 
time at room temperature. To determine 
method performance, peanut extracts 
containing known protein concentrations in 
the 3–25 ng mL−1 range were preliminarily 
tested. The results showed an excellent 
linearity (Fig. 3A) and the detection limit of 
the immunoassay method (determined as 3 times the blank standard deviation/slope of the 
calibration curve) calculated for raw peanut protein extracts was determined to be 1.5 ng 
mL
−1
. It is to be noticed that this value is directly affected by the binding affinity of the 
antibodies and by the non-specific background, since the ICP-MS instrumental detection limit 
for Eu-labeled Ab was as low as 0.1 ng mL
−1
. The ELISA ICP-MS method developed was 
then evaluated in matrix for linearity, detection limit, and selectivity using known 
concentrations of peanut in cornflakes. Peanuts could be detected in foods down to 
approximately 2 mg peanuts kg
−1
 matrix. Good linearity was demonstrated by ùusing matrix 
matching samples obtained by fortifying cornflakes with peanut in the range of 10–100 mg 
peanuts kg
−1
 matrix (r
2
 =0.998, n=10) (inset Fig. 3B). By exploring the linearity up to 700 mg 
peanuts kg
−1
 matrix, a saturation of the europium signal (corresponding to an Eu-labeled Ab 
concentration of 90 μg mL−1) was observed (Fig. 3B). Such findings indicate the limit of the  
B
 
Figure 2. Effect of incubation time on the 
incubation step with Ab II in the ELISA test 
for a negative control. Incubation time was A) 
1 hour, B) 30 minutes and C) 15 minutes. 
A
 
C
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plate immobilized antibody binding capability, 
since the response of the free in-solution Eu-labeled 
Ab was proved to be linear over the 2 ng mL
−1
 to 
100 μg mL−1 range. As for selectivity, the results 
obtained did not exhibit a detectable cross-reaction, 
demonstrating that the monoclonal antibodies used 
are very specific toward peanut proteins considering 
the food products reported in the “Experimental 
Section”. Further investigation on the cross-
reactivity will be carried out on other tree nuts and 
cereals. Taking into account that commercially 
available tests for peanut allergens have detection 
limits ranging from 0.1 to 2.5 mg peanuts kg
−1
 
matrix and that generally linearity is established in a 
narrower range [6], the ICP-MS-based method proposed is very promising, since it could 
guarantee adequate detection limits coupled with an improved linearity and reduced matrix 
effects.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3: A) ELISA test for an extract of 
peanuts protein in the 3–25 ng mL−1 
range; B) for a matrix of cornflakes up to 
700 mg peanuts kg
−1
 matrix. 
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CONCLUSIONS 
 
The capability of ICP-MS as a detection system for ELISA immunoassay in food analysis was 
proved. In particular, a selective and sensitive immunoassay able to detect low amounts of 
peanuts by using an Eu-tagged antibody was devised. The described immunoassay can be 
used as a quantitative tool to detect peanut proteins as hidden allergens in foods. In agreement 
with literature data [4, 5], the bottleneck of the resulting application was the immu- noassay 
protocol due to the non-specific reactivity of the reagents and lower detection limits could be 
reached by improving reagent quality. ICP-MS represent a powerful detection system from 
several points of view and namely in terms of sensitivity and precision of the quantitative 
data. Future perspectives are to exploit the capabilities of ICP-MS to perform multielement 
analysis by tagging directly the primary antibodies with different lanthanides and to develop a 
multi-tag ELISA assay able to simultaneously detect different allergens in food samples. 
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2.2. Metal-Tag ICP-MS Immunoassay and  
Liquid Chromatography – Eectrospray Ionization 
Tandem Mass Spectrometry: 
A Comparison 
 
Abstract. A comparison of two methods for the identification and determination of peanut 
allergens based on europium (Eu)-tagged inductively coupled plasma mass spectrometry 
(ICP-MS) immunoassay and on liquid chromatography/electrospray ionization tandem mass 
spectrometry (LC/ESI-MS/MS) with a triple quadrupole mass analyzer was carried out on a 
complex food matrix like a chocolate rice crispy-based snack. The LC/MS/MS method was 
based on the determination of four different peptide biomarkers selective for the Ara h2 and 
Ara h3/4 peanut proteins. The performance of this method was compared with that of a non-
competitive sandwich enzyme-linked immunosorbent assay (ELISA) method with ICP-MS 
detection of the metal used to tag the antibody for the quantitative peanut protein analysis in 
food. The limit of detection (LOD) and quantitation of the ICP-MS immunoassay were 2.2 
and 5 g peanuts g
-1
 matrix, respectively, the recovery ranged from 86  18% to 110  4% 
and linearity was proved in the 5–50 g g-1 range. The LC/MS/MS method allowed us to 
obtain LODs of 1 and 5 g protein g
-1
 matrix for Ara h3/4 and Ara h2, respectively, thus 
obtaining significantly higher values with respect to the ELISA ICP-MS method, taking into 
account the different expression for concentrations. Linearity was established in the 10–200 
g g
-1
 range of peanut proteins in the food matrix investigated and good precision (RSD 
<10%) was demonstrated. Both the two approaches, used for screening or confirmative 
purposes, showed the power of mass spectrometry when used as a very selective detector in 
difficult matrices even if some limitations still exist, i.e. matrix suppression in the LC/ESI-
MS/MS procedure and the change of the Ag/Ab binding with matrix in the ICP-MS method. 
 48 
INTRODUCTION 
 
     Food allergies and related syndromes are one of the arising health issues in western 
countries:
[1]
 recent estimations show that the affected population can be up to 1.5%.
[2]
 Nuts, 
and namely peanuts,
[3]
 are the major players in the food allergy scenario, even resulting in 
fatalities both in infants and adults.
[4]
 Unfortunately, no effective clinical treatment is known, 
only relief of adverse symptoms. For this reason, prevention, i.e. a strict dietary control, is the 
only effective measure to be taken in the cases of severe allergy and therefore an accurate 
declaration of ingredients on food labels is essential, as stated in recent legislative changes 
aimed at improving consumer protection such as the European Union (EU) legislation on food 
labeling that came into force in November 2005 (EU Directive 2003/89/EC amending 
Directive 2000/13/EC).  
     Taking in account that accidental contamination with allergens can occur during food 
manufacturing or handling of the raw materials,
[5]
 fast and reliable analytical methods are 
required to asses allergen levels in the final products. Although the fluorescence-based 
enzyme-linked immunosorbent assay (ELISA) is regarded as the „gold standard‟ for general 
screening of food samples for allergen detection,
[6,7]
 and it is presently used as the official 
screening method, several problems such as selectivity, accuracy and cross-reactivity lead to 
severe limitations in the applicability of this screening technique. Several approaches have 
been proposed to overcome these issues,
[8]
 such as complementary detection techniques,
[9]
 
real-time polymerase chain reaction or proteomics-based ones.  
     Recently, inductively coupled plasma mass spectrometry (ICP-MS) via element-tagged 
immunoassay has been proposed as a selective and sensitive detection technique for 
immunoassays.
[10,11]
 ICP-MS detection have several advantages if compared with 
conventional fluorescence, such as lower matrix effects caused by the other food components, 
low detection limits, excellent response linearity, long-term sample storage, and the capability 
of a multi-analyte detection using different elemental tags. However, few applications of the 
metal tagged ICP-MS immunoassay have been reported,
[10–16]
 and the potential of the 
technique has not been fully assessed up to now.  
     To overcome some limitations of immunoassay techniques in terms of false positive or 
false negative results, confirmatory methods are needed. In this case the selectivity of mass 
spectrometry could be of great benefit in identifying peanut proteins even in complex matrices 
and could be used for confirmation purposes. Very recently, the advantages of liquid 
chromatography/electrospray ionization tandem mass spectrometry (LC/ESI-MS/MS) 
methods for the detection of peanut allergens in various food matrices have been 
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demonstrated.
[17–19]
 A proteomics-based approach based on the direct identification of Ara h1 
was used as a new strategy to identify peanuts in food matrices.
[17,18]
 To improve the 
selectivity and thus the confirmation criteria in the allergen identification more than one target 
could be selected.
[19]
 For this reason our research group developed a LC/ESI-MS/MS method 
with a triple quadrupole analyzer for the identification and determination of two of the major 
peanut allergens in food: Ara h2 and Ara h3/4.
[20]
 In this paper we discuss a comparison of the 
two methods recently developed by our group, based respectively on Eu-tagged ICP-MS 
immunoassay
[11]
 and on LC/ESI-MS/MS identification, and determination of Ara h2 and Ara 
h3/4 
[20]
 applied to a complex food matrix like a chocolate rice crispy-based snack. 
 
EXPERIMENTAL SECTION 
 
     Materials. Phosphate-buffered saline (1x PBS; 150mM NaCl, 20mM sodium phosphate, 
pH 7.4), 0.01% Tween 20 in 1x PBS, 7M nitric acid (Carlo Erba, Milan), Eu-labeled anti-
mouse affinity purified rabbit polyclonal Abs (DELFIA1, Perkin Elmer Life Sciences, MA, 
USA) were used. The holmium standard solution (1000 mg L
-1
) used for ICP-MS was 
purchased from High-Purity Standards (Charleston, SC, USA). Ara h2 was purified from 
toasted peanuts following a procedure reported in the literature.
[21]
 Ara h1 and Ara h3/4 
purified peanut proteins and anti-Ara h1 (Pn-t) and anti-Arah3/4 (Pn-b) monoclonal 
antibodies raised against proteins purified from toasted peanuts were kindly provided by the 
Leibniz Center for Medicine and Biosciences at the Research Center Borstel (Borstel, 
Germany). All antibody solutions were diluted with deionized water (Millipore, Bedford, 
MA, USA). Acetonitrile (HPLC purity), trifluoroacetic acid and formic acid (analytical 
reagent grade) were purchased from Carlo Erba (Milan, Italy). Trypsin from bovine pancreas 
was from Sigma-Aldrich (St. Louis, Missouri, USA). Toasted peanuts and food products 
(chocolate/rice crispy-based snacks) used in this work were obtained at a local food store. 
 
Apparatus and procedures. 
     ELISA ICP-MS method. The assay format was based on indirect ELISA using well-plates 
coated with polyclonal immunopurified antibodies targeting total soluble peanut proteins. The 
immunoassay and flow-injection analysis (FIA)-ICP-MS procedures are described in detail in 
a previous paper.
[11]
 Briefly, the sample solutions were incubated for 15 min at room 
temperature in to well-plates coated with polyclonal immunopurified antibodies targeting total 
soluble peanut proteins. After washing, two incubation steps were performed: the first with a 
mixture of the mouse anti-Ara h3/4 and anti-Ara h1 monoclonal antibodies (Ab I) and the 
 50 
second with the Eu-labeled anti-mouse polyclonal antibodies (Ab II) for detection. After 
digestion with 7M HNO3 (100 L, 1 h, room temperature), 25 L samples were injected into 
the FIA-ICP-MS system. Limits of detection and quantitation were calculated as three and ten 
times the standard deviation of blank solution on the slope of the calibration curve, 
respectively. Linearity was tested in the 2.5–500 g peanuts g-1 matrix range. Accuracy was 
evaluated both in terms of matrix effect and recovery. In particularly, a t-test was used to 
compare the slopes of calibration curves built up in the range 2.5–50 (n = 15) g peanuts g-1 
matrix and by using aqueous peanut protein solutions. The recovery experiments were carried 
out both on unspiked food matrix and on the same matrix fortified with peanuts at three 
different concentration levels (5, 20 and 50 g peanuts g
-1
 matrix). Recovery was expressed as 
the ratio percentage of the determined total peanut concentration to the added peanut 
concentration. Precision expressed as percentage coefficient of variance (CV%) was  
calculated by carrying out the extraction procedure on three samples and performing three 
FIA-ICP-MS analyses for each sample. Experimental measurements were made on an ICP-
MS X SeriesII (Thermo Electron Corporation, Waltham, MA, USA) equipped with the trigger 
card and operating under Xt interface standard conditions. The instrument optimization was 
performed daily in the high mass range to assure a response of at least 50 000 counts per 
second (cps)/mgL
-1
 for indium and 80 000 cps/mgL
-1
 for uranium in the high mass range. A 
GS50 chromatographic pump (Dionex Corporation, Sunnyvale, CA, USA) and an EV750-100 
inert injection valve (Rheodyne, Rohnert Park, CA, USA) were used to perform fully 
automated FIA with a 2% (m/v) nitric acid aqueous solution as the mobile phase delivered at 
a flow rate of 0.5 mL min
-1
. Both isotopes of 
151
Eu and 
153
Eu together with the 
165
Ho signal 
used as internal standard (10 g L
-1
) were monitored in the experiment. For qualitative and 
quantitative purposes the signal of 
153
Eu was considered. The operating parameters of the 
ICP-MS instrument were as follows: RF power 1400 W; coolant gas flow 15.5 L min
-1
; 
auxiliary gas flow 0.98 L min
-1
; nebulizer gas flow 0.87 L min
-1
; transient; nickel standard Xt 
cones; TRA data acquisition mode: dwell time 100 ms; duration time 60 s, standard 
resolution.  
      Liquid chromatography/triple quadrupole tandem mass spectrometry. LC elution was 
carried out on a Poroshell C-18 with pore size of 300 Å column (75 x 2.1 mm, 5 m particles) 
(Agilent Technologies, Santa Clara, CA, USA) using a gradient solvent system [(A) aqueous 
formic acid 0.1% (v/v)/(B) 0.08% (v/v) formic acid in acetonitrile] as previously described.
[20]
 
The flow rate was 200 L min
-1
. The mobile phase was delivered by a 2690 series Alliance 
chromatographic system (Waters, Milford, MA, USA) equipped with a 120 vial capacity 
sample tray. Injection volume was 30 L. A Quattro LC triple quadrupole instrument 
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(Micromass, Manchester, UK) equipped with a pneumatically assisted ESI interface was used. 
The system was controlled by MassLynx software version 4.0. The nebulizing gas (nitrogen, 
99.999% purity) and the desolvation gas (nitrogen, 99.999% purity) were delivered at flow 
rates of 55 and 500 L h
-1
 respectively. Optimized conditions of the interface were as follows: 
ESI voltage 3.5 kV, cone voltage 35 V, RF lens 0.3 V, source temperature 130 °C, 
desolvation temperature 250 °C. MS/MS experiments were performed underm single reaction 
monitoring (SRM) conditions with a collision gas pressure of 2.3 x 10
-3
 mbar in the collision 
cell. The SRM transitions monitored were as follows: m/z 807/1050 collision energy (CE) 35 
eV (CCNELNEFENNQR, Ara h2), m/z 950/1120 CE 35 eV (CMCEALQQIMENQSDR, Ara 
h2), m/z 649/1089 CE 30 eV (AHYQVVDSNGDR, Ara h3/4), m/z 695/700 CE 35 eV 
(SPDIYNPQAGSLK, Ara h3/4). Leucine-enkephalin was used as internal standard (m/z 
557/397; CE 20 eV).  
     Sample treatment. Peanut-containing food extracts were prepared by adding 25 mL of 1 x 
PBS to 1 g of ground sample. Proteins were extracted by shaking for 15 min at 60 °C, then 
centrifuged (14000 rpm, 5 min) and filtered on 0.2 m nylon filter. The whole sample 
treatment procedure for the subsequent ELISA-ICP-MS method is described fully by Careri et 
al.
[11]
 In the case of the LC/ESI-MS/MS method
[20]
 peanut containing food extracts were 
prepared by adding 10 mL of 0.2M Tris HCl (pH 8.2) to 1 g of ground sample. Proteins were 
extracted by shaking for 2 h at 60°C; then the extract was centrifuged (14000 rpm, 5min) and 
filtered on a 0.2- m nylon filter. Sample concentration was performed on a 5 kDa molecular 
weight (MW) cut-off filter (Millipore, Billerica, MA, USA) by adding 5 mL protein extract 
and reducing the volume to 0.5 mL. The sample was then digested with trypsin (5 L, 0.6mM 
in Tris HCl, pH 8.2) for 24 h at 50°C before injection into the LC system.  
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Results and Discussion 
 
     Performance of the ELISA-ICP-MS based method. A non-competitive sandwich ELISA 
with ICP-MS detection was previously developed for screening purposes to detect hidden 
peanut allergens in food.
[11]
 The assay, which is based on the determination of the element 
used to tag the antibody, exhibited good performances in terms of detection limits, linearity 
and selectivity on cornflakes. In addition, ICP-MS analysis conditions were carefully 
evaluated. Due to the small sample volume available and the nature of the samples, the FIA 
mode was chosen. The FIA mode offers several advantages in the sample analysis since it 
easy to use, there is no sample loss and it is a high-throughput analysis. With this 
configuration, it was observed that the introduction of digest samples into the ICP source 
toward a LC mobile phase flow did not cause any significant clogging in the nebulization 
system and in the sample cone, usually seen in the normal analysis mode: this could more 
likely due to the high nitric acid residual concentration. However, a significant memory effect 
on the europium signal coming from the six-port injection valve was observed, probably due 
to the sample sticking on the peek parts: it was necessary to inject 7 M nitric acid twice before 
introduction of the next sample to decrease the background noise to the level usually observed 
(700 cps). Such a configuration allows the analyses of a high number of samples to be 
performed making ICP-MS suitable for a rapid screening detection.  
The method performance was further 
investigated considering a more 
complex matrix based on chocolate, 
milk and rice. The detection and the 
quantitation limits were 2.2 and 5 g 
peanuts g
-1 
matrix, respectively. In 
contrast to ELISA-UV reading, by 
injecting 25 L aliquots into the ICP 
source, the signal reading for each 
sample is performed on three different 
aliquots of the each well-plate sample 
to account for the variability in the FIA-ICP-MS method. Assessment of the dynamic 
response range in the 5–500 g peanuts g-1 matrix range evidenced linearity between 5 and 40 
g g
-1
, since a signal saturation starts to occur at the 50 g g
-1
 level as shown in Figure 1. 
 
 
 
Figure 1: ICP-MS ELISA calibration curve obtained 
by using chocolate/rice crispy-based matrix fortified 
with different amounts of peanuts (2.5–160mg peanuts 
g
-1
 matrix range). 
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Trueness of the measurements was found to be affected by the presence of matrix effect on 
the antigen/antibody (Ag/Ab) binding and thus on the ICP-MS response of Eu-labeled Abs. 
By performing a t-test on the slope values of the matrix-matched calibration curve and the 
slope of the curve obtained by aqueous dilution of peanuts extracts, a significant difference at 
the 95% confidence level (t-calculated = 48, t-tabulated12, 0.05 = 1.78) was highlighted. 
Namely, regression equations evidenced that in the presence of matrix (Y = 3913  140X) a  
20% signal suppression was observed with respect to that obtained analyzing aqueous peanut 
extracts (Y = 4874  160X) to indicate a lower Ag/Ab binding in the presence of matrix 
interferences. The lowering in the Ab/Ag binding in such a complex extract compared to 
aqueous peanut solutions was also observed by analyzing the same matrix with a 
commercially available ELISA kit (Veratox quantitative peanut allergen test; Neogen 
Corporation, Lansing, MI, USA) based on colorimetric UV detection. This result strongly 
supports the critical role of the matrix on immunoassay performance and the lack of accuracy 
of quantitative analysis. For this reason the recovery values were calculated by using the 
standard addition method. Excellent recovery values were obtained on the three concentration 
levels tested (5 g peanuts g
-1
 matrix: 86  18%; 20 g peanuts g
-1
 matrix: 110  4%; 50 g 
peanuts g
-1
 matrix: 89  2%). From these results it should be noticed that there is a significant 
increase in recovery precision as the peanut concentration increases, suggesting a better 
repeatability of data at higher fortification levels.  
     As far as the cross-reactivity is concerned, the analysis of several food components 
(hazelnuts, Brazil nuts, almonds, walnuts, pecan nuts, macadamia, milk, soybeans, cacao 
powder) showed no significant effects and demonstrating that the monoclonal Abs used are 
very specific toward peanut proteins.  
 
     Performance of the LC/ESI-MS/MS method. The availability of triple quadupole mass 
spectrometers has significantly increased in the last decade and the selectivity of operating 
acquisition modes can allow identification of peptides in complex matrices even without high-
resolution data. The capability of the LC/MS/MS method as a confirmatory tool is strongly 
related to its sensitivity. As for the immunoassay the sensitivity depends on the Ag/Ab 
binding affinity and thus on the quality of reagents used, in the case of the LC/ESI-MS/MS 
method this is strongly related to the ionization efficiency of selected peptides and to the 
presence of matrix suppression effects in the ESI source. In this work, a sudden degradation 
of performance in terms of MS/MS analyte response was observed after a few LC runs of the 
food sample extracts dependent on the source rapidly becoming dirty. In order to make 
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detection and quantification limits less dependent on the effects of the matrix complexity, it 
clearly appears that a more selective sample enrichment treatment is required.  
However, by operating under SRM conditions, LOD and LOQ values for the peptide of Ara 
h3/4 at m/z 695 
[SPDIYNPQAGSLK] were 1 and 
3.7 g protein g
-1
 matrix, 
respectively. Figure 2 shows the 
SRM chromatograms of peptide 
m/z 695/700 [SPDIYNPQAGSLK, 
Ara h3/4] in a chocolate/rice 
crispy-based matrix fortified with 
different amounts of peanuts. 
Detection and quantitation of the 
peptide biomarker of Ara h2 at m/z 
807 [CCNELNEFENNQR] led to 
poor sensitivity; LOD and LOQ 
values being 5 and 14 g g
-1
, 
respectively. Accordingly, better sensitivity was observed for the peptides selected for Ara 
h3/4 ( y = 10.48  0.23x and y = 
3.78  0.12 x; m/z 695 
[SPDIYNPQAGSLK] and m/z 649 
[AHYQVVDSNGDR], 
respectively) with respect to those selected for Ara h2 (y = 4.23  0.22x and y = 2.68  0.18x; 
m/z 807 and m/z 950 [CMCEALQQIMENQSDR], respectively). Excellent linearity was 
demonstrated for all the peptides selected by spiking the matrix extract with 1–20% peanut 
extract. Good method precision for all the peptide biomarkers investigated was obtained, the 
relative standard deviation (RSD) being lower than 10% (n =  10) when measurements were 
performed in the model food extract fortified with 1.25 and 5% w/w peanuts/matrix. The 
signals for the Ara h2 peptides were found to be strongly affected by ion suppression (from 
30–50%), whereas this drawback was more negligible in the case of the detection of Ara h3/4 
peptides (lower than 10%). The use of an internal standard allowed a reduction in the matrix 
effect of between 5% and 30% for the measurement of Ara h3/4 and Ara h2 peptides, 
respectively. The method was proved highly specific in the matrix investigated as a 
consequence of the specificity of the peptide biomarkers selected. Performing a search in 
protein databases, the sequences of the selected peptides were found to be unique for peanuts. 
 
Figure 2. LC/ESI-QqQ-MS/MS SRM chromatograms of the 
peptide m/z 695/700 [SPDIYNPQAGSLK, Ara h3/4] in a 
chocolate/rice crispy-based matrix fortified with different 
amounts of peanuts: (A) 20 g g
-1
; (B) 4 g g
-1
; and (C) 1 
g g
-1
.  
 
 55 
     Comparison of the ELISA-ICP-MS and LC/ESI-MS/MS methods and conclusions. In this 
work mass spectrometry is presented as a detection technique for either screening and 
confirmation purposes. Findings highlight that this technique has versatility in different 
approaches for the detection and determination of hidden peanut allergens. Even though the 
methods used have two different purposes, they share some major limitations. In fact, their 
application to a complex matrix pointed out that in both cases trueness of the quantitative 
analysis is strongly influenced by the food under investigation and the complexity of the 
matrix still remains the main determining factor to improve detectability. In particular, as 
discussed before in the case of the LC/MS/MS method, the whole food matrix extract is 
injected into the LC system causing a significant signal suppression effect on the analyte 
signals at the ESI interface with respect to the signal obtained by analyzing standard 
solutions. In the case of the ELISA the matrix is able to influence the Ag/Ab binding by 
reducing the amount of bound protein.  
     It should be remarked that the reasons for the lack of accuracy demonstrated for the two 
methods have different origin. In the case of the LC/MS/MS method the main limitation is 
related to the working principle of the ESI source; by contrast, in the ICP-MS-based method, 
no significant instrumental drawbacks were observed apart from the memory effect on the 
injection valve, and the bottle-necks were found to be related to the immunoassay. As for the 
LOD values, very good detection was obtained with ICP-MS detection even by using an Ab 
not optimized for this kind of detection, whereas, in the case of the LC/MS/MS method, 
poorer sensitivity was observed. These findings suggest that actually the immunoassay still 
represents the most powerful technique for the evaluation at trace level of hidden allergens in 
foods. On the other hand the development of a sample treatment able to enrich Ara h2 and 
Ara h3/4 extract content could allow a significant improvement in the LOD values of the LC 
method and fully take advantage of the highly selective MRM analysis. 
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Chapter 3 
 
Elemental Labeling of  
Monoclonal Antibodies for Multiplexed 
ICP-MS Targeted Proteomic 
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3.1. Multiplexed Determination of Protein 
Biomarkers Using Metal-Tagged Antibodies and 
Size-Exclusion Chromatography – Inductively 
Coupled Plasma mass Spectrometry (SEC-ICP-MS) 
 
 
 
 
Abstract. A liquid-phase immunoassay was developed for the simultaneous determination of 
five cancer biomarker proteins: alpha-fetoprotein (AFP), human corionic gonadotropin (hCG), 
carcino-embryonic antigen (CEA), ovarian tumour antigen (CA125/MUC16) and 
gastrointestinal tumor antigen (CA19-9). The method was based on the incubation of a serum 
(or tissue cytosol) with 5 antibodies, each labelled with a different lanthanide (Pr
3+
, Eu
3+
, 
Gd
3+
, Ho
3+
 and Tb
3+
, respectively) followed by the specific determination of the 
immunocomplex formed by size-exclusion chromatography with inductively coupled plasma 
mass spectrometric detection (SEC-ICP-MS). The sensitivity of the method was comparable 
with those attainable by ELISA or radioimmunoassay with the advantage of multiplexed 
analysis capacity, virtually no sample preparation and sample amount consumption ca. 3-
times lower than an ELISA test. The method was validated for the analysis of the proteins in 
human serum and proved to be able to discriminate ovary and uterus tumour tissue samples 
from those of healthy subjects. 
 60 
 
 61 
INTRODUCTION 
 
     The needs for the detection of low-level molecular biomarkers of disease and the 
monitoring of the efficiency of drug treatment are the driving force for the development of 
methods allowing absolute quantification of proteins (ideally several at the same time) in 
clinical samples, such as, e.g. human serum and biopsy tissues (1-2). The two principal 
classes of methods include immunoassays, based on the use of antibodies, using fluorescence 
(ELISA) or radioactivity (RIA) detection (3), or methods based on the use of isotopically 
labelled tags (ICAT or ITRAQ) followed by electrospray or MALDI mass spectrometry 
measurement (4). The procedures are relatively complex and suffer from the difficulties with 
multiplexing (immunoassays) or insufficient sensitivity or specificity for low level protein 
determination in biological matrices (molecular MS methods).  
     Elemental MS, in particular inductively coupled plasma mass spectrometry (ICP-MS), 
associated with the appropriate tagging strategies offers a number of features of interest for 
quantitative proteomics, including high sensitivity even in complex samples with reduced or 
lacking matrix effect. In addition, the availability of having up to one hundred elemental 
isotopes which can be simultaneously discriminated by ICP-MS allows multiplexing detection 
(5-6). The ICP-MS sensitivity and the possibility to produce a quantitative signal have been 
used in the concept of Metal Coded Affinity Tag (MeCAT) (7-8).  The reagent, bearing a 
lanthanide incorporated as a DOTA complex, reacted to form covalent complexes with –SH 
containing proteins which were enzymatically degraded to produce specific peptides. The 
latter could be quantified via the lanthanide signal but a parallel identification step by 
molecular MS was necessary which reduced the field of practical applications.  
     Considerable attention has been paid to the tagging of antibodies with an ICP-MS 
detectable element, absent in biological matrix (9-11). Antibodies react with antigens with an 
extremely high degree of specificity even in complex matrices. The activity of the metal-
tagged antibodies was shown to be preserved on the condition of a careful optimization of the 
labelling procedure. The tagging was usually achieved with a rare earth element introduced as 
a stable DOTA chelate (12-13) but other elements, such as Au and Ag, and more recently I 
and Hg were also used (14-17). Metal-tagged antibodies have been successfully used for the 
detection of two allergenic proteins of peanuts in food (18-19) in ELISA or for detection of 
specific proteins in Western Blot applications (20). Tissue imaging was successfully obtained 
combining laser ablation ICP-MS and immunohystochemistry techniques with labelled 
antibodies on tissue slides as well tissue microarray for cancer biomarkers (21-22). A unique 
attractiveness of ICP-MS is the possibility of straightforward multivariate (multiplex) analysis 
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owing to the simultaneous use of different tags for the different proteins and no overlap of the 
tags of different antibodies as developed for a massive multivariate single-cell bio-assay for 
detection of surface antigens in leukemia stem cells (23-29).  
     The above methods are based on a heterogeneous reaction (usually between an 
immobilized antigen and antibody in solution) and require tedious and error-prone preparation 
procedure including washing steps. During the development of the immunoassay the washing 
steps deserve particular attention, since in optimized conditions of antibody concentration and 
incubation time, they affect accuracy of the analysis as a consequence of possible high values 
of background with consequent poor sensitivity. 
     In this study, for the first time, size-exclusion chromatography with inductively coupled 
plasma mass spectrometric detection (SEC-ICP-MS) was proposed for the multiplexed 
determination of protein biomarkers using metal-tagged antibodies. The objective of this 
research was to find conditions in which a number of target proteins could be simultaneously 
determined as their complexes with antibodies directly in the sample matrix without any 
sample pre-treatment, such as e.g. solid-phase extraction or washing steps. For this purpose, 
we have made use of, on one hand, the selectivity of ICP-MS allowing the simultaneous 
determination of several rare-earth elements (each tagging a different antibody), and, on the 
other hand, of the selectivity of high-resolution size-exclusion LC allowing the on-line 
separation of the protein-antibody complex from the unreacted antibody and degradation 
products of the labelling reagent.  Size-exclusion LC has been extensively used in 
combination with classical detection systems like UV-VIS or fluorescence spectroscopy, to 
study antigen-antibody reactivity (30-35). Those studies showed the ability of size exclusion 
chromatography to perform qualitative and quantitative analysis in complex matrix. However, 
they were limited to a single antibody-antigen interaction at a time because of the co-elution 
of the immunocomplexes of different proteins, as well of the free antibodies, and the inability 
of detection systems to discriminate signals from different analytes. Here, we are proposing a 
generic procedure for a straightforward liquid-phase immunoassay allowing the determination 
of five established cancer biomarkers (AFP, hCG, CEA, CA125 and CA19-9) based on the 
reaction with a cocktail of antibodies, each tagged with a different lanthanide, and size-
exclusion ICP-MS.  
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EXPERIMENTAL SECTION 
  
Samples, Reagents and Salts. Proteins, serum and tissue lysates. Full length alpha-
fetoprotein (AFP) purified from human cord serum was from Abcam (Cambridge, UK). 
Ovarian tumor antigen (CA125/MUC6), gastrointestinal tumor antigen (CA19-9), 
carcinoembryonic antigen (CEA), human chorionic gonadotropin (hCG) were obtained from 
Sigma-Aldrich (St. Quentin-Fallavier, France). The proteins are known as established cancer 
biomarkers (36-37). The proteins were divided into single work aliquots immediately upon 
reception and stored at –20°C. Control human sera with a declared amount of tumour 
biomarkers were obtained from Data Medical Service (Milan, Italy). Samples of water-soluble 
fraction of lysates from ovaric and uterus tissues, both from tumoral (74 and 72 years old 
women with ovary carcinoma at unknown stage and uterus adenocarcinoma of 2nd degree, 
respectively) and healthy subjects were from Imgenex (San Diego, CA) and were purchased 
from Histoline (Milan, Italy). They were received in lysis buffer (phosphate buffer saline pH 
7.4 containing 0.25% sodium deoxycholate, 0.1% SDS, 1 mM of EDTA, Na3VO4, NaF and 
PMSF, and 1 g mL
-1
 of aprotin, pepstatin-A and leupeptin). The declared total protein 
concentration was 1 mg mL
-1
. Tissue lysates, received frozen, were thawed, divided into 
single work aliquots and stored at –20°C. 
 Antibodies. Rabbit polyclonal anti-mouse (whole molecule) IgG Europium labelled 
(DELFIA) was from Perkin Elmer Life Science (Waltham, MA). Mouse ascitic fluid 
containing a declared 2 mg mL
-1
 of IgG was from Sigma-Aldrich (Schelldorf, Germany). 
Mouse IgG anti-human monoclonal antibodies (mAb) for -CA19-9 (clone M39026), -
CA125 (clone X325), -AFP (clone AFP-01), -hCG (clone HCG1) and -CEA (clone 
1C11) were purchased from Abcam (Cambridge, UK). All mAbs were obtained in liquid form 
as IgG or protein A purified fractions. Upon reception, mAbs were divided into single 
working aliquots and stored at –20°C. 
 Labelling reagents. 1,4,7,10-tetraazacyclododecane-1,4,7-tris-aceticacid-10-maleimido-
ethylacetamide (DOTA) was purchased from Macrocyclics (Dallas, TX). Lanthanide 
chlorides (LuCl3, HoCl3, PrCl3, EuCl3, TbCl3, GdCl3) with natural isotopic abundances were 
from Aldrich (Schelldorf, Germany). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) 
and N-succinimidyl-S-acetylthioacetate (SATA) were from Pierce (Rockford, IL). 
Hydroxylamine (>99%) was from Fluka.  
 Salts and buffers. Analytical grade ammonium acetate, sodium phosphate monobasic 
(NaH2PO4), tris-(hydroxymethyl) aminomethane hydrochloride, sodium chloride, ethylene-
diaminotetraacetic acid disodium salt (EDTA) were purchased from Sigma-Aldrich (St. 
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Quentin-Fallavier, France). Buffers used were: ammonium acetate buffer (100 mM, pH 6.8 as 
elution buffer and 20 mM, pH 6.0 for metal complexation), phosphate buffer (100 mM, pH 
7.2, 2.5 mM EDTA), Tris buffer saline (20 mM Tris-HCl, 0,45% NaCl, pH 7.0), phosphate 
buffer saline (10 mM in phoshate, 150 mM in NaCl pH 7.4, 2.5 mM EDTA), deacetylation 
buffer (100 mM phosphate, 150 mM NaCl, 10 mM EDTA, pH 7.4). Ultrapure water 18 M  
cm from a Milli-Q system (Millipore, Bedford, MA) was used throughout the work. 
 
Instrumentation. An Agilent model 1200 binary pump, equipped with an autosampler, 
automatic injection system with a loop of 900 L and a UV-VIS detector was used as solvent 
delivery system. The system was controlled by Agilent ChemStation software. The ICP mass 
spectrometer was an Agilent 7500 CE fitted with a Meinhardt nebulizer. The exit of the 
column was connected by means of PEEK tubing to the ICP-MS nebulizer. Nanosep 
centrifugation tubes with low protein membrane and a 30 kDa cut-off (Pall, USA) were 
purchased from VWR International (Milan, Italy). Centrifugation vials were used throughout 
the work for washing steps and buffers exchange during labelling procedure of antibodies. 
 
Procedures. Mouse monoclonal IgGs anti human -AFP, -CA125, -CA19-9, -CEA and -hCG 
were labelled with Pr
3+
, Ho
3+
, Tb
3+
, Gd
3+
 and Eu
3+
, respectively. 
 Labelling of antibodies by the TCEP method. An aliquot of antibody (40 g, 266 
pmol) was washed on a cut-off filter by centrifugation (1 x 500 L, 10000 rpm, 6 minutes) 
with phosphate buffer, recovered at 1 mg mL
-1
 (6.6 M) and incubated with 6-fold molar 
excess (1.6 nmol, 40 M) of TCEP  at 37°C for 30 min to reduce disulphide bridges. The 
antibody was quickly washed (1 x 500 L) with Tris buffer saline to remove the TCEP in 
solution by centrifugation and resuspended in the same buffer at 1 mg mL
-1
. An aliquot of 0.5 
L DOTA dissolved in DMSO (24.1 mM) was added in 50-fold molar excess (12 nmol, final 
concentration 320 M ) and the mixture was incubated at 37°C for 1 h. Then, the mixture was 
washed by centrifuge with Tris buffer saline (500 L) twice to remove excess of unreacted 
DOTA, and resuspended in 20 mM ammonium acetate buffer (pH 6.0). An aliquot of LnCl3 
was added to reach 1 mM concentration and the mixture was incubated at 37°C for 30 min. 
The tagged antibody was extensively washed by centrifugation with Tris buffer saline to 
remove excess of free metal and was recovered at a nominal concentration of 0.5 mg mL
-1
. 
 Labelling of antibodies by the SATA  method. An aliquot of 40 g (266 pmol) of mAb 
was extensively washed by centrifugation with phosphate buffer saline (to remove NaN3 used 
as preservative which could quench the subsequent reaction) and recovered at 1 mg mL
-1
. An 
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aliquot of SATA solution in DMSO at a desired molar excesses of 10, 20 and 50 fold (2.6, 5.3 
and 13 nmol, respectively) was added and the mixture was incubated at ambient temperature 
for 1 h. The SATA-modified mAb was washed by centrifugation with phosphate buffer saline 
on the cut-off filter and resuspended at 1 mg mL
-1 
in the same buffer. The solution was 
deacetylated with 1:10 v/v of hydroxylamine solution by incubation at room temperature for 2 
h. The mixture was washed by centrifugation and the mAb was resuspended in Tris buffer 
saline. An aliquot of mDOTA in DMSO (24.1 mM) was added and the mixture was incubated 
for 1 h at 37°C. The mixture was centrifuged for wash out unreacted reagents with Tris buffer 
saline and resuspended in 20 mM ammonium acetate buffer (pH 6.0). An aliquot of LnCl3 
was added to reach the metal concentration of 1 mM and the mixture was incubated for 30 
min at 37°C. The tagged-mAb was washed by centrifugation extensively with Tris buffer 
saline and recovered at the concentration of 0.5 mg mL
-1
. Element tagged-antibodies were 
stored at 4°C in Tris buffer saline until use. 
 Multiplexed determination of the protein biomarkers in human serum and tissue lysates. A 
sample serum aliquot (30 µl) containing 0-100 international units (UI) per mL
-1
 of protein was 
incubated overnight at 4°C with a mixture of labelled antibodies at nominal concentration 10 
g mL
-1
 and subsequently analysed by SEC-ICP-MS.   
Tissue lysates were diluted with serum to make the biomarkers concentration fall into the 
analytical range. Several dilutions were tested.  
 Size-exclusion chromatography ICP-MS. The proteins were separated on a size exclusion 
column Superdex  200 HR 10/30 (10 mm x 300 mm x 13 m beads size) with the 
approximate bed volume of 24 ml and a declared linear separation range 10-600 kDa for 
globular proteins (GE Healthcare). The column was calibrated with a mixture of thyroglobulin 
(670 kDa), holo-transferrin (81 kDa), bovine albumin (66 kDa), chicken egg albumin (44 
kDa), Mn superoxide dismutase (39.5 kDa), Cu/Zn superoxide dismutase (32.5 kDa), 
carbonate dehydratase (29 kDa) and myoglobin (16.7 kDa) using UV/VIS detection at 280 nm 
with baseline evaluation at 800 nm. Retention times (in min) plotted versus the logarithm of 
molecular mass (in kDa) gave a straight line (y = -0.134 x + 4.385; r
2
=0.992).  Separations 
were carried out isocratically at 0.5 mL min
-1
 using 100 mM ammonium acetate (pH 6.8) as 
mobile phase. ICP-MS conditions were: plasma gas (Ar) 15 L min
-1
, forward power 1500 W, 
carrier gas 1.05 L min
-1
. The performance of the system was checked to respect the 
manufacturer indications for 1 µg L
-1
 
7
Li
+
, 
89
Y
+
 and 
205
Tl
+
 in 2% HNO3, with a dwell time of 
100 ms for each isotope. Double charge ion and oxide levels were opitimized on 
140
Ce
+
 and 
were classically <2 %. The isotopes monitored (in time resolved analysis mode with a dwell 
time of 100 ms each) were 
141
Pr, 
151
Eu, 
153
Eu, 
157
Gd, 
158
Gd, 
160
Gd, 
159
Tb, and 
165
Ho. 
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RESULTS AND DISCUSSION 
 
     The principle of the analytical approach is based on the quantitative formation of a stable 
complex between the protein to be determined and the metal-labelled antibody added to the 
sample. In order to be determined by ICP-MS, the immunocomplex formed needs to be 
separated from any other chemical forms of the labelling metal, such as, e.g. unreacted 
antibody or its reaction products with other sample components. Owing to the elemental 
(isotopic) specificity of the ICP-MS several proteins can be determined in the same time 
provided that the antibody for each of them is tagged with a different element or isotope, and 
there are no isobaric interferences among them.  
     The method development has included the following steps: (i) synthesis of antibodies 
labelled with the different metal ions; (ii) choice of the reaction conditions of the antibodies 
with the target proteins in the samples to allow a linear increase of the signal as a function of 
the antigen concentration; and (iii) choice of the sample introduction system allowing the 
introduction of the antigen-labelled antibody unaccompanied by any other species of the 
tagging metal.  
 
     Size-exclusion LC – ICP-MS for studies of antibody labelling and reactivity. A highly 
cross-linked agarose and dextran gel was preferred to silica gels in order to minimize 
interactions of the stationary phase with metal and assure the high recovery of antibodies. The 
column used (10-600 kDa) allowed to obtain the separation of the unreacted antibody (150 
kDa) and the high MW antibody – antigen complex used for quantitative analysis and to 
monitor with adequate resolution the release of the metal-bearing complex (mDOTA). The 
use of the ICP-MS detector allows the following of the reaction between the antibody and the 
antigen during the labelling reaction and the quantification of the complex. The concentration 
of the mobile phase (0.1 M ammonium acetate) was high enough to reduce the interactions 
between the proteins and the stationary phase and low enough to assure good nebulization in 
ICP-MS (36).  
     The feasibility of SEC-ICP-MS was first evaluated by studying a commercial rabbit anti-
mouse Eu-tagged IgG antibody. The chromatogram (Fig. 1a) shows a number of peaks when 
a solution of this tagged antibody was injected. Antibody signal was found at 23 min when a 
theoretical value of 23.5 min was expected as calculated from column calibration curve. 
Another peak of same intensity was found at 40 min, falling out from column separation 
range (< 10kDa). This signal was identified as impurity of commercial labelled antibody in 
the form of free DOTA-Eu complex. To confirm this hypothesis, DOTA-Lu was injected as 
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pure solution as well mixed with Eu-tagged IgG antibody and its elution profile (Fig. 1b) 
fitted reasonably with the unknown peak found 
in the chromotogram of Eu-tagged antibody. To 
be note that the size exclusion LC is unable to 
differentiate between the compounds DOTA-Lu 
and DOTA-Eu, and DOTA-Lu was choosen in 
order to observe the eventual exchange of 
lanthanides between DOTA complexes. As 
these compounds interact with the stationary 
phase and elute well after the total volume of 
the column slight shifts in the elution volumes 
can be observed. This was further washed 
extensively by centrifugation on 30 kDa filter 
and the purified form was incubated with mouse 
ascitic fluid containing a declared 2 mg mL
-1
 of 
IgG in order to observe i) elimination of free 
DOTA-Eu, ii) formation of stable complex 
between the two antibodies and iii) behaviour of 
immunocomplex in SEC, since the separation 
depends from size and shape of analytes. From 
the chromatogram of sample incubated (Fig. 1c) free DOTA-Eu was found at very low level 
as effect of high efficiency of washing steps. In addition, the elution profile shows a new peak 
at 20 min corresponding to a calculated molecular mass of 300 kDa, which represents the 
formation of an immunocomplex involving one rabbit Eu-tagged IgG with one mouse 
antibody biomolecule (150 kDa each). Another peak appeared at 30 min, giving back a 
nominal molecular mass of 70 kDa which fit well with albumin. Since it is capable to bind 
free metal complex present in IgG-Eu-tagged antibody solution and it is present at high 
concentration in ascitic fluid, a bind of free metal complex occurs. The recovery of europium 
from the column was 90 %. Column was found able to discriminate between unbound/bound 
antibody and free residue labelling reagent and therefore suitable for our purpose.  
 
     Effect of the incubation medium. Contrary to the existing methods, the solubility of the 
analytically useful immunocomplex is critically important in the liquid phase assay developed 
in this work. Indeed, poorly soluble immunocomplex may precipitate on the column filter 
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Fig. 1: Size-exclusion chromatograms of a) 
IgG-Eu-tagged antibody (30 g mL
-1
); B) 
DOTA-Lu 1 ppb; C) rAb-Eu tag (50 g mL
-1
) 
incubated with ascite fluid containing 2 mg 
mL
-1
 mouse IgG overnight at 4°C. 
Immunocomplex, free Eu tag IgG and free 
DOTA-metal complex are indicated by dotted 
lines 1, 2 and 3 respectively. 
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which would result in a decrease in sensitivity. The solubility of an Ab-Ag complex is known 
to decrease with the increasing molecular size and depends on the incubation medium. 
 Fig. 2 shows the effect of various incubation medium (differing in ionic strength, surface 
tension and protein concentration) on the signal intensity of the immunocomplex in SEC-ICP-
MS. The data show that the presence of surfactant or protein has a significant effect on the 
signal intensity. The 
composition of human 
serum virtually stabilizes 
the immunocomplex, 
thus significantly 
enhancing the SEC-ICP-
MS signal. Aspecific 
background was found to 
depend on the incubation 
medium. In the case of 
Tween 20, the 
nonspecific signal could result from the dimerization of antibody molecules as a consequence 
of hydrophobic interactions. By testing control human serum, cross-reactivity of the method 
here developed was demonstrated to be within 20%. The recoveries of the immunocomplex, 
measured as the ratio of the metal fraction recovered after chromatography exceeded 70% and 
were reproducible within 5%. Centrifugation of the sample before chromatography did not 
affect the recovery.  
 
     Synthesis of metal-labelled antibodies and verification of their stability and activity. The 
set of 5 proteins chosen for the method development consisted of alpha-fetoprotein (AFP, 
MW=70 kDa), chorionic gonadotropin (hCG, MW=40 kDa), ovarian tumor antigen 
(CA125/MUC6, MW=500 kDa), gastrointestinal tumor antigen (CA19-9, MW=360 kDa) and 
carcinoembryonic antigen (CEA, MW=200 kDa). Monoclonal antibodies developed towards 
the whole protein molecules and tested to allow the recognition of the target protein in native 
state were acquired in different immunoassay formats with limited cross-reactivities, in order 
to be  tagged with metal ions. The antibodies belong to the same class (mouse anti-human 
IgG), their structure consisting of two heavy chains and two light chains connected by a 
variable number of disulphide (S-S) bridges and supramolecular interactions (37).  
     The two methods of tagging investigated were based on the introduction of a lanthanide 
ion as a stable complex with the DOTA ligand. One was based on the reaction of the DOTA 
0 20 40 60 80 100 120 140 160 180
Tris buffer saline
Ammonium acetate 100mM
Tween-20 (0,1%)
Human serum albumin 1%
Human serum albumin 10%
Human Serum
Intensity (
165
 Ho) cps  x 10
4
 
Fig. 2: Effect of different incubation media on the signal intensity of 
the immunocomplex of CA125 with the corresponding Ho-tagged 
antibody. White dotted bars: control samples (non CA125 added); 
shadowed bars – in the presence of CA125. Error bars correspond to 
three measurements. 
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maleimide pendant arm with –SH groups generated by selective reduction with 
tris(carboxyethyl)phosphine (TCEP) of disulphide bonds of the antibody as described 
elsewhere (23). The other one was based on the initial introduction of –SH groups onto the 
antibody surface by reacting aminogroups of lysine with N-succinimidyl-S-acethylthioacetate 
(SATA) followed by the hydrolysis of the thioether to generate a free thiol group. The two 
procedures, referred below as TCEP and SATA procedures, are schematically illustrated in 
Fig.3. 
  
 
     
 As a function of the methods chosen, different regions of the mAb which may have impact 
on its biological activity (reactivity) towards the antigen are modified. A trade-off between 
the number of metal ions introduced per antibody molecule (the more the higher the 
sensitivity) and the preservation of the biological activity of the antibody is necessary. The 
success of the mAb tagging approach was verified by checking the stability of the labelled 
antibody in reaction conditions useful for the possible release of the metal, and by checking 
its reactivity with regard to the antigen. Then the results for the TCEP and SATA procedures 
were compared in terms of detection limits. 
 
     Stability of the labelled antibodies. Fig. 4 shows chromatograms obtained by the tagging 
of the five antibodies with the different lanthanides for the proteins studied. Regardless of the 
lanthanide used for tagging, they show one Gaussian peak at the same elution volume (23 
min) corresponding to the molecular mass of the antibody. No trace of free DOTA reagent 
TbCl3 (CA19-9)
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Figure 3: Scheme of the antibody labelling procedure used. 
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(otherwise eluting at 40 min) is observed indicating that the Ab-bound lanthanide is the only 
chemical form of the metal introduced into the system. The chromatograms remain unchanged 
by incubation (at 4 °C and 37 °C) in a control serum matrix showing the stability of the metal-
labelled antibody in the matrix to be analysed. 
Aspecific background was found negligible in 
most cases as human serum used for incubation 
was declared from healthy subject. Only in the 
case of AFP chromatogram, a significant 
aspecific background was evidenced in the 
appearance of a peak representing Ab-Ag2 
complex. We address this aspecific signal to the 
fact that AFP is thought to be the pre-albumin 
during fetal development and shows a high 
degree of sequence homogeneity with albumin. 
However, no aspecific background was found in 
the region of heavier immunocomplex used for 
quantification. 
 
     Reactivities of the tagged antibodies with the 
antigens. The study of the reaction of the tagged 
antibodies with the proteins of interest was 
carried out by SEC-ICP-MS by the analysis of 
mixtures containing the antigen and the antibody 
at different concentration ratios. The equilibrium 
of the reaction of the mAb-Ag complex 
formation is strongly shifted to the right (pH 7-
10) which means that the mAb-Ag2 complex 
should be observed when a 2-fold excess of the 
antibody is present unless the activity of the 
second binding site is reduced because of the steric hindrance. A typical set of chromatograms 
obtained for the proteins of interest is shown in Fig. 5 . 
    They represent two types of morphologies. For small proteins [AFP (70 kDa) and HCG (40 
kDa)] three peaks are present whereas for the larger three proteins [CA125 (>500 KDa), 
CA19-9 (>360 kDa) and CEA (200 kDa)] only two peaks are present. In all the cases a peak 
of the unreacted tagged-antibody can be observed, either because of the excess of the antibody 
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Fig 4: SEC-ICP-MS chromatograms of the 
labelled antibody by TCEP method. a) Pr-
tagged AFP mAb; b) Eu-tagged hCG mAb; 
c) Gd-tagged CEA mAb; d) Tb-tagged 
CA19-9 mAb; e) Ho-tagged CA125 mAb. 
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used or because of its partly deactivation during tagging. The middle peak in the case of AFP 
and HCG corresponds to the mAb-Ag2 stoichiometry. The most intense peak corresponds to a 
large immunocomplex eluting in the void corresponding to the mAb-Ag network. Because of 
the protein size, the mAb-Ag2 peak for the three antigens of large size co-elutes with the 
mAb-Ag network in the void. The mAb-Ag network peak was found to be a suitable measure 
of the Ag concentration in the sample. Its 
formation was favoured by sample incubation 
overnight at lower temperature (4 °C). Hence 
this condition was preferred to incubation at 37 
°C.   
 
Detection limits and choice of the tagging 
procedure. The trade-off between the tagging 
efficiency and the preservation of the biological 
activity which is the measure of the method‟s 
sensitivity was probed as a function of the molar 
excess of the reagent allowing the –SH available 
for the reaction with the lanthanide-DOTA 
complex. In order to optimize the TCEP 
procedure four aliquots of mAb -CA125 (1 mg 
mL
-1
) were reduced with 2, 4, 8, and 40-fold 
molar excess of TCEP, respectively. Taking into 
account that each S-S reduction producing two -
SH groups, 4-fold molar excess of DOTA 
maleimide ligand was then added. Similarly, for 
the SATA procedure three mAb -CA125 
aliquots were made to react with the 10, 25, 
and 50-fold molar excess of SATA. Each of 
the aliquots was further subdivided, made to 
react with different amounts of antigen (0-100 
UI mL
-1
) in human serum  and analysed by 
SEC-ICP-MS. The extrapolation of the peak 
intensity as a function of the antigen 
concentration allowed the calculation of the 
detection and quantification limits summarised in Table 1.  
a
b
c
d
e
1 2 3x 10
2
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x 102
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x 103
 
Fig. 5: SEC-ICP-MS chromatograms (one 
injection) obtained after incubation of a 
human serum sample spiked with the five 
proteins of interest with a mixture of the 
corresponding tagged antibodies. 1- high 
molecular weight (HMW) immunocomplex; 
2 -  low molecular wheight (LMW) 
immunocomplex (Ab-Ag2); 3 - unreacted 
antibody. a) Pr-channel (AFP); b) Eu-channel 
(hCG); c) Gd-channel (CEA); d) Tb-channel 
(CA19-9); e) Ho-channel (CA125). 
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The data show the maximum 
sensitivity when a 4-8-fold molar excess of 
TCEP (with regard to the antibody) was 
used. At lower TCEP concentrations, the 
competition from unlabelled antibody 
results in a decrease of sensitivity whereas 
at higher TCEP concentrations a similar 
effect is apparently caused by the 
denaturation of the antibody. The excess of 
SATA required to obtain a similar sensitivity is much higher and not detectable 
immunocomplex signal is obtained at the 10-fold molar excess. At the 50-molar excess 
dimerization of antibody was observed. It resulted in a peak in the SEC-ICP-MS 
chromatogram (not showed) at the elution volume similar to that of the immunocomplex 
rendering data interpretation difficult. As the SATA labelling procedure was also more 
affected by changes in pH and temperature and required more steps, it was found less 
attractive and was abandoned despite slightly lower detection limits. The 6-fold molar excess 
of TCEP finally chosen leads theoretically to the incorporation of 12 metal atoms (DOTA 
complexed) per one molecule of antibody.  
 
     Optimization of the concentration of the tagged-antibody: choice of the linear response 
range. The optimum Me-Ab concentration should be as small as possible in order to minimize 
the background deriving from 
aspecific interaction with matrix 
component and at the same time be 
able to produce a quantificable signal 
for the lowest antigen concentration, 
but it should be large enough to assure 
the linear response in the range up to 
the highest concentration of interest. 
In order to determine the analytically 
useful working concentration of 
labelled antibody, solutions 
containing nominal concentrations of 
1, 5, 10,  25, and 50 g mL
-1
 of Me-
Ab were prepared and incubated with the minimum concentration of wished-to-be-determined 
        
    Molar excess   LOD (UI mL
-1
) LOQ 
       
TCEP  2 x  24.1  80.3 
  4 x  11.7  39.1 
  8 x  12.3  41.0 
  40 x  23.9  79.5 
       
SATA  10 x  n.d.  n.d. 
  25 x  9.1  30.4 
    50 x   8.0   26.8 
  
Table 1: Comparison of TCEP and SATA 
effects on LOD and LOQ for CA125 antigen. 
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Fig. 6: determination of optimal metal tagged antibody 
concentration for CA125 antigen in human serum. 
Square: signal of unbound antibody; circle: signal of 
immunocomplex. Error bars correspond to three 
measurements. 
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antigen (30 UI mL
-1
) and the maximum concentration of wished-to-be-determined antigen 
(500 UI mL
-1
) respectively. Fig. 6 shows the increasing of the immunocomplex signal (circle) 
and free antibody (square) at increasing concentration of the latter: a signal distinctly different 
from the background was obtained for 30 UI mL
-1
 of antigen at the Me-Ab concentration of 5 
g mL
-1
. 
This concentration was however insufficient to assure a linearly increased response above 30 
UI mL
-1
 and needed to be increased twice. The Me-Ab concentration of 10 g mL
-1
 allowed 
the quantification of antigen concentrations up to 500 UI mL
-1
 which was satisfactory for the 
analytical purposes.  
 
     Linearity and figures of merit. The linearity and figures of merit were determined by 
establishing calibration graphs for the five biomarker proteins, each in a concentration range 
of interest in clinical sample analyses. The linear concentration range tested, regression data 
and the extrapolated limits of detection (LOD, 3 for blank matrix slope) and limit of 
quantification (LOQ, 10  for blank matrix slope) are given in Table 2.  
 
 
 
The data shows that the method developed using metal-tagged antibodies across the optmized 
6-fold molar excess of TCEP procedure, is able to detect tumor biomarkers down to the levels 
below the treshold reference values used routinely in clinical analysis to discriminate between 
healthy and disease states (38-39). The sensitivities are comparable with those attainable by 
commercially available ELISA assays (GenWay Biotech, San Diego CA) with the advantage 
of multiplexed analysis capacity. Virtually, no sample preparation and a sample quantity ca. 
3-times less than an ELISA test is required. 
 
     Validation of the liquid-phase immunoassay for the multiplexed determination of 
biomarker proteins in human serum. The simultaneous determination of several biomarker 
 
 
Antigen   Concentration range   Healthy Reference *   Linear Regression         Sensitivity     ELISA Kit ** 
            y = m ( ± S.E.) + b ( ± S.E.)   r 
2   LOD    LOQ   LOD ext 
               
AFP  2 - 110 ng / ml  < 20 ng / ml  y = 2218 (± 143) + 9750 (± 6069)  0.9796  8.2  27.4  2 
               
hCG  3 - 130 mUI / ml  < 5 mUI / ml  y = 3865 (± 60) + 72328 (± 3851)  0.9988  3.0  10.0  2 
               
CEA  0.8 - 50 ng / ml  < 5 ng / ml  y = 9393 (± 430) + 114990 (± 8048)  0.9898  2.6  8.6  1 
               
CA19-9  2 - 100 UI / ml  < 40 UI / ml  y = 9289 (± 903)+ 122069 (± 34168)  0.9378  6.0  20.0  10 
               
CA125   2 - 100 UI / ml   < 35 UI / ml   y = 7366 (± 468) + 217974 (± 41626)   0.9649   8.5  28.3   5 
 
Table 2: Linearity and limits of detection. 
 
* Treshold values for helathy/pathologycal antigen concentration. ** Expected declared. 
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proteins is useful in preliminary cancer diagnostics and monitoring chemotherapy. Table 3 
shows the results of the validation of the multiplexed protocol developed for the 5 proteins of 
interest, each at three concentration levels obtained by mixing a control serum with a serum 
sample containing certified levels of tumor 
biomarkers.  
The typical precision was below 5% for the 
antigens explored and the recovery is 
quantitative. The precision is slightly 
degraded at low and high levels of antigens 
which may require reoptimisation of the 
working concentration range in some cases.  
 
Application of the SEC-ICP-MS 
immunoassay to the discrimination between 
healthy and malignant tissues. The method 
developed was applied to the simultaneous 
quantitative determination of the five 
biomarkers in human uterine and ovarian 
tissue cytosols. Cytosol samples were diluted with human serum and as the biomarker 
concentrations were unknown different dilutions from 6 to 600 folds were tested in order to 
fall within the linearity range of the calibration graph. The dilution factors of 100-200 fold 
were eventually applied.  
Carcinoma and healthy tissues were analysed in 
parallel and the data are summarized in Fig. 7. In 
uterus adenocarcinoma samples (Fig. 7a) no 
difference between the healthy and malignant 
tissue cytosols was observed for AFP, CEA and 
CA19-9 as expected as since these proteins have 
not been brought in reference to this type of 
cancer. Despite the fact that hCG is elsewhere 
reported as potential biomarker in this kind of 
pathology, in this case similar high levels were 
found both in the healthy and malignant tissues.. 
A reliable discrimination was obtained by using 
CA125 concentration, this protein has been 
 Antigen     Accuracy       Precision 
    [Ag]added [Ag]calc   Recovery %   (± ) 
        
AFP  4.1 3.8  91  2.8 
(ng/mL)  16.5 19.4  118  1.9 
  49.4 45.9  93  5.9 
        
hCG  3.3 2.5  77  0.2 
(mUI/mL)  26.7 27.1  101  2.4 
  100.0 102.8  103  14.1 
        
CEA  1.6 1.8  110  0.4 
(ng/mL)  16.3 16.5  101  1.5 
  32.7 33.0  101  4.2 
        
CA19-9  14.1 14.3  101  1.6 
(UI/mL)  35.2 36.4  103  2.8 
  70.5 71.5  101  8.4 
        
CA125  11.7 12.1  103  2.7 
(UI/mL)  39.0 36.4  93  2.4 
    62.4 61.4   98   8.4 
  
Table 3: Validation of the multiplexed protocol. 
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Fig. 7: a) biomarkers profile of uterus tissue 
lysate and b) ovary tissue lysate. White 
dotted bars: healthy tissue; shadowed bars: 
tumoral tissue.  
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recognised elsewhere as a useful biomarker of the uterus cancer (38).  
Regarding the ovary carcinoma samples (Fig. 7b) the concentrations of all proteins except 
AFP are distinctly different in the healthy and malignant tissues. If hCG, CA19-9 and CA125 
are well-recognised biomarkers (38-39), the utility of the CEA protein as been less discussed 
since its utility depends also from different factors which are not correlate with the tumor 
presence. As example, CEA is normally found at high levels in smokers (> 10 ng mL
-1
), as 
well in a number of different chronic pathologies. For these reasons, its presence doesn‟t 
represent a sure discrimination between healthy/disease samples. 
 
 
CONCLUSIONS 
 
Size-exclusion chromatography – ICP-MS was proved very useful technique for the accurate 
and precise determination of the complexes formed by metal-labelled antibodies with target 
proteins. The chromatographic separation efficiency allows the analysis of a serum matrix 
directly upon incubation with the antibody with no additional sample preparation. The 
isotopic specificity of ICP-MS makes the multiplexing of the assay possible by using 
antibodies tagged with different isotopes for the different proteins and of general use for 
detection of water-soluble proteins. The sensitivity of the method developed for the 
simultaneous determination of five biomarker proteins characteristic of uterine and ovarian 
cancer is comparable with those attainable by ELISA or RIA assays with the advantage of 
multiplexed analysis capacity, virtually no sample preparation and sample amount 
consumption ca. 3-times lower than an ELISA test. Owing to the multielement detection 
capability of ICP-MS at the time-scale of the chromatographic peak obtained, the method 
developed can be extended to a larger number of proteins (at least 20 or so) to be measured at 
the same time provided that antibodies are available and tagged with the different isotopes. 
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3.2. Determination of Labeling Stoichiometry 
for Elemental Tagged Monoclonal Antibodies  
by High Resolution- Indutively Coupled Plasma 
Mass Spectrometry 
 
 
 
Abstract.  The introduction of elemental labelled antibodies for multiplex determination of 
proteins in complex samples by ICP-MS detection, open the way for a massively multivariate 
analysis. Howhever, the core of immunoassay rely as first in the optimization of labeling 
procedure, since the succesful introduction of elements together with the retain of biological 
activity are the engine-drive on the global sensitivity of the method. Also if a number of 
procedures for antibody modification are well established, the stoichiometry of modification 
(i.e. the ratio metal/antibody) is not simply asses by the common spectrophotometric assays. 
Making full use of High Resolution-ICP-MS capability to measure sulphur overcoming the 
problem of polyatomic interferences, a method for the determination of labeling stoichiometry 
is presented. The natural sulphur content deriving from protein backbone (cysteines and 
methionines) is used as reference value to normalize the antibody concentration after 
elemental labeling and purification steps. By the simultaneous quantification of sulphur and 
lanthanides used for labeling purposes, the stoichiometry metal/antibody is extrapolated. The 
case of labeling by modification of disulphide bridges in antibody‟s hinge region is taken into 
account and the results of 3.1  0.3 metal atoms per antibody, well correlate with the expected 
modification.   
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INTRODUCTION 
 
      Recently, elemental mass spectrometry, especially with inductively coupled plasma ions 
source (ICP-MS) has been introduced as analytical technique in the field of proteomic 
analysis. We developed a method for multiplexed determination of proteins in different 
samples (human serum and tissue lysates) performing a liquid phase immunoassay with 
detection of immunocomplexes by high resolution size exclusion chromatography (SEC) and 
ICP-MS by the use of metal labelled monoclonal antibodies. SEC was found able to 
discriminate between the boun/unbound forms of labelled antibodies, and also provides useful 
informations regarding homogeneity of labeling procedure and purity of antibody preparation. 
Indeed, after labeling and purification procedure the injection of antibodies onto the SEC-
ICPMS system, results in a single symmetric peak at the  expected corresponding to the 
expected antibody molecular weight and no other species containing the metal were observed. 
Howhever, the effect and homogeneity of labeling were checked indirectly performing an 
immunoassay and evaluating the effect of labeling extent on the gobal sensitivity of the 
method. Since labeling procedure represents the key step to retain the biological activity of 
antibody and therefore it determines the success of the immunoassay, the importance of sites 
and degree of modification is relevant. In these terms, the determination of labeling 
stoichiometry might provides additional information on the procedure adopted for a better 
rationalization of the chemistry for metal bioconjugation across DOTA ligands.            
Normally, determination of sulphur free groups on biomolecule can be assess by Ellman‟s 
reagents if the concentration of protein is known (for example by common Bradford‟s assay 
in which lysine residues are involved) by a spectrophotometric tritation. In our case, the total 
amounts of antibody prepared after metal labeling make the application of these methods 
difficult. In addition both assay  must be perform prior to metal loading, since complex of 
DOTA with lanthanides are well known to give absorbance and emission at different 
wavelenghts interfering with the analysis. The overlap  effect with the wavelenghts use in 
Ellman and in Bradford assay prevent the simple determination of free sulphidryl and total 
protein concentration respectively, and finally the stoichiometry of labeling is not 
determinable. 
     Within this frame, we approach the stoichiometry determination by the use of High 
Resolution-ICPMS (HR-ICPMS) which permits the simultaneous determination of sulphur 
and lanthanides. The problem of sulphur determination with a common quadrupole analyzer 
lies in the problem of polyatomic interference due to the formation in high amounts of 
+
O2 
that completely cover the isotopes of sulphur, especially the most abundant 
32
S. With the 
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instrumental resolution improved by the presence of a sector field, sulphur can be direct 
determines and therefore we decide to use the intrinisc content of sulphur from protein 
backbone as normalization factor to measure the protein content and stoichiometry of labelin. 
Since our method is based on the selective introduction of DOTA ligand after reduction of the 
disulphide bridges at the level of the hinge region, should be mentioned that their number is 
strictly dependent from the subclass of Gamma-Immunoglobulins. Indeed, IgGs are divided 
into four different subclasses, which exhibit a variable number of 2, 4, 11, 2 disulphide bonds 
into the hinge region for IgG1, IgG2, IgG3 and IgG4 respectively.  
 
EXPERIMENTAL SECTION 
 
     Materials. Chemicals, Salts and buffers. A complete mixture of lanthanides elemental 
standard at 100 g mL
-1
 in 4% HNO3  and ammonium sulphate in water at a concentation 
1000 g mL
-1 
in sulphur was from Scharlau (Spain). Analytical grade HNO3 (69-70%) was 
from J.T.Baker. Analytical grade ammonium acetate, sodium phosphate monobasic 
(NaH2PO4), tris-(hydroxymethyl) aminomethane hydrochloride, sodium chloride, ethylene-
diaminotetraacetic acid disodium salt (EDTA) were purchased from Sigma-Aldrich (St. 
Quentin-Fallavier, France). Buffers used were: ammonium acetate buffer (100 mM, pH 6.8 as 
elution buffer and 20 mM, pH 6.0 for metal complexation), phosphate buffer (100 mM, pH 
7.2, 2.5 mM EDTA), Tris buffer saline (20 mM Tris-HCl, 0,45% NaCl, pH 7.0), phosphate 
buffer saline (10 mM in phoshate, 150 mM in NaCl pH 7.4, 2.5 mM EDTA), deacetylation 
buffer (100 mM phosphate, 150 mM NaCl, 10 mM EDTA, pH 7.4). Ultrapure water 18 M  
cm from a Milli-Q system (Millipore, Bedford, MA) was used throughout the work. 
     Antibodies. Rabbit polyclonal anti-mouse (whole molecule) IgG Europium labelled 
(DELFIA) was from Perkin Elmer Life Science (Waltham, MA). Mouse IgG anti-human 
monoclonal antibodies (mAb) -CA125 (clone X325), -hCG (clone HCG1) and -CEA 
(clone 1C11) were purchased from Abcam (Cambridge, UK). All mAbs were obtained in 
liquid form as IgG or protein A purified fractions. Upon reception, mAbs were divided into 
single working aliquots and stored at –20°C. 
 Labelling reagents. 1,4,7,10-tetraazacyclododecane-1,4,7-tris-aceticacid-10-maleimido-
ethylacetamide (mDOTA) was purchased from Macrocyclics (Dallas, TX). Lanthanide 
chlorides (HoCl3, EuCl3, GdCl3) with natural isotopic abundances were from Aldrich 
(Schelldorf, Germany). Tris(2-carboxyethyl)phosphine hydrochloride (TCEP) was from 
Pierce (Rockford, IL).  
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     Instrumentation. An Agilent model 1100 binary pump, equipped with a manual injection 
system with a loop of 50 L was used as solvent delivery system an for injection of samples. 
The High-Resolution ICP mass spectrometer was a Thermo Scientific ELEMENT 2 XR 
(Thermo Fisher Scientific, Bremen, GmbH) fitted with a Meinhardt nebulizer. HR-ICPMS 
conditions were: plasma gas (Ar) 16 L min
-1
, forward power 1300 W, carrier gas 1.17 L min
-1
. 
The performance and calibration of the system was checked to respect the manufacturer 
indications daily. For size exclusion chromatography and flow injection experiments, 
nebulization chamber was maintained dry by set the peristaltic pump at 20 rpm (0.52 mL min
-
1
). Each isotope was acquired in chromatogram analysis mode with the instrument operating 
in medium resolution. Parameters set for isotopes monitoring were as follow:  dwell time 20 
ms for 
151
Eu and 
153
Eu , 10 ms for 
157
Gd,
 158
Gd and 
160
Gd, 20 ms for 
165
Ho, 50 ms for 
32
S and 
20 ms for 
34
S, 20 ms for 
205
Tl. 
The chromatographic system was connected by means of PEEK tubing to the ICP-MS 
nebulizer. Nanosep centrifugation tubes with low protein membrane and a 30 kDa cut-off 
(Pall, USA) were purchased from VWR International (Milan, Italy). Centrifugation vials were 
used throughout the work for washing steps and buffers exchange during labelling procedure 
of antibodies.  
 
     Procedures. Labelling of antibodies by the TCEP method. Monoclonal antibodies anti-
CA125, anti-CEA and anti-hCG were labelled with Ho
3+
, Gd
3+
 and Eu
3+
, respectively as 
described elsewhere. Briefly, an aliquot of antibody (40 g, 266 pmol) equilibrated in 
phosphate buffer at 1 mg mL
-1
 (6.6 M) was incubated with 6-fold molar excess (1.6 nmol, 
40 M) of TCEP  at 37°C for 30 min to selectively reduce disulphide bridges in the hinge 
region. The antibody was quickly washed with Tris buffer saline to remove the TCEP in 
solution by centrifugation and resuspended in the same buffer at 1 mg mL
-1
. A 20-fold molar 
excess of mDOTA previously dissolved in DMSO was added (12 nmol, final concentration of 
320 M ) and the mixture was incubated at 37°C for 1 h. Then, the mixture was washed with 
Tris buffer saline to remove excess of unreacted DOTA, and resuspended in 20 mM 
ammonium acetate buffer (pH 6.0). An aliquot of LnCl3 was added to reach 1 mM 
concentration and the mixture was incubated at 37°C for 30 min. The tagged antibody was 
extensively washed with Tris buffer saline to remove excess of free metal and was recovered 
at a nominal concentration of 0.5 mg mL
-1
. 
     Size-exclusion chromatography HR-ICPMS. Labelling of proteins and purity (absence of 
free DOTA-Ln) were checked on a size exclusion column Superdex  200 HR 10/30 (10 mm 
x 300 mm x 13 m beads size) with declared linear separation range 10-600 kDa for globular 
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proteins (GE Healthcare, Uppsala, Sweden). Elution was carried out isocratically at 0.5 mL 
min
-1
 using 100 mM ammonium acetate (pH 6.8) as mobile phase and column was connected 
by means of PEEK tubing to HR-ICPMS. 
     Flow-injection High Resultion-ICPMS. Standards mixture containing all the lanthanide 
ions and sulphur, as well the standard proteins and samples were prepared in HNO3 7% 
containing 
205
Tl at 10 ng mL
-1
 as internal standard. Samples were loaded in the injection valve 
and the 50 L filled into the loop were transferred to the HR-ICPMS by a continuos flow of 
HNO3 2% at 0.5 mL min
-1
. Each sample was run in triplicate. External calibration curves 
were obtained by injecting standard solution in a range 0.5-1000 ng mL
-1
. Antibody samples 
were diluted after labelling to a concentration range 10-100 mg mL-1 in antibody prior to 
analysis by FJ-HR-ICPMS    
 
RESULTS AND DISCUSSION 
 
      Size Exclusion Cromatography-High Resolution ICPMS. The total content of sulphur into 
the antibody, represent an intrinsic property of the molecule since its value derives from the 
aminoacid backbone of the protein. The number of cysteines and methionine define the total 
content of sulphur into the investigate proteins. In respect to the common tritation methods by 
Ellman‟s reagent based on the quantification of only free sulphydryl (reduced cysteines), in 
this case the possibility to take into account also the fraction rising from methionine represent 
an automatic increase in terms of sensitivity. To perform an accurate quantification of sulphur 
present into the backbone of the protein the purity of the samples must be determined in terms 
of other sulphur free species. Indeed, presence of polluting sulphur-containing molecule will 
results in a misleading quantification of the true protein content.  
     Initially, a commercially available labeled antibody was used in order to test the feasibility 
of the method. A rabbit anti-mouse polyclonal IgG labelled with europium (IgG-N1) was 
obtained at a declared concentration of 391 g mL
-1
 and it contain a declared average of 6-9 
atoms of Eu per antibody molecule. The procedure used for the labeling of IgG-N1 reagents 
involves the use of an isothiocyanate-DOTA by-product, which reacts with lysine groups at 
basic pH. Then the quantity of sulphur into antibody is in this case increased by the presence 
of DOTA ligands. Furthermore, eventual residue of unreacted labelling reagent might be 
present in the solutions. Then, purity of IgG-N1 was checked by directly coupling size 
exclusion chromatography to HR-ICPMS. The baseline for 
32
S and 
34
S isotopes was 
previously checked and found stable (baseline variation < 1%) at 6000 cps for 
32
S, when a 
flow of 100 mM of ammonium acetate at 0.5 mL min
-1
 was used as elution buffer. Baseline 
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value for 
153
Eu and 
151
Eu isotopes was found negligible (40 cps) since this element is not 
affected by interference species. A chromatogram for an injection of 100 L of antibody at 10 
g mL
-1
 onto SEC-HR-ICPMS is shown in Fig.1. 
      Two peaks were observed. In 
Fig.1A, peak 1 at 16 min correspond 
to the elution of IgG-N1 antibody, 
with a molecular mass calculated of 
150 kDa from column calibration 
curve. Peak 2 eluting at 28 min was 
previously identified as unbound Eu-
DOTA complex. In our previous 
work the column recovery for the 
total Eu was calculate to exceed the 
90%. Integrated signals for the two 
peaks were found similar, which 
means 50% of the elements into the 
solutions is given from labeled 
antibody, and the other 50% derives 
from the free DOTA-Eu complex. 
Moreover, after a dialysis by centrifugation on a 30 kDa filter the free DOTA-Eu complex 
was removed and a single peak at 16 min (Fig.1B) appears in the chromatogram from SEC-
HR-ICPMS. As opposite, when mouse monoclonal antibodies where prepared by the TCEP 
method the extensive washing as final steps in the procedure provides a good purity of the 
samples, since no traces of free DOTA-Ln complexes were observed. 
 
     Optimization of Flow injection High-Resolution ICPMS (FJ-HR-ICPMS) Samples were 
prepared in HNO3 at 7% containing 10 ng mL
-1
 of Tallium (
205
Tl) as internal standard for 
normalization of the signals. As first, a blank sample of HNO3 at 7% was injected to check the 
purity of this matrix, with a special regards to sulphur, and variation of baseline for each 
isotope of interest was found absent. Then, the presence of carry-over effects in the injection 
valve and system of PEEK tubes connecting the solvent delivery pump to HR-ICPMS was 
tested by injection of a multi-analyte standard solution (containing all the lanthanides, internal 
standard and sulphur) at 1000 ng mL
-1
, which represents the highest concentration used in this 
work for calibration purpose. Signals eluted in a time window of 20 seconds, and after 
additional 40 seconds the baseline value was found at the corresponding intensity measured 
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Fig.1. Chromatograms of IgG-N1 from SEC-HR-
ICPMS  for 
32
S (bold line) and 
153
Eu (thin line): A) 
injection of IgG-N1 as received from manufacturer  
and B) injection after purification by 
ultracentrifugation on 30 kDa cut-off filter. 
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before the injection. An injection of 50 L of blank HNO3 at 7% after the sample shown the 
presence of residual analytes in the injection system, which disappeared completely after three 
washing cycles. Then, an acquisition time window for each sample was set at 60 seconds and 
5 washing cycles with HNO3 at 7% between each sample injection were done. In each case no 
memory effect in the nebulization chamber of the ICPMS torch was observed, since baseline 
came back to the initial intensity after all the injections. With the parameters set as described 
above, calibration with the multi-analyte standard solution in a range 0.5-1000 ng mL
-1
 was 
performed by injecting each levels in triplicate and the linear relationships were established. 
 
     Determination of sulphur content and stoichiometry of labelling by FJ-HR-ICPMS.     
Initially, the method was applied on the IgG-N1. Antibody was diluted at 2.5-5-10-20-40-80 
g mL
-1
 and samples were analyzed by FJ-HR-ICPMS. Integrated signals were transformed 
in molar units across the external calibration and concentration of IgG was plotted versus the 
calculated concentration of the single elements. The linear relationship y=120.5x + 26913 (r
2
 
0,966) obtained is reported in Fig.2. The slope of linear regression represents the ratio 
sulphur/IgG, which was found 
120.5 for the total content of 
sulphur into the sample. 
Regarding the determination of 
Europium, in the same way a 
value of 12.3 was calculated for 
the ratio Eu/IgG. Taking into 
account the composition of the 
analyzed sample by SEC-HR-
ICPMS, in which a 50 % of 
sulphur and europium derives from the free DOTA-Eu complex, both values must be reduce 
by an half, resulting in a total content of about 60 atoms of sulphur and 6.5 atoms of 
Europium for each IgG-N1 molecule.  The obtained results from Europium are in good 
agreement with the declared average of 6-9 atoms/IgG. Regarding the content of sulpur, from 
an IgG aminoacid sequence from Protein Data Bank (IgG from Mus Musculus sequence 
number Q9D8L4 for constant region and Q5F2I8-Q5F2I1 for variable regions 
www.expasy.ch) a content of 51 atoms of sulphur into antibody is expected from the presence 
of 13 methionines and 38 cysteines. Since each incorporated DOTA, carry on an atom of 
sulphur, the real ratio sulphur/IgG can be estimate around 57, which fit reasonably with the 60 
measured. Then, we proceeded with the determination of sulphur into the three monoclonal 
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Fig.2. Linear relation for sulphur content into antibody 
as determined from FJ-HR-ICPMS. 
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unlabelled antibodies -CA125, -CEA and -hCG which results in the range 57  5. This 
latter value was used to normalize the antibody concentration in the elemental tagged 
antibodies injected after the entire procedure of labeling. For the antibodies tagged with Ho, 
Gd and Eu respectively, a stoichiometry of labeling of 3.1  0.3 was calculated. Since all the 
antibodies analyzed were of subclass 1, two disulphide bonds are present in their hinge region 
which originate four free sulphidryl groups sensisble to the DOTA attachment for a maximum 
labeling with four lanthanide ions.  
 
CONCLUSIONS 
 
As first approach, can be concluded from this former study that the selective reduction of 
disulphide bridges in the hinge region was accomplished, since labeling stoichiometry never 
exceed the maximum number of free sulphidryl sites and aspecific modification of other 
cysteine into the biomolecule was avoided. For the first time, HR-ICPMS was demonstrate to 
be able to perform analysis of sulphur content into antibodies, which can in turn be use for the 
normalization of biomolecule concentration in unknown samples like the labelled preparation. 
The quantities of sample required for the analysis are lower ( as total 5 L of antibody at a 
declared concentration 0.5 mg mL
-1
 were used) than required for classical UV/VIS tritation 
methods like Bradford or Ellman assay and therefore the method developed results very 
useful when aliquotes of 20 L of labelled antibody were prepared. Howhever, to check the 
validity of the method developed, a comparison with data obtains from classical UV/VIS 
tritation methods and the identification of modification sites by molecular MS are necessar. 
These aspects are under investigations. 
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3.3. Enhancement of Sensitivity in Immunoassay 
with Antibody-Dendrimers Conjugate and 
Inductively Coupled Plasma Mass Spectrometry. 
 
Abstract. A procedure for labeling of antibodies with metals for Inductively Coupled Plasma 
Mass Spectrometry (ICP-MS) based immunoassay using DOTA modified dendrimers is 
presented. The principal advantage given by the labeling wioth dendritic polymers rely in the 
possibility to insert an increased number of metal atoms for each site of modification onto 
antibody molecule. The derivatization of commercially polyamidoamine (PAMAM) 
dendrimers on the functional amine terminal groups with a DOTA moiety is investigate by the 
use of size exclusion chromatography and MALDI-MS. Finally, a comparison of sensitivities 
by liquid-phase immunoassay between the dendrimer modified antibody and a classical single 
DOTA modification is carried out for the determination of human chorionic gonadotropin in 
human serum as model system. 
 
 
 
 
 
 
 
 88 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 89 
INTRODUCTION 
 
     The introduction of ICP-MS as analytical technique in proteomic analysis, provides 
several valuable features. The wide linear dynamic range, excellent sensitivity, the virtual 
indipendence of the signal (isotopic) from sample matrix and especially its multi-analyte 
capability are key characteristic to deal with quantification of proteins. Indeed, when analysis 
of a proteome is taken into account, the principal problem to cope with is the spread of 
concentrations of the analytes in a range of several orders of magnitude. Recently, we 
introduced a method for multiplex proteins quantification by an integrated approach of liquid-
phase immunoassay and ICP-MS. The key note of this strategy lies in the versatility of 
introduction of “elemental tag” by labeling with a common DOTA ligand and further the 
complexation of lanthanide ions. The species-specific determination of each protein (antigen) 
is then assured by the insertion of an unique tag for each antibody. The use of size exclusion 
chromatography (SEC) allowed the chromatographic separation between immunocomplex 
and free form of antibody and quantification was performed by on-line coupling to ICP-MS 
by measuring the immunocomplex (1).  
     Principally, the global power of ICP-MS for the quantification of antigens present into the 
sample is driven by two well distinct characteristic of the analytical system developed: i) the 
intrinsic affinity of antibody toward its antigen and ii) the sensitivity directly related to the 
quantity of inserted elemental tag into antibody. Regarding the former point, optimization of 
labeling strategy is necessary in order to limit the loss of biological activity (affinity), which 
increase with the grow of DOTA incorporation. On the other hand, for the latter an increase of 
DOTA and then final element content, give back a more sensible detection from the 
instrumental point of view. Across our strategy of labeling, the highest number of DOTA 
molecules rely from the number of disulphide bridges present into the hinge region of the 
antibody, ranging from 2 to 12 depending by the IgG subclass. Howhever, for higher labeling 
yields a suppression effect of biological activity, which results in worst global sensitivity of 
analysis was observed.  
     To overcome these contrary effects, Tanner and co-workers approach the problem 
disfruting the MaxPar  linear polymers bringing multiple copies of DOTA ligands 
synthesized by Lou et al. (2). In opposite to linear polymers, dendrimers are well-defined, 
spherical and low polydisperse polymeric structures which make them attractive for many 
novel applications including as a catalyst, as a host molecule, in analytical chemistry, in gene 
and drug delivery, and as a diagonistic reagent (3-5). Dendrimer size and related number of 
surface groups available for modification depend by the generation, obtained as results of 
 90 
cycles of amplification in branch. Especially poly-amido-amine (PAMAM) dendrimers were 
the most used since their amine terminal groups offers a good versatility for different 
modifications (Fig.1).  
 
      
     A wide variety of analytical techniques have been considered to characterize dendrimers 
during the last years: low angle laser light scattering, infrared (IR) spectroscopy (6), capillary 
electrophoresis (CE) (7,8), mass spectrometry (MS) (9-11) and high-performance liquid 
chromatography (HPLC) (12), low angle laser light scattering (13) and 
1
H, 
2
H, 
13
C nuclear 
magnetic resonance (NMR) (6,9,14,15) were used for this purpose. Across these techniques, 
informations regarding molecular mass, presence of synthetic defect or impurities as well 
structural properties can be  achieved. Unfortunately, the performance of all these techniques 
declines with increasing size of dendrimers. In their recent works, Maiti et al. used fully 
atomistic simulation to a deeper understanding of denrimers characteristic like size (radius of 
gyration), shape tensor, asphericity, molecular surface area, spatial arrangement of branch 
points, terminal groups and monomer density distribution, solvent accessible surface area and 
molecular volumes as a function of generation (16-18). Results from these simulations are in 
good agreement with the experimental data available in literature.  
     By far, size exclusion chromatography (SEC) is the most preferred method for determining 
the absolute molar masses and molar mass distribution of polymers. Since separation in SEC 
is based on the sizes of molecules, this is ideal for the characterization of different generations 
of dendrimers and the first precise experimental data about the rough size of dendrimers came 
from size exclusion chromatography. Baker and co-workers used SEC coupled with 
multiangle laser light scattering (MALLS), differential reflactive index and UV-visible to 
determine average molar mass and polydispersity, especially size-dependent dispersity of 
.
..
.
 
 
Fig.1. Left: schematic presentation of dendrimer structure with information regarding core 
(EDA), amplification region for generation growth and surface with terminal groups (amino). 
Right: molecular structure of PAMAM generation 3 with 32 amino surface groups ready for 
modification. 
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different generation of PAMAM dendrimers (12). Different stationary phase and column 
format for SEC, including Superdex 75 column, were explored for separation of 
polypropylenamine (POPAM) dendrimers by Mengerink et al. the authors observed only good 
separation within generations at acid condition (pH 2.5) but an uncomfortable effect of 
oligomers formation within dendrimers of same generation was observed in these conditions. 
Formation of supramolecular species was avoided only by adding organic solvent, but 
Superdex gel media do not support more then 30 % of organic component (19). 
     In this context, we make full use of PAMAM dendritic polymers to increase the number of 
elemetal tags bring by the antibody. To the best of our knowledge is the first time that 
dendrimer are used for carry out an immunoassay coupled with detection by ICP-MS. The 
scope of this work is to check the feasibility to perform liquid phase immunoassay followed 
by SEC-ICPMS with denrimers-antibody conjugates aims to enhance the global sensitivity of 
the method. Then, basic points are explored here: i) the behaviour of different generations of 
PAMAM dendrimers for SEC separation; ii) the development of an opportune strategy for 
dendrimer modification, characterization of the products and conjugation with the antibody; 
iii) evaluation of the antibody-dendrimer conjugates performances in a liquid phase 
immunoassay based on SEC-ICPMS detection.   
 
EXPERIMENTAL SECTION 
 
Materials.  
     Chemicals. Polyamidoamine (PAMAM) dendrimers of generations 0-7 (G0-G7) were 
purchased from Sigma-Aldrich (St. Quentin-Fallavier, France) in methanol solution. 1,4,7,10-
tetraazacyclododecane-1,4,7-tris-acetic acid-10-maleimidoethylacetamide (mDOTA) and 
1,4,7,10-tetraazacyclododecane-1,4,7,10-tetra-acetic acid mono (N-hydroxysuccinimide ester) 
(NHS-DOTA) were from Macrocyclics (Dallas, TX). Tris-(2-carboxyethyl) phosphine 
hydrochloride (TCEP), 1,11-bis(maleimido) triethylene glycol (BM(PEG)3) and N-
succinimidyl-S-acetylthioacetate (SATA) were from Pierce (Rockford, IL). Water-dried 
dimethyl sulfoxide, triethylamine, 2,5-dihydroxybenzoic acid and hydroxylamine chloride 
(>99%) were from Fluka. Holmium chloride was from Aldrich (Schelldorf, Germany).  
     Antibody and proteins. Mouse IgG anti-human monoclonal antibodies (mAb) -hCG 
(clone HCG1) was purchased from Abcam (Cambridge, UK). Human chorionic gonadotropin 
(hCG) and human serum were from Sigma-Aldrich (St. Quentin-Fallavier, France). 
     Salts and buffers. Analytical grade ammonium acetate, citric acid, sodium phosphate 
monobasic (NaH2PO4), tris-(hydroxymethyl) aminomethane hydrochloride, sodium chloride, 
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ethylene-diaminotetraacetic acid disodium salt (EDTA) were purchased from Sigma-Aldrich 
(St. Quentin-Fallavier, France). Buffers used were: ammonium acetate buffer (100 mM, pH 
6.8 as elution buffer and 20 mM, pH 6.0 for metal complexation), citric acid buffer (100 mM, 
pH 2.74), phosphate buffer (100 mM, pH 7.2, 2.5 mM EDTA), Tris buffer saline (20 mM 
Tris-HCl, 0,45% NaCl, pH 7.0), phosphate buffer saline (10 mM in phoshate, 150 mM in 
NaCl pH 7.4, 2.5 mM EDTA), deacetylation solution (100 mM phosphate, 10 mM EDTA, pH 
7.4). Nanosep centrifugation tubes with low protein membrane and a 30 kDa cut-off (Pall, 
USA) were purchased from VWR International (France). Centrifugation vials were used 
throughout the work for washing steps and buffers exchange during labelling procedure of 
antibodies. Ultrapure water 18 M  cm from a Milli-Q system (Millipore, Bedford, MA) was 
used throughout the work. 
 
Methods. 
      Size Exclusion Chromatography UV-VIS. SEC experiments were performed using a 
Superdex  200 HR 10/30 and Superdex  75 HR 10/30 glass columns (10 mm x 300 mm x 
13 m beads size, GE Healthcare, Uppsala, Sweden), both with the approximate bed volume 
of 24 ml and a declared linear separation range 10-600 kDa (1000 kDa exclusion limit) and 3-
70 kDa (100 kDa exclusion limit) respectively for globular proteins. An Agilent model 1200 
binary pump, equipped with an autosampler, automatic injection system with a loop of 900 
L and a UV-VIS multiwave detector was used as solvent delivery system and for on-line 
UV-VIS analysis. Column were calibrated with an appropriate mixture of proteins and 
peptides as indicated by manufacturer using UV/VIS detection at 280 nm with baseline 
evaluation at 800 nm. Retention times (in min) plotted versus the logarithm of molecular mass 
(in kDa) gave a straight lines y = -0.134 x + 4.385 and y = -0.18 x + 4.38 (r
2
=0.992) 
respectively for Superdex  200 and Superdex  75. 100 L of dendrimer solution at 1 mg 
mL
-1
 were injected and the elution was carried out isocratically with a flow rate of 0.7 mL 
min
-1
. For dendrimers characterization purposes both ammonium acetate buffer 100 mM (pH 
6.8) and citric buffer 100 mM (pH 2.74) were evaluated in terms of effectiveness to reduce 
aspecific interaction with stationary phase and optimal resolution. In both cases dendrimers 
elution was monitored by absorbance at 210, 214, 254 and 280 nm with a reference baseline 
set at 800 nm.  
     Size Exclusion Chromatography ICP MS. Antibody-dendrimer conjugates 
165
Ho labeled, 
were characterized by SEC-ICP MS analysis using ammonium acetate 100 mM (pH 6.8) as 
elution buffer at a flow rate of 0.7 mL min
-1
. The Agilent model 1200 binary pump was used 
for solvent delivery purposes and automatic injection of samples. The ICP mass spectrometer 
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was an Agilent 7500 CE fitted with a Meinhardt nebulizer. The exit of the column was 
connected by means of PEEK tubing to the ICP MS nebulizer. ICP MS conditions were: 
plasma gas (Ar) 15 L min
-1
, forward power 1500 W, carrier gas 1.05 L min
-1
. The 
performance of the system was checked to respect the manufacturer indications for 1 µg L
-1
 
7
Li
+
, 
89
Y
+
 and 
205
Tl
+
 in 2% HNO3, with a dwell time of 100 ms for each isotope. Double 
charge ion and oxide levels were opitimized on 
140
Ce
+
 and were classically <2 %. The 
isotopes were monitored in time resolved analysis mode with a dwell time of 100 ms each. 
     MALDI-TOF of dendrimers and their DOTA derivatives. The positive-ion MALDI-TOF 
mass spectra were recorded on a Voyager DE mass spectrometer (Applied Biosystem) 
operating in reflector or linear mode with delayed extraction. Instrument calibration was 
performed with a mixture of known peptides for reflector mode or with a mixture of 
myoglobin, bovine serum albumin and gamma-immunoglobulin for the linear mode. Laser 
intensity was adjusted for each dendrimer generation to maximize signal to noise ratio and 
reduce dendrimer‟s fragmentation. In reflector mode, classical operating parameter were: 
applied voltage 20 kV, grid voltage % 85, delay time 100 ns, 100 laser shot per spectra were 
acquired.  2,5-dihydroxybenzoic acid (DHB) was used at 10 mg mL
-1
 in pure methanol as 
matrix. Dendrimer samples were diluted as necessary in pure methanol and finally mixed 
50/50 (% v/v) with the matrix solution. Then 1 L of sample was spotted onto plate by the 
dry-droplet methods. Classically 50-100 ng of dendrimer were deposed and the solvent were 
permitted to dry by air evaporation prior to analysis. 
Procedures. 
     Derivatization of PAMAM Dendrimers (Gy). To a 50 L of PAMAM Gy (y = 0-7) solution 
in dimethyl sulfoxide at a concentration 10 mM in amino terminal groups, 9 L of 
trietylamine (final concentration 1 M) are added and the solution is mixed for 2 min. Then, 
from freshly prepared solutions in dimethyl sulfoxide of NHS-DOTA (100 mM) and SATA 
(43 mM), a 2-fold molar excess on PAMAM Gy amino terminal groups of NHS-DOTA (10 
L, 1 mol) and a 0.75 molar fold respect to PAMAM Gy of SATA (i.e. for G0: 2.9 L, 125 
nmol) are added. The solution is briefly mixed and incubated at 50 °C for 15 min. The 
reaction is subsequently quenched by adding 10 L of NaOH 1 M, further neutralized with 10 
L of  HCl 1 M and the solvent are evaporated under vacuum to give the desired product 
SATA-Gy- DOTA.  
     Activation of sulphydryl moiety. SATA-Gy-DOTA is resuspended in 50 L of phosphate 
buffer and 5 L of deacetylation solution are added and the mixture is incubated for 2 h at 
room temperature to achieve the deprotection of acetylated sulphydryl. The mixture obtained 
containing the active PAMAM Gy DOTA derivative (SH-Gy-DOTA) for a theoretical 
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maximal concentration of active sulphydryl of 0.75 fold respect to initial concentration of 
PAMAM Gx dendrimer. The prepared solution was promptly used without further purification 
for conjugation with antibody and keep frozen at –20 °C for further preparations. 
     Conjugation of antibody -hCG (IgG) and DOTA-Gy-SH. To 10 L of mouse monoclonal 
antibody at 1 mg mL
-1
 (66.6 pmol) in phoshate buffer, a 20-fold molar excess of TCEP (1.33 
nmol, 133 M) and a 100-fold molar excess (6.6 nmol, 600 M) of BM(PEG)3 are added and 
the mixture is incubated for 1 h at 37 °C. Excess of BM(PEG)3 and TCEP byproducts are 
washed away by centrifugation on 30 kDa molecular filter with 3 x 500 L of phosphate 
buffer and then a 20-fold molar excess of SH-Gy-DOTA (1.3 nmol) dendrimer is added to the 
recovered antibody solution from the freshly prepared solution and the mixture incubated at 
37 °C for 2 h. Antibody-dendrimer conjugate (IgG-Gy-DOTA) is washed by centrifugation 
against 5 x 500 L of phosphate buffer on Nanosep 30 kDa molecular filter and the buffer is 
changed by 2 x 500 L additional washing step with ammonium acetate 20 mM pH 6.0. 
HoCl3 is added to a final concentration 5 mM and the sample is incubated  for 30 min at 37°C. 
Finally, IgG-DOTA-Gy-(Ho) holmium labeled is extensively washed against 3 x 500 L of 
ammonium acetate and then with 3 x 500 L of tris buffer saline. Antibody is recovered at 0.5 
mg mL
-1
 and stored at 4°C until use. 
     Labeling of antibody -hCG with maleimido-DOTA (mDOTA).  Four aliquots of 10 L of 
antibody at 1 mg mL
-1
 in phosphate buffer are incubated with 1, 2, 6, 20-fold molar excess of 
TCEP in presence of a 50-fold molar excess of mDOTA for 1 h at 37 °C. Then mDOTA and 
TCEP byproducts are washed away by centrifugation on 30 kDa molecular filter (3 x 500 L). 
The buffer is changed with ammonium acetate 20 mM pH 6.0, HoCl3 is added to a final 
concentration 5 mM  and the samples are incubated for 30 min at 37 °C. Lanthanide excess is 
washed by centrifugation against 3 x 500 L of ammonium acetate 20 mM pH 6.0 and the 
with 3 x 500 L of tris buffer saline. IgG-mDOTA(Ho) labeled antibodies are stored at 4°C 
until use at a concentration 0.5 mg mL
-1
. 
      Liquid phase immunoassay and SEC-ICP MS analysis. Human chorionic gonadotropin 
antigen (hCG) was prepared in human serum sample of 100 L at different concentration 
levels: 0-5-10-50-75-100 mUI mL
-1
. One set of hCG samples was prepared for each 
preparation of mAb-mDOTA and mAb-Gy-DOTA conjugates holmium labeled. Antibody are 
added to a final concentration of 5 g mL
-1
 and the samples are incubated for 1 h at 37°C. 
Then 50 L of each samples are injected onto SEC and analyzed by ICP MS. 
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RESULTS AND DISCUSSION 
 
      Size exclusion chromatography of PAMAM dendrimers. In order to perform a liquid phase 
immunoassay, based on the use of antibody-dendrimers conjugates, followed by a size-
exclusion separation between immunocomplex and free antibody, the behaviour of dendritic 
polymers in the chromatographyc system became imperative. Infact, by parity of dendrimer 
conjugates for antibody molecule, the content of elemental tag grows up with the increasing 
generation (Gx) of dendrimer. The presence of higher dendrimer Gx in the composition of the 
bioconjugate might affect the separation, since side-effects of aspecific interactions driven by 
the dendrimer part, and the final shape of the bioconjugate are both involved when a SEC is 
performed.  
     Pure amine-terminated PAMAM dendrimers were analyzed by Superdex  75, which 
exhibit a linear separation range appropriate for the pure dendrimer sizes, and by Superdex  
200  which represent the elected column for the separation of high molecular weights 
molecules like immunocomplex and antibody-dendrimer conjugates. Dendrimer‟s elution was 
evaluated with two elution buffers, ammonium acetate buffer 0.1 M (pH 6.8 and pH 4.75) and 
citric acid buffer 0.1 M (pH 2.74),  since the presence of different counter-ions and degree of 
amines protonation are known to influence chemical-physical characteristic of dendrimers and 
therefore the separation performances in SEC. When ammonium acetate buffer was used at 
both pH values, all dendrimer generations were eluted in a range of 20-25 min by both 
columns, corresponding to a mass 6-0.75 kDa and 50-10 kDa for Superdex 75 and 200, 
respectively. At the increase in dendrimer generation, broader and tailed peaks were 
registered, which indicates an effect of absorption on the stationary phase. The cause for this 
interaction with the stationary phase lie in the effect of pH, since at this values (pH 6.8 and 
4.75) not all the amine groups are protonated. In fact, only the terminal primary amine groups 
are protonated (pKa 10), while the secondary amino groups (pKa  7) presents at each 
branch point of the dendrimers and the tertiary amine groups (pKa  4) at the etylenediamine 
(EDA) core are not. In their recent works Maiti et al. shown that denrimers branches exhibits 
an high molecular dynamic and a significant amount of terminal groups are back-folded in the 
interior of the molecule at each level of pH, in opposition of what is expected from the 
classical misleading two-dimensional representation of dendrimers (17). Then if not 
completely protonated, amino groups tend to interact aspecifically with the agarose based gel 
media of the stationary phase. At pH 2.74 of citrate buffer, all amine groups are protonated 
and consequently dendrimers absorption on stationary phase was completely avoided. 
 96 
Chromatogram profiles from Superdex  200 and 
Superdex  75 column for each Gx of dendrimer eluted 
in citric acid buffer are shown in Figure1. 
As appears, both columns were able to to discriminate 
between each dendrimer generation. Surprisingly, also 
dendrimer of lower generation (G0-G2) which 
molecular masses lie down of the lowest limit of 
column separation range, where disciminate within 
them and from the highest generation (G3-G7). Each 
generation was eluted with a profile of at least two 
peaks, indicating the formation of oligomers in this 
buffer conditions. Since no reference materials exhist to 
perform a calibration curve for dendrimers, a calibration 
obtained across a mixture of standard proteins was 
applied, and the molecular mass values calculated are 
reported in Table 1.  
In general, from both columns the masses calculated, 
exceed the theoreticals for each generation of dendrimer. 
Furthermore, the molecular weights calculated by the 
two columns are not in agreement, showing a substantial 
mass increment for each generation when dendrimers 
are eluted from Superdex  200 respect to Superdex  
75 column. From the latter, calculated values fit with 
dimer species for G1-G6, except for G7 dendrimer, 
which molecular mass (116 kDa) fall up to the exclusion 
limit (100 kDa) of the column, and therefore dimer 
formation could not be checked. The molecular masses 
calculated for the same generations when eluted from 
Superdex  200 represents the formation of extense 
agglomerates ( tri- or tetra- forms) of single denritic 
polymer. These data are not in agreement with other 
results in literature, where dendrimers molecular weights 
were determined by SEC (12). In this case dendrimer‟s sizes were calculated without apply an 
external calibration curve, but the absolute molecular weight was determined by multi angle 
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Fig.1. SEC of generation 0-7 
PAMAM dendrimers eluted with 
citric acid buffer at pH 2.74 by 
Superdex 75  (A) and Superdex 
200  (B). Detection was 
performed by UV/VIS monitoring 
the absorbance at 254 nm. 
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laser light scattering (MALLS), suggesting that deviation in dendrimer size in our 
experiments might be due partially to the calibration curve applied.  
 
 
 
 
In addition, the mismatch within calculated molecular weights by the two colums suggest 
additional features which might interfer with SEC separation of dendrimers. The recorded 
mass increment is not linear respect to dendrimer generations, but tends to decrease for higher 
generation as shown in Figure 2. 
This observation might find partial 
confirmation in a recent fully 
atomistic study of dendrimers in 
water solvent (17). The authors 
highlighted an effect of swelling due 
to the solvent and the counter-ion 
ability to penetrate into dendrimer 
structure, and therefore increment 
their size. In the same work was also 
pointed out the aspherical character 
of denrimers shape, which tends to 
be greater for the lower generations. 
As consequence, the increased sizes of dendrimers as observed in our SEC experiments, 
might be the reflex of swelling and aspherical shapes of polymers, since this separation 
technique is sensible not only to the size but also to the shape of eluted molecules. Then 
  Dendrimer     Superdex 75     Superdex 200   
 Gx NH2 
Mw  
(g/mol)   Time (min) 
Mn  
(g/mol)    Time (min) 
Mn  
(g/mol) 
         
G0 4 517  23.9 1197  25.4 9581 
G1 8 1430  21.7 2979  24.1 14309 
G2 16 3256  19.7 6823  22.4 24177 
G3 32 6909  17.9 14388  20.9 38406 
G4 64 14215  16.2 29107  19.3 62922 
G5 128 28826  14.7 54200  17.6 106316 
G6 256 58048  13.5 89125  16.2 163757 
G7 256 116493  12.6 129420  14.9 244568 
                  
 
Table 1: dendrimer characteristic (surface amine terminal groups and molecular 
weights) and the corresponding results obtained from SEC-UV/VIS analysis after 
injection of 100 L at 2 mg mL
-1
 for each generation onto Superdex  75 and 
Superdex  200. 
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Fig.2. expected molecular wheights (Mw) for dendrimer 
generation are reported versus the calculated values from 
SEC (Mn) by Superdex 75 (circle) and Superdex 200 
(square).  
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dendrimers of low generation, characterized by a less spherical shape, tends to escape a 
correct interaction with stationary phase along the column, by a minor capacity to penetrate its 
pores and finally results in a faster elution. Howhever, a MALDI-TOF analysis of each peak 
eluted revealed only the presence of dendrimer monomers, suggesting that oligomerization 
depends from the solution conditions by supramolecular interactions of dendrimer molecules. 
  
     Derivatization of PAMAM dendrimers and MALDI-TOF characterization. Since 
sensitivity of an ICP MS based immunoassay is direct related, at least from the instrumental 
point of view, with the number of element bound to the antibody, dendrimers were modified 
to give a bioconjugate with the purpose of maximize the lanthanide atoms carried by each 
antibody molecule. A synthetic strategy based on the modification of terminal amine groups 
was optimized to obtain a bifunctional dendrimer, which brings on one hand the highest 
number of DOTA moieties as chelators for lanthanide ions, and on the other hand a free 
sulphydryl group useful for conjugation with antibody. Derivatization steps are schematically 
presented in Figure 3.   
      
Both reagents used for amine terminal modification of dendrimer (NHS-DOTA and SATA), 
shown the same active ester group, allowing their simultaneous use in the reaction mixture. 
Molar ratios of both esters were optimized to reach the maximal derivatization with DOTA 
groups, and at the same time limit the insertion of one SATA group. The importance of 
avoiding insertion of more than one SATA group rise in the danger of turn the dendrimer 
molecule into a reactive cross-linker, which might act both between antibody molecules or 
dendrimers with a consequent formation of undesired agglomerates. Optimization of reaction 
steps was carried out on dendrimer G0, since it is an ideal model for MALDI-TOF 
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Fig. 3. synthetic strategy for preparation of G0 dendrimer active thiol free DOTA derivatives SH-G0-
DOTA3. The procedure was applied to each generation Gy-(NH2)n, where n represents the number of 
surface amine groups to give the corresponding SH-Gy-DOTAn-1 products. 
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characterization of each component into the reaction mixture and the final products. Infact, 
MALDI-TOF mass spectrometry was succesfully applied for PAMAM dendrimers 
characterization, but resolution is lost starting from G2 PAMAM, when unresolved 
background signals emerge (20,21). Still, for each generation of pure PAMAM dendrimer a 
general molecular weight distribution is well observed. Results for the optimization are 
reported in Figure 4 (A, B and C) by the MALDI-TOF spectra acquired after the 20 min of 
reaction at 50°. In each case the signal of original PAMAM G0 at m/z 517.5 was never 
detected.  
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
As first, the required concentration of NHS-DOTA to obtain quantitative conversion of all 
NH2 terminal groups of G0 PAMAM was optimized. A 2-fold molar excess of NHS-DOTA 
respect to NH2 groups (8-fold molar excess respect to dendrimer G0) was found enough for 
this purpose as reported in Fig. 4A, where the G0-DOTA4 product (M3) was found at m/z 
2062. To be note, presence of other peaks in the mass spectra derive from structural 
deviations in the starting PAMAM dendrimer, like a missing arm (signal M1) and intra-
cyclization of one dendrimer arm (signal M2) as well established by Lopp and co-workers 
(20). Mass number exceeding the ideal mass by +22 and +38 are the corresponding Na and K 
salts.  The use of an high excess of trietylamine was found essential, since for lower 
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Fig.4. MALDI-TOF spectra for dendrimer G0 preparation of active SH-G0-DOTA3 product. 
Spectra A, B and C for reaction mixtures at different concentration of SATA reagent respect to 
fix amount of NHS-DOTA and PAMAM G0. Respectively: A) absence of SATA; B) SATA at 
0.5 molar ratio to G0; C) SATA at 1 molar ratio to G0. Spectra D: analysis of mixture form  
spectra B after deprotection of the inserted thiol group. 
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concentrations the reaction do not proceed until complete derivatization, with a consistent 
signal in the MALDI spectra of original PAMAM G0. Then, insertion of SATA group was 
optimized by the use of different molar ratios respect to denrimer molecule, in presence of the 
defined amounts of NHS-DOTA. Increasing SATA reagent in the mixture from 0 to 1 
equivalents respect to dendrimer, brings to a maximal derivatization to mono-SATA 
derivative SATA-G0-DOTA3 (M4) at m/z 1792 with 0.75 equivalents as shown in Fig. 4B. 
By the use of an equimolar use of SATA reagent, formation of the undesired bis-adduct 
SATA2-G0-DOTA2 M5 at m/z 1522, was found. After vacuum removal of volatile 
components and resuspension in acqueous buffer, the deacetylation step carried out with an 
excess of hydroxylamine give the active SH-G0-DOTA3 (M6) at m/z 1750 and its 
corresponding M7 at m/z 1718 from the in-source loss of the SH group. The procedure was 
scaled up to each generation and molecular masses of desired products were determined by 
MALDI-TOF until G6 and are reported in Table 2.  
 
To be note that molecular mass spectra for dendrimers of growing generation results in a lost 
of resolution and sensitivity due to the increased polydispersity, which is multiplied in the 
case of the derivatized compounds. Signals appear with a classical gaussian shape, so values 
reported for generations above G2 are extracted from the center of the molecular weights 
distribution.  
 
     SEC-ICP MS of derivatized PAMAM dendrimer. Modified PAMAM dendrimer (SH-Gy-
DOTAn-1; y= 0-7) were loaded with holmium and further injected onto SEC and analysed by 
ICP MS. Ammonium acetate (pH 6.8) and citric acid (pH 2.74) buffers were used, and 
separation on both column Superdex 75 and 200 was explored. When elemental labeled 
denrimers were injected in presence of citric acid as elution buffer, an increase of the baseline 
Dendrimer Surface groups Gx HS-Gx-(DOTA)n-1 
Maldi-Tof 
Gx  NH2 (n) Mw (g mol
-1
) calc Mw (g mol
-1
) meas Mw (g mol
-1
) 
      
G0 4 517 1791 1791 
G1 8 1430 4248 4248 
G2 16 3256 9162 9000 
G3 32 6909 18991 18400 
G4 64 14215 38649 33600 
G5 128 28826 77964 68400 
G6 256 58048 156594 132000 
G7 512 116493 313855 N.D. 
 
Table 2. calculated molecular weight for derivatized dendrimer generation (SH-Gy-DOTAn-1) and 
the corresponding measured mass by MALDI-TOF analysis. 
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value since the void volume belong the total chromatographic run was observed, due to loss 
of metal from its DOTA-complex form. On the other hand, use of ammonium acetate fall in 
the interaction between derivatized denrimer molecule and the stationary phase, as observed 
for the experiments with pure compounds by SEC-UV/VIS experiments. SH-Gy-DOTAn-1 (y 
=0-5) were not discriminate, appearing as a single peak at 27 min in both column, but a 
different behaviour was observed for SH-Gy-DOTAn-1 (y =6-7). On both column, 
discrimination was achieved only for derivatized dendrimer of generation 6 and 7. When 
injected onto Superdex 75, for which both molecules exceed the column exclusion limit, a 
tailed peak was observed respectively molecular characterized by molecular masses 
exceeding the column exclusion limit, gave a signal at 12 min. The same compound appears 
with multiple signals when injected onto Superdex 200.  
  
     DOTA-dendrimer- antibody conjugation. Antibody and sulphydryl free-DOTA dendrimers 
(SH-Gy-DOTAn-1) were conjugate by the use of BM(PEG)3, an homo-bifunctional linker 
which provides a centered polyethylene motif as spacer between two identical maleimido 
groups at the extremities. The latter are sensible for the selective coupling of two free 
sulphydryl groups. Bio-conjugation is schematically presented in Figure 5. 
      
As first, antibody was modified with BM(PEG)3 across the selective reduction of disulphide 
bridges in the hinge region by the use of TCEP as described elsewhere (1). In order to find the 
optimal condition of coupling, different aliquotes of antibody were reduced with a 2-fold 
molar excess of TCEP in presence of an 100-fold molar excess of BM(PEG)3 linker. For 
optimization purposes modified G0 dendrimer was used, and to each aliquote of modified 
antibody IgG-BM(PEG)3 different amounts (20-50-100 molar excess) of prepared active SH-
G0-DOTA3 were added. After steps of incubation and buffer exchange, modified IgG-G0-
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Fig. 5. Bio-conjugation scheme of DOTA-dendrimers to IgG antibody. 
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DOTA3 were loaded with holmium. To demonstrate the dependence of labeling yield from the 
amount of TCEP used for reduction of disulphide bridges into IgG, other aliquotes were 
prepared with a 20- or 40-fold molar excess of TCEP and conjugation with increasing molar 
excess (20-50-100) of SH-G0-DOTA3 was carried out. Labeled samples were diluted to 5 g 
mL
-1 
in antibody concentration and analyzed by SEC-ICP MS.  
As shown in Figure 6, the 20-fold molar excess of prepared SH-G0-DOTA3 was found 
enough for a complete reaction of all BM(PEG)3 moieties inserted, indipendently by the used 
molar excess of TCEP, into antibody 
molecule. For increasing concentrations of 
SH-G0-DOTA3 (50 and 100 molar excess) no 
significant variations for the signal at 16 min 
related to the holmium labeled IgG-G0-
DOTA3 were observed. Peak at 27 min 
represents the free holmium labeled SH-G0-
DOTA3, which increase as consequence of 
molar excess used. Maximum labeling was 
obtained when a 20-fold molar excess of 
TCEP was used, since no difference in signal 
intensity at 16 min was observed when the 
40-fold molar excess was employed. Then a 
20 fold-molar excess of TCEP, as well a 20-
fold molar excess of each SH-Gy-DOTAn-1 
were chosen for IgG modification. Labeling of each IgG-Gy-DOTAn-1 (y = 0-7) was further 
checked by injection of samples diluted to5 g mL
-1 
in IgG concentration into SEC-ICPMS 
system. Signal at 16 min for labeled antibody grew until the use of G2 dendrimer. Starting 
from G3 denrimer signal was found to decrease, and further disappeared corresponding to G5 
dendrimer, when only the signal related to free labeled dendrimer was observed. This effect 
might be the result of an ineffectiveness availability of free thiol group inserted into 
dendrimers, due to an elevated back-folding of surface groups as well from a steric hindrance 
given by the molecular sizes of  higher dendrimer generations during the reaction with 
antibody molecule. 
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Fig.6. Overlay of injected holmium labeled 
IgG-G0-DOTA3 at 5 g mL
-1
. Modified IgG 
signal appears at 16 min, and labeled free G0-
DOTA3 at 27 min. Signal for reactions carried 
out with a 2-fold molar excess of TCEP and 
increased amount (20-50-100 molar excess) of 
SH-G0-DOTA3 are presented by lines black, 
grey and blue respectively. Red line represents 
the elution of IgG modified with a 20-fold 
molar excess of TCEP. 
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     Liquid phase immunoassay. Reactivity of modified IgG-Gy-DOTAn-1 (y = 0-4) was tested 
by liquid phase immunossay as described elsewhere (1). Briefly, human serum samples 
containing human chorionic gonadotropin (hCG) antigen at different levels were incubated 
with the labeled IgG at 10 mg ml-1. for comparison purpose, a set of samples was incubated 
with a modified IgG with maleimido-DOTA (mDOTA) prepared as described in the 
experimental section. After incubation for 1 hour at 37°C, samples were analyzed by SEC-
ICPMS. Areas of signal immunocomplex eluted at 10 min was found to increase directly with 
the concentration of antigen and a linear relationship was established for each set of samples. 
For the other sets of samples results are reported in Table 3.        
Sensitivity of the 
immunoassay tends to 
increase with the number 
of elements loaded into 
antibody from the use of 
mDOTA to G1 dendrimer, 
when the limit of detection 
was reduced of more than 
10-fold. Starting from the 
labeling with G2 
dendrimer a decrease in sensitivity was achieved, and for G3 and G4 dendrimers it was not 
calculable since signal of immunocomplex was not observed in the chromatograms.  
The presence of dendrimers of 21.5 and 43.7 kDa respectively for G3 and G4, might affects 
the formation of immunocomplex, reducing the mobility necessary for a correct orientation of 
antibody arms carring the site for specific recognition of epitope of antigen. This effect of 
suppression in immunocomplex formation might be avoided by the use of a longer spacer 
than BMPEG3, and further developments in this direction are under exploration. 
 
 
 
 
 
 
 
 
 
Table 3. Sensitivities and limits of detection from liquid phase 
immunoassay for modified monoclonal antibody anti-hCG in 
human serum. 
Labeled IgG form   Linear regression   
LOD 
(mUI/mL) 
     
mDOTA  y = 0.15x + 732  10.1 
G0-DOTA3  y = 0.66x + 367  2.4 
G1-DOTA7  y = 2.61x + 884  0.6 
G2-DOTA15  y = 1.38x + 1105  1.1 
G3-DOTA31  N.C.  N.C. 
G4-DOTA63  N.C.  N.C. 
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CONCLUSIONS 
 
A new general approach based on PAMAM dendrimer for elemental labeling of monoclonal 
antibodies was investigated, for the first time, for application in immunoassay with ICP-MS 
detection. The approach provides the possibility of increase the number of elemental tags 
inserted into the biomolecule for each site of modification. Modification of amine surface 
groups to obtain the active DOTA modified dendriemr was succesfully followed and 
characterized by MALDI-MS, which permits, at least for dendrimer of lower generation (G0-
G2) the identification and consequent synthetic optimization of all species of interest. As 
result, after performing a liquid phase immunoassay with SEC-ICPMS method introduced 
recently by our work, an enhancement in sensitivity was recorded respect to the use of single 
labeling reagents. Howhever, various problems emerged from this former study. Regarding 
the effect of dimension of modified DOTA dendrimers on the antibody labeling, the coupling 
of dendritic reagent higher than fourth generation was found not possible. We ascribe this 
latter principally to two possible distinct effects as i) the steric hyndrance of dendrimer 
exceeding the 30-40 kDa in the insertion to the hinge region of antibody or ii) the not 
available free sulphidryl group onto dendrimer surface for the coupling with the cross-linker. 
Regard to the second point the use of a longest arm emerging from dendrimer surface might 
be a solution and is now under investigation. Furthermore, retain of immunoactivity was 
found only until labeling with second generation dendrimers, higlighting also an effect of 
steric hyndrance which prevent the formation of immunocomplex. These results suggest for 
further developments the use of dendrimer of low or half generation, if the modification of 
disulphide bridge for labeling purpose is taken into account.  
     In addition, a former study of behaviour of PAMAM dendrimers by size exclusion column 
based on an agarose-dextran polymeric matrix, shown peculiar features of these fascinating 
chemical structures. Indeed, the solution behaviour and the elution profiles support literature 
data from fully atomistic studies, especially in terms of pH effects and swelling due to solvent 
penetration into cavities of branched dendrimers. 
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Chapter 4 
 
The Role of ICP-MS in  
Metallodrugs-Proteins Interaction Monitoring  
 108 
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4.1. Reactivity of Anticancer Metallodrugs  
with Serum Proteins:  
New Insights from Size Exclusion 
Chromatoghraphy-ICP-MS and ESI-MS 
 
 
Abstract. A method based on the coupling of high resolution size-exclusion liquid 
chromatography using a polymer stationary phase with inductively coupled plasma mass 
spectrometry was developed to study the interactions of two metallodrugs - cisplatin and 
RAPTA-T (Ru(
6
-C6H5Me)(PTA)Cl2), where PTA = 1,3,5-triaza-7-phosphadamantane) - 
with the serum proteins albumin and transferrin. In contrast to previous approaches, the 
technique allowed the total recovery of the metals from the column and was able to 
discriminate between the different species of the metallodrug and its complexes with the 
proteins at femtomolar detection levels. Metal binding was found to be dependent on the 
protein concentration and on the incubation time of the sample. Cisplatin was found to bind 
the serum proteins to the same extent, whereas RAPTA-T showed marked preference for 
transferrin. The affinity of the ruthenium complex for holo-transferrin was higher than for the 
apo-form suggesting a cooperative iron-mediated metal binding mechanism. RAPTA-T 
binding to holo-transferrin was further investigated by electrospray mass spectrometry using 
both the intact protein and a model peptide mimicking the iron-binding pocket. 
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INTRODUCTION 
 
     Dating back to the Renaissance and to Paracelsus‟s alchemical studies, metals and 
minerals have profoundly fascinated physicians and have played a major role in the history of 
medicine.
1
 A large number of different metal salts and compounds are still used to treat a 
wide range of deseases. Notably, platinum coordination complexes are extensively used to 
treat cancer. Indeed, following the discovery of the anticancer properties of cisplatin in 1965 
by Rosenberg,
2
 considerable efforts have been made to both unravel the mechanism by which 
it exerts its anticancer effect and to develop alternative metal-based drugs.
3-5
 In recent years a 
vast number of non-platinum compounds have been prepared and evaluated as experimental 
anticancer drugs.
6, 7
 Among them, ruthenium(II)-arene complexes bearing 1,3,5-triaza-7-
phosphaadamantane (PTA) ligands – named RAPTA – have been found to exhibit promising 
antimetastatic properties in vivo.
8
 Their mechanism of action is still largely unknown, 
however, there is evidence to suggest that RAPTA compounds work on molecular targets 
other than DNA implying a biochemical mode of action profoundly different from classical 
platinum anticancer drugs.
9, 10
 Indeed, ruthenium compounds have been shown to directly 
interfere with specific proteins involved in signal transduction pathways and/or to alter cell 
adhesion and migration processes.
11
   
     An understanding of metallodrug-protein interactions is crucial since the pharmacological 
activity of a drug, even for drugs where DNA is the ultimate target, is usually modified upon 
protein binding. Metal drug-protein interactions are not only important with regard to 
apoptosis, but also with respect to unwanted side-effect (due to indiscriminate protein 
binding), drug resistance (due to binding/deactivation by metallothioneins,
12
 glutathione 
transferases,
13, 14
 etc.) and even possibly drug delivery and storage.
15
 Upon intravenous 
application, serum proteins including albumin, transferrin and globulins are thought to play a 
crucial role in the transport, delivery, and storage of anticancer metallodrugs. Human serum 
albumin (HSA) is the most abundant protein (about 52% of total serum protein) with a 
concentration of 40-45 g L
-1
 in healthy humans (ca. 600 M; Mw 66-67 kDa). It comprises a 
single chain of 585 amino acids organized in three similar domains, each composed of two 
subdomains.
16
 HSA is known to bind a remarkably wide range of drugs, thereby restricting 
their free, active concentrations.
17
 Reducing this binding affinity represent a major challenge 
in drug development. However, HSA can also be exploited for targeted delivery strategies, as 
in the case of organometallic ruthenium(II)-arene anticancer compounds, to develop 
compounds that can selectively accumulate in tumors cells.
18
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     Human serum transferrin (Tf) is a single-chain glycoprotein containing 679 amino acids 
with a molecular mass of about 80 kDa and is found in blood at a concentration of about 2.5 g 
L
-1
 (35 μM). Tf acts as an iron transporter and is capable of binding two iron(III) ions (Fe3+ is 
bound selectively over Fe
2+
).
19
 Tf is normally only 30% saturated with iron in the body,
19
 and 
at least 30 other metal ions can also bind to Tf.
20
 Therefore, it is possible to use Tf as a metal 
transporter within the body and the cellular uptake mechanism via the Tf-transferrin receptor 
transport system has the potential to be exploited for site-specific delivery of various 
therapeutic metal ions, drugs, proteins and genes.
21
 In the case of metallodrugs the resulting 
conjugates significantly improve the cytotoxicity and selectivity of the drugs itself. For 
example, anticancer Ru(III) complexes were reported not only to bind to Tf,
22, 23
 but it has 
been shown that injection of Ru(III)-Tf conjugates resulted in high tumor uptake of the 
metal,
24
 which suggests that Tf uptake appears to be the more important mode of transport of 
Ru(III) anticancer complexes to the tumor. In some cases, the Ru-Tf adducts exhibit a 
significantly higher antitumor activity against human cancer cells than the Ru(III) complex 
itself, attributable to the Tf-mediated uptake mechanism, which may also lower drug 
toxicity.
25
 
     The development of analytical methods capable of providing a better understanding of how 
metallodrugs interact with proteins remains challenging.
26, 27
 The direct monitoring of real-
time protein-mediated metabolism of anticancer agents using hyphenated (coupled, tandem) 
techniques, that combine chromatographic separation with sensitive and element-specific 
detection techniques such as inductively coupled plasma-mass spectrometry (ICP-MS) have 
been effectively used.
28-30
 In terms of separation techniques, high performance liquid 
chromatography (HPLC)
31, 32
 and capillary zone electrophoresis (CZE)
29,33-35 
 were proposed 
for the study of platinum and ruthenium based drugs, to assess kinetic constants of hydrolysis 
and subsequent reactions with a variety of physiological targets. This concept has also been 
transferred to study the distribution of gallium-based pharmaceuticals in human serum.
36
 
     Within this frame, we propose size-exclusion liquid chromatography (SEC) coupled to 
ICP-MS to study metal complexes-proteins interactions. We believe that SEC has certain 
advantages compared to other separation techniques to characterize metallodrug binding to 
biomolecules, and that in any case it could be used in concomitance with other hyphenated 
systems to obtain complementary information. In comparison to ion exchange 
chromatography (IEC), the main advantage of the SEC approach lies in the more "gentle" 
conditions, as IEC usually requires buffers with high ionic strength and extreme pH values.
37
 
The importance of working under more physiological-type conditions is crucial when 
studying metallodrugs to avoid interferences which might alter the metal-protein adducts and 
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the coordinative metal-ligand bonds. With respect to capillary electrophoresis (CE) the major 
advantage of the SEC separation lies in the ease and robustness of the coupling to ICP-MS 
which is considered one of the main problems of CE-ICP-MS and usually leads to higher 
limits of detection compared to LC-ICP-MS.
35, 38, 39 
Up to now, the SEC coupled to ICP-MS has been used to probe protein interactions with 
ruthenium drugs, but suffers from the poor recoveries because of the reactivity of the 
compounds with the column stationary phase.
40
 This problem was alleviated by using a short 
size-exclusion column at expense of the chromatographic resolution, or it was simply used as 
a first separation technique to roughly discriminate between bound and unbound species prior 
to ion-exchange separation.
40
 Therefore, the primary objective of our research was to evaluate 
a polymeric stationary phase with regard to the unspecific retention, reactivity and carryover 
of an organometallic drug RAPTA-T (Ru(
6
-C6H5Me)(PTA)Cl2) (Chart 1), and its adducts, 
with the serum proteins albumin and transferrin, in comparison to cisplatin. The binding of 
RAPTA-T towards intact Tf and the possible binding sites of the metallodrugs on a model 
peptide mimicking one of the iron-binding pockets of Tf were also investigated using 
electrospray ionization-mass spectrometry (ESI-MS). 
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EXPERIMENTAL SECTION 
 
     Reagents. Cisplatin, human serum albumin (>99%, HSA), human holo transferrin (>98%, 
hTf) and human apo transferrin (>97%, apo-Tf) were obtained from Sigma-Aldrich. Sodium 
chloride, formic acid, Tris(hydroxymethyl)aminomethane hydrochloride, ammonium acetate 
and ammonium hydrogencarbonate were also purchased from Aldrich and were of analytical 
reagent grade. Buffers used for SEC-ICP-MS analysis were prepared as follows: ammonium 
acetate buffer (100 mM, pH 6.8) and Tris buffer saline (20 mM Tris-HCl, 100 mM NaCl, pH 
7.2). De-ionized water (18 M /cm) (Millipore, Bedford, MA) was used throughout. RAPTA-
T was synthesized as described elsewhere.
8
 The HPLC-purified model peptide 
(KDCHLAQVPSHTV) was purchased from PSL (Heidelberg, Germany). 
     ICP-MS instrumentation. An Agilent model 1200 binary pump, equipped with an 
autosampler, automatic injection system with a loop of 900 L and a UV-VIS detector was 
used as the solvent delivery system and was controlled by Agilent ChemStation software. An 
Agilent 7500ce ICP-MS fitted with a Meinhardt nebulizer was used as the detector in SEC-
ICP-MS experiments, employing the following conditions: plasma gas (Ar) 15 L min
-1
, 
forward power 1500 W, carrier gas 1.05 L min
-1
. The working conditions were optimised 
using a 1 µg L
-1
 solution of 
7
Li
+
, 
89
Y
+
 and 
205
Tl
+
 in 2% HNO3, with a dwell time of 100 ms for 
each isotope. For iron isotope monitoring, a collision cell was used to remove polyatomic 
interferences with H2 (3-3.5 ml min
-1
) and He (1.0 ml min
-1
) as auxiliary gases. Double 
charged ions and oxide levels were minimized by using 
140
Ce
+
 and were typically < 2%. The 
isotopes monitored (in time resolved analysis mode with a dwell time of 100 ms each) were 
54
Fe, 
56
Fe, 
195
Pt, 
196
Pt
 
, 
197
Pt
 
, 
198
Pt
 
, 
100
Ru, 
101
Ru and 
102
Ru. The 
54
Fe, 
56
Fe, 
102
Ru,
 195
Pt and  
isotopes were used for quantification of binding and uptake. 
     Size-exclusion chromatography. Samples were analyzed on a Superdex  200 HR 10/30 
(10 mm x 300 mm x 13 m) (GE Healthcare) exclusion column with approximate bed volume 
of 24 mL and a linear separation range of 10-600 kDa for globular proteins. The column was 
calibrated as specified by the manufacturer with a mixture of thyroglobulin (670 kDa), hTf 
(81 kDa), bovine albumin (66 kDa), chicken egg albumin (44 kDa), Mn superoxide dismutase 
(39.5 kDa), Cu/Zn superoxide dismutase (32.5 kDa), carbonate dehydratase (29 kDa) and 
myoglobin (16.7 kDa) using UV/VIS detection at 280 nm with baseline evaluation at 800 nm. 
Retention times (in min) plotted versus the logarithm of molecular mass (in kDa) showed 
linear correlation (y = -0.134 x + 4.385; r
2
=0.992). Elution was carried out isocratically at 0.7 
mL min
-1
 using 100 mM ammonium acetate (pH 6.8) as the mobile phase. Solvent flow from 
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the chromatographic system was introduced into the ICPMS nebulizer by means of PEEK 
tubing. 
     Sample preparation for SEC-ICP-MS. Cisplatin and RAPTA-T stock solutions were 
prepared by dissolving the compounds in ammonium acetate buffer or in Tris buffer. Proteins 
were dissolved in ammonium acetate at a concentration 0.5 mM. To investigate the 
interactions between serum proteins and the metal complexes, samples were initially prepared 
with various protein concentrations (1, 50 and 250 M) and adding the appropriate amounts 
of metal complex to achieve different protein:metal stoichiometric ratios (1:1, 1:2 or 1:5) at 
each protein concentration. In the case of 250 M protein samples only a maximum two-fold 
molar excess of the metal complex was applied due to protein precipitation phenomena for 
transferrin. Samples were then incubated for 1 hour at 37°C and then diluted in ammonium 
acetate buffer to yield a final protein concentration of 1 M prior to injection into the SEC 
column. Alternatively, for the evaluation of maximum metal binding, the protein 
concentration was fixed at 50 M, while each metal complex was added in stoichiometric 
amount or in 2, 5, 10 and 18-fold excesses. Metal complex solutions were added freshly 
prepared (sample Set A) or 24 h after preparation (sample Set B; solution stored at 4°C) in 
ammonium acetate buffer. Samples were then incubated for 1 h at 37 °C and diluted to 1 M 
protein before injection. Quantification of the metal content in each chromatographic fraction 
was calculated directly from the integrated signal from the SEC-ICP-MS chromatograms 
using the formula cb = Mb x cinj x D, where cb represents the initial concentration of metal in 
the original sample, Mb is the fraction of metal bound to protein in the chromatogram 
(calculated as a percentage of bound metal signal with respect to the total sum of signals), cinj 
is the concentration of metal injected for analysis and D is the dilution factor applied to the 
samples prior to injection.  
     ESI-MS analysis. For ESI-MS experiments with the model peptide, samples were prepared 
with a metallodrug:peptide ratio of 1:1 (25 M) in 20 mM carbonate buffer (pH 7.4) and 
incubated for 24 h at 37° C prior to analysis. Samples were then mixed with acetonitrile and 
formic acid (final concentration 30% and 0.1%, respectively) and placed into a 96-well plate 
in an Advion TriVersa robot (Advion Biosciences, Ithaca, NY) equipped with a 5.5 μm-
nozzle chip. The ESI robot was controlled with ChipSoft v7.2.0 software employing the 
following parameters: gas pressure 0.45 psi; voltage 1.7 kV. The samples were analyzed in 
positive ion mode using a LTQ XL mass spectrometer (ThermoFisher Scientific, Bremen, 
Germany). The Xcalibur software bundle was utilized for data acquisition and data analysis. 
ESI-MS measurements of apo transferrin-metallodrug interactions were carried out on an 
Ultima II q-TOF mass spectrometer (Waters, Manchester, UK) operated in positive mode. 
 116 
Data acquisition and analysis were carried out using the MassLynx software bundle (Waters). 
The instrument was calibrated daily using a 0.01% phosphoric acid solution in 50% 
acetonitrile. Samples were prepared with a metallodrug:protein ratio of 5:1 in 20 mM 
carbonate buffer (pH 7.4) and incubated for up to 24 h at 37° C. Prior to analysis, samples 
were ultracentrifuged using 30kDa cut-off filters (VWR, Switzerland) to remove unbound 
metallodrugs and injected into the ESI-MS system after dilution with acetonitrile and formic 
acid (final concentrations 25% and 0.05%, respectively). 
 
RESULTS AND DISCUSSION 
 
Size-exclusion chromatography of cisplatin and RAPTA-T.  
     SEC-ICP-MS system was initially used to evaluate solutions of 
the two metal drugs, cisplatin and RAPTA-T (Chart 1), in the 
absence of any protein in order to establish the evolution of metal 
species. Based on the molecular weight of the complexes (300-
400 Da) an expected single peak with a total bed column volume 
(  24 ml), corresponding to 35 min at flow rate of 0.7 mL min
-1
, 
might be expected to elute from the column. Two different buffers, 
namely Tris buffer saline (TBS) and ammonium acetate (pH  7), 
were evaluated as incubation media and 
eluent for cisp latin and RAPTA-T 
hydrolysis. For method development, 
50 l of 1 M cisplatin (195ng mL
-1
, 
50pmol of Pt) or RAPTA-T (102ng mL
-1
, 
50pmol of Ru) in the respective buffers 
were injected into the SEC column either 
freshly prepared or pre-incubated for 12 
hours at 37 °C. Elution profiles for the 
two drugs in TBS are shown in Figure 1. 
In the case of cisplatin (Figure 1, top 
spectrum), freshly prepared solution 
gave signals at 32 and 42 min, while for 
the sample obtained after 12 hours 
incubation an additional peak appeared 
at 28 min. In both cases the peak at 42 min (intact cisplatin) was the most intense. Peaks at 32 
P
N
N
N
Ru
Cl
Cl
Pt
Cl
Cl
H3N
H3N
 
 
Chart 1. Structures of 
cisplatin (up) and 
RAPTA-T (bottom). 
Figure 1. SEC-ICP-MS elution profiles of the 
investigated metallodrugs. The upper chromatogram 
compares a freshly prepared cisplatin solution (black 
trace) to a cisplatin solution after 12 h incubation at 
37°C (red trace): peak 3 at 28 min: diaqua complex; 
peak 2 at 31 min: monoaqua complex; peak 1 at 40 
min: intact cisplatin. The bottom chromatogram 
shows the single elution peak (peak 4) of RAPTA-T 
at 28 min. 
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and 28 min corresponded to cisplatin hydrolysis products (mono- and bis-aqua species, 
respectively) as confirmed by ESI-MS analysis. In ammonium acetate buffer, these 
compounds were detected at the same elution times, but more extensive hydrolysis of 
cisplatin was observed due to the absence of chlorido ions in the buffer. To be note, the 
separation of different forms of metallodrugs arise from aspecific interactions with the 
stationary phase, since no differentiation is possible based on their low molecular wheights. 
Howhever, elution times were found constants after multiple injection of metallodrug. Only 
for peak eluting at 40 min well after a total column volume, slight shifts of  2 min in its 
elution time were observed. When RAPTA-T was injected, either freshly prepared or after 12 
hours of incubation, only a single symmetric peak at 28 min of the chromatographic run was 
observed regardless of the buffer employed (Figure 1, bottom spectrum). This peak probably 
corresponds to the intact complex or to the mono-acqua [Ru(
6
-C6H5Me)(PTA)ClH2O] 
species as suggested by ESI-MS analysis and UV-visible spectrophotometry (data not shown). 
Recovery experiments, based on the comparison of the metal content in the injected sample 
and the eluate, showed that the metals were not retained on the stationary phase. Indeed, 
recovery values for cisplatin and RAPTA-T were 100  2% and 93  3% respectively, in both 
buffers. The baseline remained stable during the analyses and a post-analysis injection of 
HSA gave a blank chromatogram. 
 
Interaction of metallodrugs with serum proteins.  
     The binding of cisplatin and RAPTA-T to transferrin - both holo (hTf) and apo-transferrin 
(apo-Tf) - and human serum albumin was investigated by SEC-ICP-MS. Since no differences 
in the chromatographic separation of the complexes were observed as a function of the buffer, 
ammonium acetate was selected as it exhibited sufficient ionic strength to limit the 
interactions of the proteins with the stationary phase and is better tolerated in ICP-MS.
41
 The 
two proteins investigated in this study have a molecular mass which is not expected to be 
separated by this SEC column. In fact, calculated elution times for transferrin and albumin 
from column calibration curve are 18.5 and 18.9 minutes when molecular weights of 80 and 
70 kDa are taken into account.  
     Holo- and apo-transferrin were analyzed first in order to establish their elution time; note 
that hTf carries iron which can be used for ICP-MS analysis. Figure 2 shows the 
chromatograms (
56
Fe
+
) of 1 M hTf and apo-Tf samples in comparison to the ion 
chromatograms (
102
Ru
+
, 
195
Pt
+
) of the metallodrugs to demonstrate the baseline separation of 
the iron-containing protein peak from the other metal species present in solution. The results 
show that the apo-Tf is not completely iron-free. To establish the amount of iron present in 
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holo- and apo-transferrin, the 
proteins were digested and 
analyzed by ICP-MS. The results 
reveal a stoichiometric 
metal:protein ratio of 1.22  0.12 
for hTf and 0.20  0.05 for apo-Tf. 
Notably, there is no change in 
retention time for both Tf and 
HSA keep upon adduct formation 
with the metallodrugs, since the 
resulting increase in the molecular 
mass is negligible. It is worth 
mentioning that in the case of the 
incubation mixtures between Tf 
and HSA with both drugs, recovery 
experiments shown values as 
calculated for the free compounds. 
Due to the high resolution 
separation of the metal-containing 
species and their excellent 
recovery rates, quantitative data on 
the amount of drug binding could 
be extracted directly from the 
chromatograms. With the 
optimized method two types of 
experiments were set up. These 
experiments aimed at, first, 
observing the effect of different 
protein concentrations and relative protein:metal ratios on the adduct formation, and second, 
quantitating the extent of adduct formation at increasing metallodrug concentrations. 
 
     Effect of protein concentration on adduct formation. Different concentrations (1, 50 and 
250 M) of single serum proteins were incubated with each metal complex at different 
protein:metal ratios (1:1, 1:2 and 1:5) for 1 hour at 37°C. Representative SEC-ICP-MS 
chromatograms for samples of HSA incubated with RAPTA-T are given in Figure 3, the 
 
Figure 2. Overlay of selected ion chromatograms for both 
holo-transferrin (red trace) and apo-transferrin (blue trace) 
eluting at 19 min (peak 1: Tf; 
56
Fe
+
) with chromatograms of 
both RAPTA-T (dotted line in peak 2: free complex; 
102
Ru
+
) 
and cisplatin (peak 3: intact complex, peak 4: monoacqua 
complex, and peak 5: diaqua complex; 
195
Pt
+
). 
 
Figure 3. SEC-ICP-MS chromatogram of HSA incubated 
with RAPTA-T at different protein:metal ratios for 1 h at 
37°C. 1:1 (top) and 1:5 (bottom). Protein concentrations are 
1 M (dotted line), 50 M (thin line) and 250 M (bold 
line). All samples were diluted to 1 M (protein) prior to 
injection into the SEC-ICP-MS system. The peak at 19 min 
corresponds to the HSA-RAPTA-T adduct, the peak at 28 
min to free RAPTA-T. 
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whole dataset for interactions of the serum proteins with RAPTA-T and cisplatin is 
summarized in Table 1. The data indicate that RAPTA-T can bind equally to both hTf and 
apo-Tf but to a significantly greater 
extent compared to cisplatin, 
regardless of the applied 
concentrations and metal 
complex:protein ratios.  
In contrast, similar metal binding of 
both metallodrugs with HSA was 
observed. In particular, since the short 
incubation time does not allow 
reaching the thermodynamic 
equilibrium, a kinetic preference of 
RAPTA-T for binding to Tf was 
detected with respect to HSA. 
However, it must be considered that 
HSA is about 20-times more 
concentrated than Tf in blood and 
therefore favoured for metal binding, 
as shown for the ruthenium(III) 
anticancer compound KP1019.
42
 Interestingly, the incubation concentrations affect the 
formation of protein-metal adducts, metal binding being favoured at higher concentrations of 
both the metallodrugs and the proteins.  
 
Influence of hydrolysis on protein binding.  
     Further experiments on protein binding and relative binding affinities of the metallodrugs 
were performed using a fixed concentration of proteins, 50 M, (which represents a 
concentration similar to that of Tf in blood) incubated with different amounts of the 
metallodrugs. Quantitative metal binding data were calculated based on the fraction eluted at 
19 minutes in the SEC-ICP-MS profiles. In Table 2, results from each protein sample treated 
with RAPTA-T or cisplatin and incubated for 1 hour at 37 °C are shown. Dataset A represents 
data for samples with freshly prepared solutions of the metal complexes and Dataset B for 
samples with metal complex solutions pre-incubated for 24 hours prior addition to the protein 
to study the effect of metallodrug hydrolysis on protein binding. 
Protein 
( M) 
Drug 
( M) 
Molar ratio 
metal:protein 
Metal bound (%) 
  
 
cisplatin 
RAPTA-
T 
hTf     
250 250 1 17.3 38.4 
250 500 2 16.0 30.4 
50 50 1 5.9 19.0 
50 250 5 5.7 16.9 
1 1 1 0.2 1.1 
1 5 5 0.3 0.8 
apo-Tf      
250 250 1 14.5 37.2 
250 500 2 14.8 36.6 
50 50 1 2.9 10.1 
50 250 5 3.2 9.7 
1 1 1 0.2 0.7 
1 5 5 0.2 0.7 
HSA      
250 250 1 21.1 18.7 
250 500 2 20.8 18.1 
50 50 1 6.6 7.5 
50 250 5 5.3 6.8 
1 1 1 0.5 0.3 
1 5 5 0.6 0.4 
 
Table 1. Evaluation of metal binding by SEC-ICP-MS 
for samples with different metallodrug:protein ratios, 
incubated for 1 h at 37°C. Results are the average of 
three independent experiments with S.D. < 2%. 
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     The most notable difference between the two preparations corresponds to the availability 
of the different forms of the metallodrugs. For instance, in Dataset B higher contents of 
hydrolyzed products are present for cisplatin with respect to Set A. Since cisplatin hydrolysis 
products carry a positive charge, their interaction with negatively charged amino acid residues 
on the protein chains (possible under these conditions considering calculated pI values are 
5.92 and 6.81 for HSA and Tf, respectively)
43
 potentially increases interactions compared to 
the neutral starting compound. Moreover, the hydrolized product is more reactive as the aqua 
ligands are more labile than chlorido ligands. In Set B, platinum adducts are formed to a  
 
Compound 
Molar ratio 
metal:protein 
(theoret.) 
Set A ( M)  
Molar ratio  
metal:protein 
(experimental) 
Set B ( M)  
 Molar ratio  
metal:protein 
(experimental) 
  hTf 
 1 1.4 0.03 1.7 0.03 
 2 2.7 0.05 3.3 0.07 
Cisplatin 5 6.4 0.13 7.5 0.15 
 10 8.1 0.16 14.4 0.29 
 18 11.4 0.23 16.9 0.34 
      
 1 8.5 0.17 8.2 0.16 
 2 14.7 0.29 15.3 0.31 
RAPTA-T 5 33.1 0.66 32.3 0.65 
 10 56.8 1.14 57.0 1.14 
 18 70.9 1.42 69.4 1.39 
  apo-Tf 
 1 1.0 0.02 1.7 0.03 
 2 2.0 0.04 3.1 0.06 
Cisplatin 5 4.4 0.09 7.0 0.14 
 10 7.6 0.15 14.0 0.28 
 18 12.2 0.24 19.2 0.38 
      
 1 3.2 0.06 4.6 0.09 
 2 7.8 0.16 8.8 0.18 
RAPTA-T 5 16.0 0.32 18.5 0.37 
 10 26.1 0.52 34.7 0.69 
 18 33.1 0.66 52.9 1.06 
  HSA 
 1 2.1 0.04 3.9 0.08 
 2 4.3 0.09 6.8 0.14 
Cisplatin 5 7.3 0.15 11.8 0.24 
 10 10.0 0.20 16.7 0.33 
 18 11.2 0.16 17.4 0.35 
      
 1 3.3 0.07 3.8 0.08 
RAPTA-T 2 6.7 0.13 7.1 0.14 
 5 13.3 0.27 15.9 0.32 
 10 20.3 0.41 30.4 0.61 
 18 24.2 0.48 32.0 0.64 
 
Table 2. Quantification of adduct formation between cisplatin and RAPTA-T with the serum proteins hTf, apo-Tf and 
HSA. Protein concentration was fixed at 50 M, the metal:protein ratio varied between 1:1 and 18:1. Samples were 
incubated for 1 h at 37°C (Set A: freshly prepared metal complex solution added. Set B: 24 h pre-incubated metal 
complex solution added.). Results are the average of three independent experiments with S.D. < 2%. 
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greater extent with respect to Set A at any concentration. In general, for both datasets, 
cisplatin shows a slightly increased affinity towards HSA at lower molar excess of drug and 
no apparent preference for the two forms of transferrin. Upon increasing the drug excess, the 
reaction proceeds more rapidly and, as expressed by an increased number of metal ions bound 
per protein molecule, the proteins are metallated to a higher degree. 
For RAPTA-T, a higher affinity is found for hTf with respect to apo-Tf and HSA, and the 
amount of ruthenium bound to hTf is similar in Set A and Set B. For apo-Tf and HSA, 
increased binding is observed for the Set B samples, especially at high metal:protein ratios. 
Based on the ratio of the metal concentration of the bound fraction, for cisplatin maximum 
binding was in the range from 0.2 to 0.35 for all three proteins. For RAPTA-T the highest 
metal binding was observed for hTf, with an average of ca. 1.4 ruthenium ions per protein. 
For apo-Tf and HSA an average 0.5 to 1.0 ruthenium ions bind per protein, which is higher 
than observed for cisplatin. In comparison to previously reported data using CZE-ICP-MS, 
which shows extensive binding of cisplatin toward the protein (up to 4 Pt ions per molecule of 
HSA for a sample containing a 10-fold excess of metal complex after 24 hours incubation in 
PBS buffer), the values obtained for cisplatin-HSA adduct formation in our experiments were 
unexpected.
33
 Therefore, protein samples incubated for 24 hours with a 10-fold excess of 
cisplatin or RAPTA-T were studied. For all the three proteins increased metal binding for 
both metallodrugs was detected (Table 3), although not to the same levels observed by CZE-
ICP-MS.  
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
Incubation 
time 
 Cisplatin RAPTA-T 
  
metal 
bound 
( M) 
metal:protein 
ratio 
metal 
bound 
( M) 
metal:protein 
ratio 
 hTf 8.1 0.16 56.8 1.14 
1 hour 
apo-
Tf 
7.6 0.15 26.1 0.52 
 HSA 10.0 0.20 20.3 0.41 
      
 hTf 31.6 0.6 93.5 1.9 
24 hours 
apo-
Tf 
25.6 0.5 50.8 1.0 
 HSA 36.6 0.7 46.3 0.9 
 
Table 3. Influence of different incubation times (1 and 24 h) on the extent of adduct formation 
between metallodrugs and the serum proteins. Protein concentration was fixed at 50 M with a 
metal complex:protein ratio = 10:1. Results are the average of three independent experiments with 
S.D. < 2%. 
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Overall, the low detection limits of the applied method allowed analysis of samples 
containing 400 fmol of metals bound to the proteins, with as little as 2 pmol of protein 
injected into SEC column. In the case of RAPTA-T, the higher amount of ruthenium bound to 
hTf with respect to apo-Tf suggests that the presence of iron bound to protein might influence 
the formation of metal complex adducts, most likely maintaining a protein folding which 
favours metallodrug binding.  
 
Metallodrug binding versus iron loss in holo-transferrin.  
     Despite the higher affinity of RAPTA-T than cisplatin for hTf, no differences in terms of 
the released iron were observed. Figure 4 shows the binding behaviour of both metal 
complexes for hTf, together with the 
decrease of the iron signal recorded by 
ICP-MS, for each concentration of 
metal complex. The graph shows that 
the iron is not released in a linear 
fashion. In fact, the iron signal 
decreases only slightly until a 10-fold 
molar excess (500 M) of the 
metallodrug and then immediately drops 
to the half of its original value.  
As the employed hTf was only ca. 60% 
loaded with iron, these data suggest that initially metallodrug binding occurs at the iron-free 
protein active sites and therefore does not affect the iron release. Afterwards, in the presence 
of excess of metallodrug, significant iron release may result from the partial denaturation or 
conformational changes of Tf upon addition of excess of metal, in agreement with previous 
observation on cisplatin binding to hTf by Hoshino et al..
33
 
 
ESI-MS studies with transferrin and an iron binding site-model peptide.  
     As the interactions of cisplatin with intact transferrin studied by ESI-MS have already been 
reported earlier,
44
 only the binding of RAPTA-T to transferrin was further investigated by 
ESI-MS in this study. Figure 5 shows the spectrum of apo-Tf treated with a 5-fold excess of 
RAPTA-T and incubated for 1 hour at 37° C, in comparison to the pure protein. The spectra 
of the RAPTA-T treated samples show additional signals corresponding to adduct formation 
with the ruthenium compound. Based on the mass difference, these signals are attributable to 
RAPTA-T after loss of both chlorido and PTA ligands and subsequent addition of a carbonate 
 
Figure 4. Concentration dependent binding of cisplatin 
and RAPTA-T towards holo-transferrin. 
 Pt = square; Ru = circle. Dotted traces represent the 
corresponding iron signal.  
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anion. The fact that only the arene ligand stays attached to the metal centre is in good 
agreement with data obtained for interactions of RAPTA compounds with cytochrome c,
45
 
and the coordination of carbonate is also not surprising under the conditions employed. It is 
worth noting that a synergistic carbonate anion interaction is also crucial for stabilizing the 
binding site to ensure efficient binding of iron to transferrin. 
 
 
 Furthermore, the exact binding 
mode of cisplatin and RAPTA-T 
towards Tf and the nature of the 
species that bind to the protein as 
well the identification of the 
amino acids involved were 
probed by ESI-MS utilizing a 
model peptide consisting of the 
active site residues 
239
KDCHLAQVPSHTV
251
 of 
Tf. This peptide contains the 
His249 residue, which is 
involved in the iron binding in 
Tf, but also threonine and 
cysteine, residues which are 
possible binding partners.
44, 46, 47
 The model peptide was incubated with the metallodrugs 
under simulated physiological conditions (pH 7.4, 37 °C) for 24 hours and then analysed. The 
bound species were identified as RAPTA-T and cisplatin after loss of the chlorido ligands, 
indicating a bidentate binding to the peptide. Although loss of a chlorido ligand could also be 
induced during ionization, a multidentate binding mode seems more probably due to 
hydrolysis of the compounds under the used incubation conditions. Different amino acids 
  
Figure 5. ESI-MS spectrum of pure apo-transferrin (left) and incubated with RAPTA-T for 1 h at 
37° C at a metallodrug:protein ratio of 5:1 (right). Stars indicate the additional peaks caused by the 
adduct formation. 
 
 
Figure 6. MS/MS spectra of the transferrin iron-binding 
site model peptide after incubation with RAPTA-T 
revealing histidine as the binding partner. The insets 
show the [M+Ru(T)]
2+
 (T = toluene) ion at 813.6 m/z as 
well as the [b4+Ru(T)-H]
+
 ion at 675.9 m/z with an 
isotopic distribution characteristic for ruthenium. The 
fragmented parent ion corresponds to 
[M+Ru(PTA)(T)+H]
3+
. 
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depending on the metal complex were identified as binding partners upon collision induced 
dissociation (CID) of the modified peptide, as can be seen from Figures 6 and 7. The insets 
show signals of metallated ions, exhibiting characteristic isotopic patterns induced by the 
ruthenium and platinum, which facilitate the identification of modified residuies. In general, 
the remaining ligands of the metallodrugs (amino for cisplatin, toluene and PTA for RAPTA-
T) were dissociated more easily than the peptide bonds under fragmentation conditions, 
indicating the formation of strong bonds between the amino acids and the metals. For 
RAPTA-T (Figure 6), the first histidine residue appears to be the major binding partner, as 
evidenced by the presence of the modified b4 ion in contrast to the unmodified y9 ion 
following CID. This is not surprising since nitrogen donor ligands are known to form strong 
complexes with ruthenium. Interestingly, no binding towards the histidine residue in position 
11 of the peptide (iron binding His249 in transferrin) could be detected for the ruthenium 
compound, indicating that the cysteine residue might also be involved in the binding of 
RAPTA-T. It also worth mentioning that cleavage of the peptide occurs predominately next to 
the metal binding site, resulting in low relative abundances of other b and y fragment ions. 
In the case of cisplatin (Figure 7), the sulphur containing cysteine residue seems to be 
responsible for the binding. 
CID resulted in a more 
extensive fragmentation of the 
peptide as compared to 
RAPTA-T, and unmodified b2 
and y10 in contrast to modified 
b3 and y11 ions allow 
unambiguous identification of 
the binding site. Although these 
data are in agreement with 
previous studies which show 
that cisplatin readily reacts with 
sulphur containing 
biomolecules such as glutathione or metallothionein within the cell,
48
 caution should be 
applied to the validity of the model peptide in terms of comparability to intact proteins. As it 
has been shown in earlier proteomic studies of transferrin-cisplatin interaction
44
 as well as on 
samples extracted from E. coli upon incubation with a ruthenium-arene compound and 
cisplatin,
49, 50
 oxygen atoms in the carboxy- and hydroxyl-functions of certain residues (e.g. 
aspartate, serin, threonine) may also serve as binding partners in biological systems. 
 
Figure 7. MS/MS spectra of the transferrin iron-binding site 
model peptide after incubation with cisplatin revealing cysteine 
as the binding partner. The insets shows the [y11+Pt(NH3)-H]
+
 
ion at 1401.2 m/z with an isotopic distribution characteristic of 
platinum. The fragmented parent ion corresponds to 
[M+Pt(NH3)2+H]
3+
. 
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Consequently, protein conformation has a strong influence on the site and type of adduct 
formed as exposed residues might be more easily accessible and therefore more reactive than 
those buried in the folded protein. Although such structural features cannot be mimicked by a 
short, linear model peptide, the general reactivity of a compound in the presence of several 
possible binding amino acids can be assessed. 
 
CONCLUSIONS 
      
     High resolution SEC-ICP-MS based on a polymer stationary phase was demonstrated, for 
the first time, to be a powerful tool for the analysis of metal drugs with serum proteins. The 
approach provides information on the affinity of each metallodrug for the selected proteins, 
quantification of metal uptake and on the stoichiometry of the metal-protein complexes. The 
primary advantage of this approach over the previous SEC-ICP-MS methods is that all the 
metal species are quantitatively recovered under the separation conditions. Although the SEC 
system was not suitable for the baseline separation of samples containing both HSA and Tf, it 
proofed to be an efficient tool to analyze the binding of metallodrugs to single proteins and in 
principle could be developed to investigate complex protein mixtures. Indeed, recently the use 
of SEC hyphenated to ICP atomic-emission spectrometry has been successfully applied for 
metalloproteome studies of human plasma.
51
 The reported results highlight the different 
reactivity of cisplatin and the antimetastatic ruthenium-based drug RAPTA-T. The latter 
compound showed a preferential binding for Tf with respect to HSA, while cisplatin was less 
selective, being able to bind both proteins to a similar extent. Differences in the selectivity of 
cisplatin and RAPTA compounds were already identiﬁed using an ESI-MS based approach to 
study protein mixtures.
52, 53
 In particular, cisplatin was found to be moderately reactive 
towards the protein without any discrimination/selectivity, whereas the RAPTA compound 
was considerably more reactive and could also bind selectively. Such selectivity has important 
implications for the mode of action of the metallodrugs in the cell, leading to the efficacy of 
the compound towards specific tumor types, and presumably also for their toxic side effects. 
 126 
References 
 
1. C. S. W. Koehler, Today's Chemists at Work, 2001, 61-65. 
2. B. Rosenberg, L. Vancamp and T. Krigas, Nature, 1965, 205, 698-&. 
3. M. J. Clarke, F. C. Zhu and D. R. Frasca, Chem Rev, 1999, 99, 2511-2533. 
4. J. Reedijk, P Natl Acad Sci USA, 2003, 100, 3611-3616. 
5. A. Casini, C. Hartinger, C. Gabbiani, E. Mini, P. J. Dyson, B. K. Keppler and L. Messori, J Inorg 
Biochem, 2008, 102, 564-575. 
6. S. Nobili, E. Mini, I. Landini, C. Gabbiani, A. Casini and L. Messori, Med Res Rev, 2009. 
7. T. Gianferrara, I. Bratsos and E. Alessio, Dalton T, 2009, 37, 7588-7598. 
8. C. Scolaro, A. Bergamo, L. Brescacin, R. Delfino, M. Cocchietto, G. Laurenczy, T. J. Geldbach, G. 
Sava and P. J. Dyson, J Med Chem, 2005, 48, 4161-4171. 
9. P. J. Dyson and G. Sava, Dalton T, 2006, 1929-1933. 
10. A. Bergamo and G. Sava, Dalton T, 2007, 1267-1272. 
11. A. Bergamo, A. Masi, P. J. Dyson and G. Sava, Int J Oncol, 2008, 33, 1281-1289. 
12. M. Knipp, Curr Med Chem, 2009, 16, 522-537. 
13. W. H. Ang, L. J. Parker, A. De Luca, L. Juillerat-Jeanneret, C. J. Morton, M. Lo Bello, M. W. Parker 
and P. J. Dyson, Angew Chem Int Edit, 2009, 48, 3854-3857. 
14. W. H. Ang, A. De Luca, C. Chapuis-Bernasconi, L. Juillerat-Jeanneret, M. Lo Bello and P. J. Dyson, 
Chemmedchem, 2007, 2, 1799-1806. 
15. J. Reedijk, Chem Commun, 1996, 801-806. 
16. X. M. He and D. C. Carter, Nature, 1992, 358, 209-215. 
17. J. Ghuman, P. A. Zunszain, I. Petitpas, A. A. Bhattacharya, M. Otagiri and S. Curry, J Mol Biol, 2005, 
353, 38-52. 
18. W. H. Ang, E. Daldini, L. Juillerat-Jeanneret and P. J. Dyson, Inorg Chem, 2007, 46, 9048-9050. 
19. P. T. Gomme and K. B. McCann, Drug Discov Today, 2005, 10, 267-273. 
20. H. Z. Sun, H. Y. Li and P. J. Sadler, Chem Rev, 1999, 99, 2817-2842. 
21. H. Y. Li and Z. M. Qian, Med Res Rev, 2002, 22, 225-250. 
22. C. A. Smith, A. J. SutherlandSmith, B. K. Keppler, F. Kratz and E. N. Baker, J Biol Inorg Chem, 1996, 
1, 424-431. 
23. F. Kratz, M. Hartmann, B. Keppler and L. Messori, J Biol Chem, 1994, 269, 2581-2588. 
24. P. Som, Z. H. Oster, K. Matsui, G. Guglielmi, B. R. R. Persson, M. L. Pellettieri, S. C. Srivastava, P. 
Richards, H. L. Atkins and A. B. Brill, Eur J Nucl Med, 1983, 8, 491-494. 
25. F. Kratz, B. K. Keppler, M. Hartmann, L. Messori and M. R. Berger, Metal Based Drugs, 1996, 15-23. 
26. A. R. Timerbaev, C. G. Hartinger, S. S. Aleksenko and B. K. Keppler, Chem Rev, 2006, 106, 2224-
2248. 
27. X. S. Sun, C. N. Tsang and H. Z. Sun, Metallomics, 2009, 1, 25-31. 
28. J. S. Becker and N. Jakubowski, Chem Soc Rev, 2009, 38, 1969-1983. 
29. E. E. M. Brouwers, M. Tibben, H. Rosing, J. H. M. Schellens and J. H. Beijnen, Mass Spectrom Rev, 
2008, 27, 67-100. 
30. R. Lobinski, D. Schaumloffel and J. Szpunar, Mass Spectrom Rev, 2006, 25, 255-289. 
31. S. Hann, Z. Stefanka, K. Lenz and G. Stingeder, Anal Bioanal Chem, 2005, 381, 405-412. 
 127 
32. D. Esteban-Fernandez, M. Montes-Bayon, E. B. Gonzalez, M. M. G. Gomez, M. A. Palacios and A. 
Sanz-Medel, J Anal Atom Spectrom, 2008, 23, 378-384. 
33. A. R. Timerbaev, K. S. Aleksenko, K. Polec-Pawlak, R. Ruzik, O. Semenova, C. G. Hartinger, S. 
Oszwaldowski, M. Galanski, M. Jarosz and B. K. Keppler, Electrophoresis, 2004, 25, 1988-1995. 
34. K. Polec-Pawlak, J. K. Abramski, O. Semenova, C. G. Hartinger, A. R. Timerbaev, B. K. Keppler and 
M. Jarosz, Electrophoresis, 2006, 27, 1128-1135. 
35. M. Groessl, C. G. Hartinger, K. Polec-Pawlak, M. Jarosz and B. K. Keppler, Electrophoresis, 2008, 29, 
2224-2232. 
36. M. Groessl, A. Bytzek and C. G. Hartinger, Electrophoresis, 2009, 30, 2720-2727. 
37. B. Michalke, Trac-Trend Anal Chem, 2002, 21, 142-153. 
38. M. Moini, Anal Bioanal Chem, 2002, 373, 466-480. 
39. X. B. Yin, Y. Li and X. P. Yan, Trac-Trend Anal Chem, 2008, 27, 554-565. 
40. J. Szpunar, A. Makarov, T. Pieper, B. K. Keppler and R. Lobinski, Anal Chim Acta, 1999, 387, 135-
144. 
41. A. Makarov and J. Szpunar, Analusis, 1998, 26, M44-M48. 
42. M. Sulyok, S. Hann, C. G. Hartinger, B. K. Keppler, G. Stingeder and G. Koellensperger, J Anal Atom 
Spectrom, 2005, 20, 856-863. 
43. www.expasy.org. 
44. I. Khalaila, C. S. Allardyce, C. S. Verma and P. J. Dyson, Chembiochem, 2005, 6, 1788-1795. 
45. A. Casini, G. Mastrobuoni, W. H. Ang, C. Gabbiani, G. Pieraccini, G. Moneti, P. J. Dyson and L. 
Messori, Chemmedchem, 2007, 2, 631-+. 
46. C. S. Allardyce, P. J. Dyson, J. Coffey and N. Johnson, Rapid Commun Mass Sp, 2002, 16, 933-935. 
47. J. Will, D. A. Wolters and W. S. Sheldrick, Chemmedchem, 2008, 3, 1696-1707. 
48. D. Wang and S. J. Lippard, Nat Rev Drug Discov, 2005, 4, 307-320. 
49. J. Will, W. S. Sheldrick and D. Wolters, J Biol Inorg Chem, 2008, 13, 421-434. 
50. J. Will, A. Kyas, W. S. Sheldrick and D. Wolters, J Biol Inorg Chem, 2007, 12, 883-894. 
51. S. A. Manley and J. Gailer, Expert Rev Proteomic, 2009, 6, 251-265. 
52. A. Casini, Gabbiani, C., Michelucci, E., Pieraccini, G., Moneti, G., Dyson, P.J., Messori, L., J. Biol. 
Inorg. Chem., 2009, 14, 761-770. 
53. A. Casini, A. Karotki, C. Gabbiani, F. Rugi, M. Vasak, L. Messori and P. J. Dyson, Metallomics, 2009, 
1, 434-441. 
 
 
 128 
 
 
 
 
 
 
 129 
During the Ph.D. work, the author faced up with the problems involves in the development of 
analytical methods able to detect and quantify multiple proteins in complex systems under 
investigation. The scope relies in the idea to reach, one day, the ability to check the state of a 
given system, by the systemic knowledge of its components. As personal point of view, this is 
particular important for living system, since their functional properties emerges only at 
various level of organization in complex networks. Taking into account the role of proteins as 
expression of all the activities at each level of organization in living systems, the knowledge 
and the ability to identify, quantify and establish the correct relationships between them and 
with their environment, represents a possible approach to understand the whole process at the 
base of life.  
Until now, promising steps have been done towards this purpose and proteomics, relates as 
the study of whole (or well defined) proteomes, play a central role in this task and mass 
spectrometry, seems nowadays the only technique able to address the way. At this point, is 
necessary to underline the non availability of a preferential mass spectrometric techniques, 
since the investigation of complex systems requires versatile tools and taking into account the 
variety of the proteome, one size does not fit at all. Laws of chemistry, physic or biology can 
be succesfully apply to explain in detail the characteristic of single components, but in 
opposite we cannot derive simply from them the behaviour of complex systems, where 
repetition is just an exception. 
After these three years of research in this growing field, a renew enthusiasm surround the idea 
in my mind regarding the possibility to have access to the knowledge of how simple 
molecules can talk together and find a such agreement between them to maintain us alive.  
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